1-substituted tetrahydroisoquinoline compound

ABSTRACT

Provided is a compound useful as an N-type Ca 2+  channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca 2+  channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca 2+  channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.

TECHNICAL FIELD

The present invention relates to a medicament, and specifically to a1-substituted tetrahydroisoquinoline compound which is useful as anactive ingredient of a pharmaceutical composition for preventing and/ortreating pain, abdominal symptoms, spastic constipation, and irritablebowel syndrome.

BACKGROUND ART

Pain is an important biological defense mechanism which reflects theaddition of any invasion to organisms. When pain or dysesthesia stilllasts even after tissue damage or diseases responsible for the onset ofpain have been cured, such a condition is recognized as a disease. Painis broadly classified into nociceptive pain and neuropathic pain.Nociceptive pain includes pain caused by tissue inflammation,cancer-induced nerve compression, or the like (inflammatory pain, cancerpain, etc.). Non-steroidal anti-inflammatory drugs (NSAIDs) or opioidsare therapeutically effective for the treatment of nociceptive pain.

On the other hand, neuropathic pain is chronic pain caused by nervetissue damage or compression, or the like. Symptoms of neuropathic paininclude unpleasant dysesthesia such as continuous or sudden spontaneouspain, numbness, burning sensation, the pain of being cut into smallpieces, and stabbing pain; a condition which is a painful response to ausually non-painful weak stimulus (hyperalgesia); pain due to a stimulusthat does not normally provoke pain (allodynia), such as caused bycontact with clothing or changes in temperatures; and the like. Specificdiseases of neuropathic pain include trigeminal neuralgia, complexregional pain syndrome, post spinal surgery syndrome, phantom limb pain,pain after brachial plexus injury, post-spinal cord injury pain,post-stroke pain, painful diabetic neuropathy, postherpetic neuralgia,HIV-induced neuropathy, and further some cases of cancer pain and lowback pain on which analgesic effects of opioids are not sufficientlyexerted, in addition to anticancer drug- and anti-HIV drug-inducedneuropathy.

Neuropathic pain is known as pain on which NSAIDs or opioids which areeffective on nociceptive pain exhibit difficulty in beingtherapeutically effective. In practical medication therapy, alleviationof pain is effected by hemp, capsaicin cream, or intraspinaladministration of opioids, as well as by administration ofantidepressants (duloxetine, amitriptylin, etc.), antiepileptic drugs(pregabalin, carbamazepine, etc.), or local analgesics (mexiletine,etc.). Unfortunately, effects of these drugs are limited since manyneuropathic pains are developed by an overlap of multiple pathogeniccauses and individual patients have different disease backgrounds.Further, there are also problems associated with inherent side effectsof individual drugs. To this end, there is a strong need for ananti-neuropathic pain agent which has more potent and broader analgesicspectrum and lower side effects.

Irritable bowel syndrome (IBS) is a syndrome which brings aboutabdominal symptoms such as abdominal pain and abdominal distension andstool abnormalities such as diarrhea or defecation urgency andconstipation or difficulty in defecation, due to the dysfunction of thelower digestive tract around the large intestine, despite no occurrenceof organic alteration such as inflammation and tumor. Depending onpredominant bowel habits, IBS is broadly subclassified into diarrheatype IBS (IBS-D), constipation type IBS (IBS-C), and mix type IBS(IBS-M) with alternating diarrhea and constipation (Gastroenterology130: 1377-90, 1480-91 (2006)). As a medication therapy for IBS, theremay be mentioned anticholinergic drugs for abdominal pain, tricyclicantidepressants (TCAs) for improving decreased pain threshold of thedigestive tract, and in the case of bowel movement disturbance,antidiarrheals or intestinal remedies for diarrhea and cathartic saltsfor constipation, which are merely allopathic therapies and are alsouncertain in their effects (Irritable bowel syndrome˜Communicationbetween the brain and the intestines (ISBN4-521-67671-5, 2006)).

As drugs which are recently attracting attention, alosetron which is a5-HT₃ receptor antagonist and tegaserod which is a 5-HT₄ receptoragonist are used for IBS-D and IBS-C, respectively. However, use ofalosetron is limited due to the incidence of constipation in 30% to 35%of patients, in conjunction with serious side effects of ischemiccolitis (including death), even though it exhibits a comparatively highimprovement rate of 40% to 60% for abdominal symptoms and diarrhea (DrugToday 36: 595-607 (2000), FDA information about lotronex,GlaxoSmithKline press release). In addition, it is said that tegaserodhas little effect on abdominal symptoms due to poorconstipation-alleviating effects, which may result in the risk oftachyphylaxis (phenomenon of producing resistance to a drug afterrepeated doses over a short period of time) (Clinical Therapeutics 25:1952-1974 (2003)). In addition, an application of tegaserod is alsostrongly limited in terms of side effects, due to having adverse effectson the circulatory system (FDA information about zelnorm, Novartis pressrelease).

Opioids, such as morphine, which have been commonly used aspain-relieving drugs, are known to cause severe dysfunction of thedigestive tract including constipation, which is called opioid boweldysfunction (OBD). Among symptoms of OBD, the onset of constipation isvery high without creating drug resistance unlike other opioid-inducedcentral nervous system side-effects, so it is necessary to takeappropriate measures to deal with the situation (American J. Surgery182: 11S-18S (2001), Jpn. Cancer Chemother. 32: 1377-1383 (2005)). Forthese reasons, in opioid treatment particularly on cancer pain patients,a combined prophylactic treatment with a laxative agent is essentialfrom the beginning of administering an opioid drug, but it is not easyto control defecation by means of the laxative agent (Drugs 63: 649-671(2003), Pharmacotherapy 22: 240-250 (2002)).

The digestive tract is provided with an independent nerve network,called the enteric nervous system. Various kinds of neurons are presentin the enteric nervous system and are responsible for governingrespective digestive tract functions. Among those neurons, IntrinsicPrimary Afferent Neutrons (IPANs) are neurons that primarily receivechanges in the digestive tract lumen. IPANs detect physical or chemicalchanges in the digestive tract lumen and transmit the information tomotor neurons or sensory neurons. Therefore, drugs altering the activityof IPANs bring about changes in the digestive tract function, calledperistaltic motion or visceral perception (Progress in Neurobiol. 54:1-18 (1998)). Further, from the fact that the N-type Ca²⁺ channel isexpressed in IPANs and contributes to the activity of IPANs (J. Comp.Neurol. 409: 85-104 (1999)), it can be considered that a compoundblocking the N-type Ca²⁺ channel would be useful for functionaldigestive tract diseases by altering digestive tract functions.

In addition, it is known that abdominal pain signals, like somatic pain,travel to the brain via the dorsal root ganglion (DRG) and the spinalcord (Neurogastroentel. Motil. 16: 113-124 (2004)). This signalingpathway is hypersensitized in IBS patients, suggesting significantoccurrences of abdominal symptoms (Gut 53: 1465-1470 (2004)). Therefore,it is anticipated that a blocker of the N-type Ca²⁺ channel involved inthis pain-signaling pathway would be an effective therapeutic agentagainst abdominal symptoms of IBS. In fact, it has been reported thatgabapentin or pregabalin, which is a ligand for the Ca²⁺ channel α2δsubunit, exerts analgesic effects in animal models of abdominal painhypersensitization (J. Pharmacol. Exp. Ther. 295: 162-167 (2000),Anesthesiology 98: 729-733 (2003)).

There are many kinds of Ca²⁺-dependent functional proteins in cells, andchanges in the intracellular Ca²⁺ concentration play an important rolein the expression or regulation of various physiological functions suchas neuronal viability, synaptic plasticity, and gene expression. AmongCa²⁺ channels present on the cell membrane, a channel using a membranepotential as a trigger in the opening of the channel is called avoltage-dependent Ca²⁺ channel (VDCC), which consists mainly of an α1subunit forming the channel body, a β subunit controlling an expressionlevel of the α1 subunit or functions of the channel, and an α2δ subunit(Trends Neurosci. 21 148-154 (1998)). The Ca²⁺ channels are classifiedinto high-threshold Ca²⁺ channels such as L-type (α1S, C, D, and F),P/Q-type (α1A), N-type (α1B), and R-type (α1E); and low-threshold Ca²⁺channels such as T-type (α1G, H, I), depending on α1 subunit type andactivation threshold potential (Rev. Physiol. Biochem. Pharmacol. 139:33-87 (1999)).

Among the high-threshold Ca²⁺ channels, the P/Q-, N-, and R-type Ca²⁺channels are present in neuron synaptic terminals and serve as a triggerof the neurotransmitter release. In particular, the N-type Ca²⁺ channelis highly expressed in the dorsal root ganglion (DRG) (J. Neurosci. 15:4315-4327 (1995)) which is a collection of cell bodies of the sensoryneurons or the spinal dorsal horn (J. Neurosci. 18: 6319-6330 (1998))which is a synaptic projection region of sensory neurons. Further, thespinal dorsal horn of neuropathic pain model rats exhibited an increasedexpression of the N-type Ca²⁺ channel in synchronization with theprogression of hyperalgesia (Exp. Brain Res. 147: 456-463 (2002)). Fromthese facts, it is believed that the N-type Ca²⁺ channel plays a role asa trigger that transmits an excess of pain signals to the brain.

With recent observations showing that a selective N-type Ca²⁺channel-blocking peptide, ω-conotoxin (ω-CTx) exhibits broad analgesiceffects in animal models of nociceptive, inflammatory and neuropathicpain, respectively (J. Pharmacol. Exp. Ther. 279: 1243-1249 (1996), J.Pharmacol. Exp. Ther. 287: 232-237 (1998), J. Pharmacol. Exp. Ther. 269:1117-1123 (1994)), and no neuropathic pain occurs in α1B-deficient mice(EMBO J. 20: 2349-2356 (2001)), it has been suggested that the N-typeCa²⁺ channel is deeply implicated in the pathogenesis of neuropathicpain. In fact, it has been reported that chronic spinal administrationof ziconotide (ω-conotoxin MVIIA:ω-CTxMVIIA) by means of an implantablepump improves hyperalgesia and allodynia in morphine non-responsiveneuropathic pain patients (Clin. J. Pain 13: 256-259 (1997)). Further,it has been demonstrated that gabapentin or pregabalin, frequently usedas an anti-neuropathic pain agent, binds with a high affinity to theCa²⁺ channel α2δ subunit to exert thereby analgesic effects (J. Pharm.Sci. 100: 471-486 (2006)). Based on the above-mentioned findings, theN-type Ca²⁺ channel blocker is expected to be an excellent therapeuticagent for pain, particularly neuropathic pain. Further, from the factthat the N-type Ca²⁺ channel is involved in hyperactivity of neurons,cellular death and the like, the N-type Ca²⁺ channel blocker isconsequently expected to be useful for the prevention or treatment ofconditions or diseases associated with activation of the N-type Ca²⁺channel, in addition to the above-mentioned pain. Taken altogether, itis believed that a compound having the N-type Ca²⁺ channel-blockingaction would be useful for various pains such as neuropathic pain andnociceptive pain, headaches such as migraine and cluster headache,central nervous system diseases such as anxiety, depression, epilepsy,cerebral stroke and restless legs syndrome, digestive system diseasessuch as abdominal pain and irritable bowel syndrome, and urinary systemdiseases such as overactive bladder and interstitial cystitis.

N-type Ca²⁺ channel-blocking compounds have been hitherto reported. Forexample, it has been described that the following benzazepinederivatives have an action of blocking N-type Ca²⁺ channels and areuseful as an agent for preventing and/or treating cerebral infarction,transient cerebral ischemic attack, encephalomyelopathy after cardiacsurgery, spinal cord vascular disorders, stress-induced hypertension,neurosis, epilepsy, asthma, frequent micturition, and ophthalmicdiseases, or as anti-pain drugs (Patent Document 1).

(See the above-referenced document for symbols in the formula)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.

Further, it has been described that the following diarylalkene ordiarylalkane derivatives have an action of blocking N-type Ca²⁺ channelsand are useful for treating pain, brain infarction, cerebral disorderscaused by acute ischemia after the onset of cerebral hemorrhage,Alzheimer's disease, AIDS-associated dementia, Parkinson's disease,progressive degenerative diseases of the brain, neurological disorderscaused by head injury, bronchial asthma, unstable angina, irritablecolon inflammatory diseases, and withdrawal symptoms of drug addiction(Patent Document 2).

(See the above-referenced document for symbols in the formula)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.

Further, it has been described that the following tricyclicheteroaromatic compounds have an action of blocking N-type Ca²⁺ channelsand are useful as a medicament, particularly an analgesic agent (PatentDocument 3).

(See the above-referenced document for symbols in the formula)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.

Further, it has been described that the following substituted piperazinecompounds have an action of blocking N-type Ca²⁺ channels and are usefulfor treating cerebral stroke, pain, anxiety, depression,gastrointestinal disorders, genitourinary disturbance, cardiovasculardisturbance, epilepsy, diabetes, and cancer (Patent Document 4).

(See the above-referenced document for symbols in the formula)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.

Further, it has been reported that the following azacyclo compounds areuseful for treating or preventing diseases associated with a flow ofsodium ions of the sensory neuron channel, for example, pain such aschronic and acute pain, hypersensitivity diseases such as bladderdiseases and irritable bowel syndrome, and demyelinating diseases(Patent Document 5).

(See the above-referenced document for symbols in the formula)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.

Further, it has been reported that the following compounds have afarnesyl protein transferase inhibitory activity and are useful as ananticancer drug (Patent Document 6).

(See the above-referenced document for symbols in the formula)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.In addition, there is no disclosure or suggestion of their effects onN-type Ca²⁺ channel-blocking action, pain including neuropathic pain,and digestive system diseases including irritable bowel syndrome.

Further, it has been reported that the following compounds have ananti-arrhythmic action (Non-Patent Document 1).

(See the above-referenced document for symbols in the formula)

However, an English Abstract attached to the above-referenced Documentcontains no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.In addition, there is no disclosure or suggestion of their effects onN-type Ca²⁺ channel-blocking action, pain including neuropathic pain,and digestive system diseases including irritable bowel syndrome.

Further, it has been reported that the following compounds have ananti-arrhythmic action (Non-Patent Document 2).

(See the above-referenced document for symbols in the formula)

However, an English Abstract attached to the above-referenced Documentcontains no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.In addition, there is no disclosure or suggestion of their effects onN-type Ca²⁺ channel-blocking action, pain including neuropathic pain,and digestive system diseases including irritable bowel syndrome.

Further, it has been reported that the following compounds have anaction of blocking Ca²⁺ channels and are useful as a hypotensive agentand an anti-arrhythmic agent (Non-Patent Document 3).

(See the above-referenced document for symbols in the formula)

However, an English Abstract attached to the above-referenced Documentcontains no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.In addition, there is no disclosure or suggestion of their effects onN-type Ca²⁺ channel-blocking action, pain including neuropathic pain,and digestive system diseases including irritable bowel syndrome.

Further, it has been reported that the following compounds have a Ca²⁺channel-blocking action, a Na⁺ channel-blocking action and a calmodulininhibitory activity and are possibly useful in neuroprotective therapy(Non-Patent Documents 4 and 5).

(See the above-referenced document for symbols in the formula)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.

Further, the following compounds have been reported as an Orexin-2receptor antagonist (Non-Patent Document 6). Additionally, it has alsobeen suggested that an Orexin-2 receptor is involved in the transmissionof nociceptive stimuli.

(Me in the formula represents methyl)

However, there is no specific disclosure of a 1-substitutedtetrahydroisoquinoline compound which pertains to the present invention.

As other references which disclose compounds having atetrahydroisoquinoline skeleton, there are Patent Documents 7 to 9.However, these documents contain no specific disclosure of a1-substituted tetrahydroisoquinoline compound which pertains to thepresent invention.

[Patent Document 1] JP-A-2002-363163

[Patent Document 2] Pamphlet of International Publication No. WO03/018538

[Patent Document 3] Pamphlet of International Publication No. WO2004/089950

[Patent Document 4] Pamphlet of International Publication No. WO2005/021523

[Patent Document 5] Pamphlet of International Publication No. WO2005/005392

[Patent Document 6] European Patent Application Laid-open PublicationNo. EP 0 696 593

[Patent Document 7] Pamphlet of International Publication No. WO01/85693

[Patent Document 8] Pamphlet of International Publication No. WO02/079189

[Patent Document 9] Pamphlet of International Publication No. WO03/082828

[Non-Patent Document 1] Fudan University Journal of Medical Science,1987, 14 (1), 15-20

[Non-Patent Document 2] Fudan University Journal of Medical Science,1989, 16 (1), 71-74

[Non-Patent Document 3] Journal of China Pharmaceutical University,1993, 24 (4), 193-201

[Non-Patent Document 4] Biological & Pharmaceutical Bulletin, 2000, 23(3), 375-378

[Non-Patent Document 5] Neurochemical Research, 2003, 28 (12), 1813-1818

[Non-Patent Document 6] Bioorganic & Medicinal Chemistry Letters, 2003,13 (24), 4497-4499

DISCLOSURE OF THE INVENTION Problem that the Invention is to Solve

It is an object of the present invention to provide a medicament havinga selective blocking action on N-type Ca²⁺ channels, and specifically acompound useful as an active ingredient of a pharmaceutical compositionfor preventing and/or treating pain and irritable bowel syndrome.

The compound of the present invention has a structural characteristic inthat in the formula (I), at least one of R^(1a) and R^(1b) is asubstituent other than —H, and R²² is a hydroxyl-containing substituent.Further, the compound of the present invention has pharmacologicalproperties in that it has an N-type Ca²⁺ channel-blocking action, anantinociceptive pain action, an antineuropathic pain action, anabdominal pain-inhibitory action and an opioid-inducedconstipation-improving action.

Means for Solving the Problem

As a result of intensive studies on compounds having a selectiveblocking action on N-type Ca²⁺ channels, the present inventors foundthat a 1-substituted tetrahydroisoquinoline compound of the presentinvention has a selective N-type Ca²⁺ channel-blocking action, anantinociceptive pain action, an antineuropathic pain action, anabdominal pain-inhibitory action and an opioid-inducedconstipation-improving action. The present invention has been completedbased on these findings.

That is, the present invention relates to a compound of the formula (I)or a pharmaceutically acceptable salt thereof, and a pharmaceuticalcomposition comprising a compound of the formula (I) or apharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable excipient.

[1]

A compound of the formula (I):

wherein the symbols in the formula have the following meanings:

R^(1a) and R^(1b): the same or different and —H, C₁₋₆ alkyl which may besubstituted, cycloalkyl which may be substituted, aryl which may besubstituted, or an aromatic hetero ring which may be substituted,provided that both of R^(1a) and R^(1b) cannot be —H, and R^(1a) andR^(1b), taken together with the carbon atom to which they are attached,may represent cycloalkyl which may be substituted,

R^(3a), R^(3b), R^(4a) and R^(4b): the same or different and —H, or C₁₋₆alkyl,

R⁵, R⁶, R⁷ and R⁸: the same or different and —H, C₁₋₆ alkyl which may besubstituted, —O—(C₁₋₆ alkyl) which may be substituted, cyano, carbamoylwhich may be substituted with one or two C₁₋₆ alkyl, or halogen, and anytwo adjacent groups of R⁵, R⁶, R⁷ and R⁸ taken together may form—O—CH₂—O— or —O—(CH₂)₂—O—,

R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶: the same or different and —H or C₁₋₆alkyl,

R²¹: —H, C₁₋₆ alkyl which may be substituted, or cycloalkyl which may besubstituted,

R²²:

(1) cycloalkyl which is substituted with one or more groups selectedfrom the group consisting of —OH and —CH₂OH and which may be furthersubstituted;

(2) C₁₋₈ alkyl substituted with one or two —OH, wherein the C₁₋₈ alkylmay further have a substituent, and one or two methylene groups (—CH₂—)contained in this alkyl chain may be replaced with —O—; or

(3) C₁₋₆ alkyl substituted with cycloalkyl which is substituted with oneor more groups selected from the group consisting of —OH and —CH₂OH andwhich may be further substituted, wherein the C₁₋₆ alkyl may besubstituted with —OH, and one or two methylene groups (—CH₂—) containedin this alkyl chain may be replaced with —O—;

n and m: the same or different and are 0 or 1,

R¹² and R²¹ taken together may form methylene, ethylene, ortrimethylene, and in this case, R¹¹ may represent —OH, or

R²¹ and R²², taken together with the nitrogen atom to which they areattached, may form azetidine, pyrrolidine, piperidine, azepane, azocane,morpholine, tetrahydroisoquinoline or thiomorpholine which aresubstituted with —OH or C₁₋₆ alkyl substituted with —OH; or apharmaceutically acceptable salt thereof.

[2]

The compound according to [1], wherein m is 0, n is 0, and R^(1a),R^(3a), R^(3b), R^(4a), R^(4b), R¹¹, R¹² and R²¹ are each —H; or apharmaceutically acceptable salt thereof.

[3]

The compound according to [2], wherein R^(1b) is isopropyl,methoxymethyl, phenyl, 2-(trifluoromethyl)benzyl, or cyclohexyl; or apharmaceutically acceptable salt thereof.

[4]

The compound according to [2] or [3], wherein R⁵, R⁶, R⁷ and R⁸ are thesame or different and are independently selected from the groupconsisting of —H, methyl, ethyl, methoxy, and fluoro; or apharmaceutically acceptable salt thereof.

[5]

The compound according to [2], [3] or [4], wherein R²² is2-hydroxypropan-1-yl, 2-hydroxy-3-methoxypropan-1-yl, or(1-hydroxycyclohexyl)methyl; or a pharmaceutically acceptable saltthereof.

[6]

The compound according to [1], which is

-   1-[({2-[(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   (2S)-1-({2-[(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)-3-methoxy    propan-2-ol,-   1-({[2-(1(1S)-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   (2R)-1-({2-[(1S)-8-methoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)propan-2-ol,-   1-[({2-[(1R)-7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   (2S)-1-methoxy-3-[(2-oxo-2-{1(1S)-[2-(trifluoromethyl)benzyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,-   1-({[3-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxo    propyl]amino}methyl)cyclohexanol,-   (2R)-1-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,-   (2R)-1-[(2-oxo-2-{1-[2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,-   (2S)-1-{[2-(1-cyclohexyl-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}-3-methoxy    propan-2-ol,-   (2R)-1-({2-oxo-2-[(1S)-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}amino)propan-2-ol,-   1-[({2-[7-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-({[2-(1-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-[({2-[5-methoxy-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[1-(methoxymethyl)-6-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   (1S,2S)-2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}-1-phenyl    propane-1,3-diol,-   1-({(2R)-2-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]pyrrolidin-1-yl}methyl)cyclohexanol,-   (2R)-1-{[2-(1-cyclohexyl-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,-   1-({[2-(3′,4′-dihydro-2′H-spiro[cyclohexane-1,1′-isoquinolin]-2′-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   (2R)-1-[(2-oxo-2-{1-[2-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,-   (2R)-1-{[2-(1-cyclohexyl-7-ethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,-   1-({[2-(6-fluoro-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1,1-dicyclopropyl-2-({2-[6-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)ethanol,-   1-({[2-(1-tert-butyl-8-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-({[2-(1-isopropyl-6-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-({[2-(6-fluoro-1-propyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-[({2-[1-(methoxymethyl)-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-({[2-(5-fluoro-1-propyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-[({2-[5-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[8-methoxy-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[1-(ethoxymethyl)-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,    or-   (1R,2S)-2-({2-[(1R)-1-(2-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)cyclopentanol;    or a pharmaceutically acceptable salt thereof.

[7]

A pharmaceutical composition comprising a compound of [1] or apharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable excipient.

[8]

An N-type Ca²⁺ channel blocker comprising a compound of [1] or apharmaceutically acceptable salt thereof.

[9]

A pharmaceutical composition for preventing or treating pain,neuropathic pain, abdominal symptom, spastic constipation,opioid-induced constipation, irritable bowel syndrome, orconstipation-type irritable bowel syndrome, comprising a compound of [1]or a pharmaceutically acceptable salt thereof.

[10]

The pharmaceutical composition according to [9], which is apharmaceutical composition for preventing or treating pain.

[11]

The pharmaceutical composition according to [10], which is apharmaceutical composition for preventing or treating neuropathic pain.

[12]

The pharmaceutical composition according to [9], which is apharmaceutical composition for preventing or treating abdominal symptom.

[13]

The pharmaceutical composition according to [9], which is apharmaceutical composition for preventing or treating spasticconstipation.

[14]

The pharmaceutical composition according to [13], which is apharmaceutical composition for preventing or treating opioid-inducedconstipation.

[15]

The pharmaceutical composition according to [9], which is apharmaceutical composition for preventing or treating irritable bowelsyndrome.

[16]

The pharmaceutical composition according to [15], which is apharmaceutical composition for preventing or treating constipation-typeirritable bowel syndrome.

[17]

A pharmaceutical composition comprising a compound of [1] or apharmaceutically acceptable salt thereof and an opioid as activeingredients.

[18]

A pharmaceutical composition comprising a compound of [1] or apharmaceutically acceptable salt thereof as an active ingredient,wherein the composition is used in combination with an opioid.

[19]

Use of a compound of [1] or a pharmaceutically acceptable salt thereoffor the manufacture of a pharmaceutical composition for preventing ortreating pain, neuropathic pain, abdominal symptom, spasticconstipation, opioid-induced constipation, irritable bowel syndrome, orconstipation-type irritable bowel syndrome.

[20]

A compound of [1] for use as an active ingredient of a pharmaceuticalcomposition for preventing or treating pain, neuropathic pain, abdominalsymptom, spastic constipation, opioid-induced constipation, irritablebowel syndrome, or constipation-type irritable bowel syndrome.

[21]

A method for preventing or treating pain, neuropathic pain, abdominalsymptom, spastic constipation, opioid-induced constipation, irritablebowel syndrome, or constipation-type irritable bowel syndrome,comprising administering to a patient an effective amount of a compoundof [1] or a pharmaceutically acceptable salt thereof.

Further, the present invention relates to a pharmaceutical compositionfor treating pain, in a certain embodiment neuropathic pain; abdominalsymptoms; spastic constipation, in a certain embodiment opioid-inducedconstipation; or irritable bowel syndrome, in a certain embodimentconstipation-type irritable bowel syndrome, comprising a compound of theformula (I) or a pharmaceutically acceptable salt thereof, that is, apharmaceutical composition for preventing and/or treating pain, in acertain embodiment neuropathic pain; abdominal symptoms; spasticconstipation, in a certain embodiment opioid-induced constipation; orirritable bowel syndrome, in a certain embodiment constipation-typeirritable bowel syndrome, comprising a compound of the formula (I) or apharmaceutically acceptable salt thereof.

Further, the present invention relates to use of a compound of theformula (I) or a pharmaceutically acceptable salt thereof for themanufacture of a pharmaceutical composition for treating pain, in acertain embodiment neuropathic pain; abdominal symptoms; spasticconstipation, in a certain embodiment opioid-induced constipation; orirritable bowel syndrome, in a certain embodiment constipation-typeirritable bowel syndrome, and a method for treating pain, in a certainembodiment neuropathic pain; abdominal symptoms; spastic constipation,in a certain embodiment opioid-induced constipation; or irritable bowelsyndrome, in a certain embodiment constipation-type irritable bowelsyndrome, comprising administering to a patient an effective amount of acompound of the formula (I) or a pharmaceutically acceptable saltthereof.

EFFECT OF THE INVENTION

The compound of the present invention can be used as a pharmaceuticalcomposition for preventing and/or treating various pains such asneuropathic pain and nociceptive pain, headaches such as migraine andcluster headache, central nervous system diseases such as anxiety,depression, epilepsy, cerebral stroke and restless legs syndrome,abdominal symptoms such as abdominal pain and abdominal distension,stool abnormalities such as diarrhea and constipation, digestive systemdiseases such as irritable bowel syndrome, urinary system diseases suchas overactive bladder and interstitial cystitis, etc.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described in detail.

In the definitions of this specification, the “C₁₋₆ alkyl” means alinear or branched alkyl having 1 to 6 carbon atoms, and examplesthereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like. The “C₁₋₈ alkyl”means a linear or branched alkyl having 1 to 8 carbon atoms, andexamples thereof include n-heptyl, n-octyl, diisopropyl ethyl, and thelike, in addition to the above-described C₁₋₆alkyls.

The “halogen” means F, Cl, Br, or I.

The “cycloalkyl” is a C₃₋₁₀ saturated hydrocarbon ring group, andexamples thereof include cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, and the like. It alsoincludes cyclohexenyl, cyclooctadienyl, and the like, which contain apartially unsaturated bond. Further, it also includes groups wherein oneor two methylene groups on the ring are replaced with —O—, for example,tetrahydropyranyl, tetrahydrofuranyl, and the like. Further, its ringmay be condensed with a benzene ring, and examples thereof includeindenyl, indanyl, dihydronaphthyl, and tetrahydronaphthyl.

The “aryl” is a C₆₋₁₄ monocyclic to tricyclic aromatic hydrocarbon ringgroup, and examples thereof include phenyl, naphthyl, and the like.

The “aromatic hetero ring” is a 5- to 6-membered monocyclic hetero ringgroup containing 1 to 3 hetero atoms selected from oxygen, sulfur, andnitrogen, and examples thereof include furyl, thienyl, pyrrolyl,pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isothiazolyl, triazinyl,pyridyl, pyrazyl, pyrimidinyl, pyridazinyl, and the like.

The “which may be substituted” means that it is “not substituted” or“substituted with 1 to 5 substituents which are the same or different”.Further, if it has multiple substituents, the substituents may be thesame or different from each other.

Examples of the substituent for the “C₁₋₆ alkyl which may besubstituted” in the definition of R^(1a) and R^(1b) include —OH;—OR^(z); or phenyl which may be substituted with one or more same ordifferent groups selected from the group consisting of halogen, R^(Y),and —OR^(Y). R^(Y) represents C₁₋₆ alkyl which may be substituted with 1to 5 halogens, and R^(z) represents C₁₋₆ alkyl which may be substitutedwith one or more same or different groups selected from the groupconsisting of —O—(C₁₋₆ alkyl) and —OR^(Y) (the same shall applyhereinafter).

Examples of the substituent for the “cycloalkyl which may besubstituted” in the definition of R^(1a) and R^(1b) include —OH,halogen, R^(Y), and —OR^(Y).

Examples of the substituent for the “aryl which may be substituted” andthe “aromatic hetero ring which may be substituted” in the definition ofR^(1a) and R^(1b) include —OH, halogen, R^(Y), —OR^(Y), —SR^(Y), cyano,and cycloalkyl.

Examples of the substituent for the “C₁₋₆alkyl which may be substituted”and the “—O—(C₁₋₆ alkyl) which may be substituted” in the definition ofR⁵, R⁶, R⁷ and R⁸ include —OH, halogen, —OR^(Y), and —NHCO—(C₁₋₆ alkyl).

Examples of the substituent for the “C₁₋₆ alkyl which may besubstituted” in the definition of R²¹ include —OH, halogen, —OR^(Y), andcycloalkyl.

Examples of the substituent for the “cycloalkyl which may besubstituted” in the definition of R²¹ include —OH, halogen, R^(Y), and—OR^(Y).

The “cycloalkyl which is substituted by one or more groups selected fromthe group consisting of —OH and —CH₂OH and which may be furthersubstituted” in the definition of R²² means that the cycloalkyl has atleast one or more same or different groups selected from the groupconsisting of —OH and —CH₂OH, as substituents, and may be furthersubstituted with other substituents. Examples of the acceptableadditional substituents include halogen, R^(Y), —OR^(Y), oxo (═O), andoxo protected with ethylene glycol.

The “C₁₋₈ alkyl substituted with one or two —OH, wherein the C₁₋₈ alkylmay further have a substituent, and one or two methylene groups (—CH₂—)contained in this alkyl chain may be replaced with —O—” in thedefinition of R²² means that methylene group(s) on the alkyl chain ofthe C₁₋₈ alkyl may be replaced with —O—, and the C₁₋₈ alkyl has at leastone or two —OH as substituents and may be further substituted with othersubstituents. Examples of the acceptable additional substituent includehalogen; —OR^(Y); cycloalkyl; or aryl that may be substituted with oneor more same or different groups selected from the group consisting of—OH, halogen, R^(Y), and —OR^(Y).

The “C₁₋₆ alkyl substituted with cycloalkyl which is substituted withone or more groups selected from the group consisting of —OH and —CH₂OHand which may be further substituted, wherein the C₁₋₆ alkyl may besubstituted with —OH, and one or two methylene groups (—CH₂—) containedin this alkyl chain may be replaced with —O—” in the definition of R²²means that the C₁₋₆ alkyl may be substituted with —OH, methylenegroup(s) on the alkyl chain may be replaced with —O—, and the C₁₋₆ alkylhas at least cycloalkyl which may be substituted, as a substituent.Cycloalkyl as a substituent of the C₁₋₆ alkyl has at least one or moresame or different groups selected from the group consisting of —OH and—CH₂OH, as substituents, and may be further substituted with othersubstituents. Examples of the acceptable additional substituents includehalogen, R^(Y), —CR^(Y), oxo (═O), and oxo protected with ethyleneglycol.

The “pain” means a variety of pains including nociceptive pain andneuropathic pain.

The “nociceptive pain” is a pain which is caused by the addition ofnociceptive stimuli through nociceptors and examples thereof includepain caused by tissue damage, pain caused by tissue inflammation(inflammatory pain), pain caused by cancer-induced nerve compression(cancer pain).

The “neuropathic pain” is chronic pain which is caused by nerve tissuedamage or compression or the like and examples thereof includetrigeminal neuralgia, complex regional pain syndrome, post spinalsurgery syndrome, phantom limb pain, pain after brachial plexus injury,post-spinal cord injury pain, post-stroke pain, painful diabeticneuropathy, postherpetic neuralgia, HIV-induced neuropathy, and furthersome cases of cancer pain and low back pain on which analgesic effectsof opioids are not sufficiently, in addition to anticancer drug- andanti-HIV drug-induced neuropathy.

The “abdominal symptom” means abdominal discomfort such as abdominalpain and abdominal distension.

The “spastic constipation” is constipation caused by spastic dysmotilityof the digestive tract, and examples thereof include opioid-inducedconstipation, and constipation found in constipation-type irritablebowel syndrome (IBS-C).

The “opioid-induced constipation” means constipation caused by opioidssuch as morphine.

The “irritable bowel syndrome” is a disease which brings about abdominalsymptoms such as abdominal pain and abdominal distension and stoolabnormalities such as diarrhea or defecation urgency and constipation ordifficulty in defecation, due to the dysfunction of the lower digestivetract around the large intestine, despite no occurrence of organicalterations such as inflammation and tumor and the like, and is adisease which is classified into diarrhea type IBS (IBS-D), constipationtype IBS (IBS-C), and mix type IBS (IBS-M) with alternating diarrhea andconstipation, depending on bowel conditions.

Hereinafter, some embodiments of the present invention will bedescribed.

(1) In the formula (I), a compound wherein R^(1a) is —H or C₁₋₆ alkylwhich may be substituted. In another embodiment, a compound whereinR^(1a) is —H or methyl. In yet another embodiment, a compound whereinR^(1a) is —H.

(2) In the formula (I), a compound wherein R^(1b) is C₁₋₆ alkyl whichmay be substituted, cycloalkyl which may be substituted, or aryl whichmay be substituted. In another embodiment, a compound wherein R^(1b) isn-propyl, isopropyl, tert-butyl, methoxymethyl, ethoxymethyl, phenyl,2-methoxyphenyl, 2-(trifluoromethyl)phenyl, 2-(trifluoromethoxy)phenyl,2-(trifluoromethyl)benzyl, or cyclohexyl. In yet another embodiment, acompound wherein R^(1b) is isopropyl, methoxymethyl, phenyl,2-(trifluoromethyl)benzyl, or cyclohexyl.

(3) In the formula (I), a compound wherein R^(1a) and R^(1b), togetherwith the carbon atom to which they are attached, represent cycloalkylwhich may be substituted. In another embodiment, a compound whereinR^(1a) and R^(1b), together with the carbon atom to which they areattached, represent cyclohexyl.

(4) In the formula (I), a compound wherein R^(3a), R^(3b), R^(4a) andR^(4b) are each —H.

(5) In the formula (I), a compound wherein m is 0, and n is 0 or 1. Inanother embodiment, a compound wherein m is 0, and n is 0.

(6) In the formula (I), a compound wherein R⁵, R⁶, R⁷ and R⁸ are thesame or different and are independently selected from the groupconsisting of —H, C₁₋₆ alkyl, —O—(C₁₋₆ alkyl), and halogen. In anotherembodiment, a compound wherein R⁵, R⁶, R⁷ and R⁸ are the same ordifferent and are selected from the group consisting of —H, methyl,ethyl, methoxy, and fluoro.

(7) In the formula (I), a compound wherein R¹¹, R¹², R¹³, R¹⁴, R¹⁵ andR¹⁶ are each —H.

(8) In the formula (I), a compound wherein m is 0, n is 0, R¹¹ is —H,and R¹² and R²¹ taken together represent methylene, ethylene ortrimethylene. In another embodiment, a compound wherein m is 0, n is 0,R¹¹ is —H, and R¹² and R²¹ taken together represent trimethylene.

(9) A compound wherein R²¹ is —H.

(10) In an embodiment, a compound wherein R²² is cycloalkyl substitutedwith one or more groups selected from the group consisting of —OH and—CH₂OH. In another embodiment, a compound wherein R²² is cyclopentyl orcyclohexyl substituted with one or more groups selected from the groupconsisting of —OH and —CH₂OH. In yet another embodiment, a compoundwherein R²² is 2-hydroxycyclopentyl.

(11) In an embodiment, a compound wherein R²² is C₁₋₈ alkyl which issubstituted with one or two —OH and is further substituted with one ormore the same or different groups selected from the group consisting of—O—(C₁₋₆ alkyl), cycloalkyl, and aryl. In another embodiment, a compoundwherein R²² is C₁₋₈ alkyl which is substituted with one or two —OH andis further substituted with one or more the same or different groupsselected from the group consisting of methoxy, cyclopropyl, and phenyl.In a further embodiment, a compound wherein R²² is ethyl or propyl whichis substituted with one or two —OH and is further substituted with oneor more same or different groups selected from the group consisting ofmethoxy, cyclopropyl, and phenyl. In a still further embodiment, acompound wherein R²² is 2-hydroxypropan-1-yl,2-hydroxy-3-methoxypropan-1-yl, 1,3-dihydroxy-1-phenylpropan-2-yl, or2-hydroxy-2,2-dicyclopropylethyl. In yet another embodiment, a compoundwherein R²² is 2-hydroxypropan-1-yl or 2-hydroxy-3-methoxypropan-1-yl.

(12) In an embodiment, a compound wherein R²² is C₁₋₆ alkyl substitutedwith cycloalkyl which is substituted with one or more groups selectedfrom the group consisting of —OH and —CH₂OH. In another embodiment, acompound wherein R²² is cyclohexylmethyl substituted with —OH. In yetanother embodiment, a compound wherein R²² is(1-hydroxycyclohexyl)methyl.

(13) In an embodiment, a compound as set forth in (10), (11), or (12).In another embodiment, a compound as set forth in (11) or (12).

(14) A compound which is a combination of any two or more selected fromthe group consisting of (1), (2), (4), (5), (6), (7), (9), and (13).

(15) A compound which is a combination of any two or more selected fromthe group consisting of (3), (4), (5), (6), (7), (9), and (13).

(16) A compound which is a combination of any two or more selected fromthe group consisting of (1), (2), (4), (6), (8), and (13).

(17) A compound which is a combination of any two or more selected fromthe group consisting of (3), (4), (6), (8), and (13).

(18) In an embodiment, a compound which is any one of (14) to (17). Inanother embodiment, a compound as set forth in (14).

(19) A compound which is a combination of any two or more of (1) to (12)which are not inconsistent with each other.

Examples of the compounds encompassed by the present invention includethe following compounds.

-   1-[({2-[(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   (2S)-1-({2-[(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)-3-methoxy    propan-2-ol,-   1-({[2-(1(1S)-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   (2R)-1-({2-[(1S)-8-methoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)propan-2-ol,-   1-[({2-[(1R)-7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   (2S)-1-methoxy-3-[(2-oxo-2-{1(1S)-[2-(trifluoromethyl)benzyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol.

As another embodiment of compounds that are encompassed in the presentinvention, the following compounds may be mentioned.

-   1-({[3-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl]amino}methyl)cyclohexanol,-   (2R)-1-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,-   (2R)-1-[(2-oxo-2-{1-[2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,-   (2S)-1-{[2-(1-cyclohexyl-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}-3-methoxy    propan-2-ol,-   (2R)-1-({2-oxo-2-[(1S)-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}amino)propan-2-ol,-   1-[({2-[7-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-({[2-(1-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-[({2-[5-methoxy-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[1-(methoxymethyl)-6-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   (1S,2S)-2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}-1-phenylpropane-1,3-diol,-   1-({(2R)-2-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]pyrrolidin-1-yl}methyl)cyclohexanol,-   (2R)-1-{[2-(1-cyclohexyl-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,-   1-({[2-(3′,4′-dihydro-2′H-spiro[cyclohexane-1,1′-isoquinolin]-2′-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   (2R)-1-[(2-oxo-2-{1-[2-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,-   (2R)-1-{[2-(1-cyclohexyl-7-ethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,-   1-({[2-(6-fluoro-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1,1-dicyclopropyl-2-({2-[6-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)ethanol,-   1-({[2-(1-tert-butyl-8-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-({[2-(1-isopropyl-6-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-({[2-(6-fluoro-1-propyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-[({2-[1-(methoxymethyl)-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-({[2-(5-fluoro-1-propyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,-   1-[({2-[5-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[8-methoxy-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   1-[({2-[1-(ethoxymethyl)-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,-   (1R,2S)-2-({2-[(1R)-1-(2-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)cyclopentanol.

The compound of the present invention may in some cases exist in theform of other tautomers or geometrical isomers, depending on the kind ofthe substituents. In the present specification, the compound may bedescribed only in one form of isomers, and the present inventionincludes these isomers as well as isolated forms or mixtures thereof.

Further, the compound of the formula (I) may have asymmetric carbonatoms or axial asymmetries in some cases, and correspondingly, it mayexist in the form of optical isomers such as R- and S-forms. All of themixtures and isolates of these optical isomers are included in thepresent invention.

Further, a pharmaceutically acceptable prodrug of the compound of theformula (I) is also included in the present invention. The“pharmaceutically acceptable prodrug” is a compound having a group whichcan be converted into an amino group, a hydroxyl group, a carboxyl groupor the like of the present invention by solvolysis or under aphysiological condition. Examples of the group for forming a prodruginclude those as described for example in Prog. Med., 5, 2157-2161(1985) or “Iyakuhin no Kaihatsu (Development of Pharmaceuticals)”(Hirokawa Shoten Ltd., 1990), Vol. 7, “Bunshi Sekkei (MolecularDesign)”, pp. 163-198.

Further, the compound of the present invention may form an acid additionsalt or a salt with a base, depending on the kind of substituents, andthis salt is included in the present invention, as long as it is apharmaceutically acceptable salt. Specifically, examples of such saltsinclude acid addition salts with inorganic acids such as hydrochloricacid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, andphosphoric acid, or with organic acids such as formic acid, acetic acid,propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid,maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid,dibenzoyl tartaric acid, ditoluoyl tartaric acid, citric acid,methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid,p-toluenesulfonic acid, aspartic acid, and glutamic acid, salts withinorganic bases such as sodium, potassium, magnesium, calcium, andaluminum, or with organic bases such as methylamine, ethylamine,ethanolamine, lysine, and ornithine, salts with various amino acids andamino acid derivatives such as acetylleucine, ammonium salts, and thelike.

In addition, the present invention also includes various hydrates orsolvates, and crystalline polymorphs of the compound of the presentinvention and a pharmaceutically acceptable salt thereof. Further,compounds labeled with various radioactive or non-radioactive isotopesare also included in the present invention.

(Production Methods)

The compound of the present invention and a pharmaceutically acceptablesalt thereof can be prepared by applying various known syntheticmethods, making use of the characteristics based on its basic skeletonor type of substituents. In that case, depending on the kind offunctional groups, there is an effective case from the productiontechnology point of view to replace the functional group with anappropriate protecting group (a group which can be easily converted intothe functional group), at the stage of starting materials tointermediates. Examples of such a protecting group include thosedescribed for example in “Protective Groups in Organic Synthesis (3^(rd)edition, 1999)”, edited by Greene and Wuts, and the like, which may beappropriately selected and used depending on the reaction conditions.According to such a method, a desired compound can be obtained byintroducing the protecting group and carrying out the reaction, and thenremoving the protecting group, if desired.

In addition, the prodrug of the compound (I) can be produced in the samemanner as the case of the above-mentioned protecting groups, by carryingout the reaction after introducing a specific group at the stage ofstarting materials to intermediates or using the obtained compound ofthe present invention. The reaction can be carried out by employingmethods known to those skilled in the art, such as usual esterification,amidation, dehydration and the like.

Hereinafter, the representative production processes for the compound ofthe present invention will be described. Each of the productionprocesses may also be carried out with reference to References appendedto the corresponding description. Further, the production processes ofthe present invention are not limited to the examples as shown below.

(Production Process 1)

(In the formula, X represents a leaving group, and other symbols are asdefined above. The same shall apply hereinafter)

This production process is a method in which the compound (I) of thepresent invention is produced by reacting a compound (1a) having aleaving group with an amine derivative (1b).

In this case, examples of the leaving group include halogen,methanesulfonyloxy, and p-toluenesulfonyloxy.

The reaction can be carried out using the compound (1a) and the compound(1b) in equivalent amounts or one of them in an excess amount, fromunder cooling to under heating, for example, at 0° C. to 80° C. usuallystirring for 0.1 hour to 5 days, in a reaction-inert solvent or withouta solvent. There is no particular limit to the solvent that can be usedherein. Examples of such a solvent include aromatic hydrocarbons such asbenzene, toluene, and xylene; ethers such as diethyl ether,tetrahydrofuran (THF), dioxane, and dimethoxyethane (DME); halogenatedhydrocarbons such as dichloromethane (DCM), 1,2-dichloroethane (DCE),and chloroform; N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO),ethyl acetate, acetonitrile, and a mixture thereof. It may beadvantageous in some cases for smooth progress of the reaction to carryout the reaction in the presence of an organic base such astriethylamine, N,N-diisopropylethylamine (DIPEA),1,8-diazabicyclo[5.4.0]-7-undecene, or N-methylmorpholine, or aninorganic base such as potassium carbonate, sodium carbonate, cesiumcarbonate, or potassium hydroxide, or otherwise in the co-presence of aphase-transfer catalyst such as tetrabutylammonium iodide or18-crown-6-ether.

REFERENCE LITERATURE

-   S. R. Sandler and W. Karo, Editors, Organic Functional Group    Preparations, 2^(nd) edition. Vol. 1, Academic Press Inc., 1991-   Courses in Experiment Chemisty, 5^(th) edition, edited by The    Chemical Society of Japan, Vol. 14 (2005), Maruzen Co., Ltd.

(Production Process 2)

(the symbols in the formula are as defined above)

This production process is a method in which the compound (I-2) of thepresent invention is produced by reacting an acrylic derivative (2a)with the amine derivative (1b).

The reaction can be carried out using the compound (2a) and the compound(1b) in equivalent amounts or one of them in an excess amount, fromunder cooling to under heating, for example, at 0° C. to 120° C. usuallystirring for 0.1 hour to 5 days, in a reaction-inert solvent or withouta solvent. There is no particular limit to the solvent that can be usedherein. Examples of such a solvent include aromatic hydrocarbons,ethers, halogenated hydrocarbons, alcohols such as methanol, ethanol,and 2-propanol, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO),ethyl acetate, acetonitrile, and a mixture thereof. When the aminederivative is in the form of a salt, it may be advantageous in somecases for smooth progress of the reaction to carry out desalination inthe presence of an organic base such as triethylamine,N,N-diisopropylethylamine (DIPEA), 1,8-diazabicyclo[4.5.0]-7-undecene,or N-methylmorpholine, or an inorganic base such as potassium carbonate,sodium carbonate, or potassium hydroxide.

(Production Process 3)

(the symbols in the formula are as defined above)

This production process is a method in which the compound (I) of thepresent invention is produced by reacting a tetrahydroisoquinolinederivative (3a) with an amino acid derivative (3b).

The reaction can be carried out using the compound (3a) and the compound(3b) in equivalent amounts or one of them in an excess amount in thepresence of a condensing agent, from under cooling to under heating, forexample, at −20° C. to 60° C. usually stirring for 0.1 hour to 5 days,in a reaction-inert solvent. There is no particular limit to the solventthat can be used herein. Examples of such a solvent include aromatichydrocarbons, halogenated hydrocarbons, ethers, N,N-dimethylformamide(DMF), N-methylpyrrolidone, ethyl acetate, acetonitrile, water, and amixture thereof. Examples of the condensing agent include, but are notlimited to, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (WSC),dicyclohexylcarbodiimide (DCC), 1,1′-carbonyldiimidazole (CDI),diphenylphosphoryl azide, and phosphorus oxychloride. It may beadvantageous in some cases for smooth progress of the reaction to carryout the reaction using, for example, an additive such as1-hydroxybenzotriazole (HOBt).

Further, a method can also be used in which the amino acid derivative(3b) (with respect to a carboxyl group serving as a reaction site) isconverted into a reactive derivative thereof, and then the reactivederivative is reacted with the tetrahydroisoquinoline derivative (3a).In this case, examples of the reactive derivative include acid halidesobtained by reaction with a halogenating agent such as phosphorusoxychloride or thionyl chloride, mixed acid anhydrides obtained byreaction with isobutyl chloroformate or the like, and active estersobtained by condensation with HOBt or the like. The reaction between thereactive derivative of the compound (3b) and the compound (3a) can becarried out from under cooling to under heating, for example at −20° C.to 60° C., in a reaction-inert solvent such as halogenated hydrocarbons,aromatic hydrocarbons, or ethers.

REFERENCE LITERATURE

-   S. R. Sandler and W. Karo, Editors, Organic Functional Group    Preparations, 2^(nd) edition. Vol. 1, Academic Press Inc., 1991-   Courses in Experimental Chemistry, 5^(th) edition, edited by The    Chemical Society of Japan, Vol. 16 (2005), Maruzen Co., Ltd.

(Production Process 4)

(In the formula, Y represents a leaving group, and other symbols are asdefined above. The same shall apply hereinafter).

This production process is a method in which the compound (I) of thepresent invention is produced by reacting an amine derivative (4a) witha compound (4b) and/or (4c) having a leaving group.

The reaction can be carried out in the same manner as in ProductionProcess 1. When R²¹ represents —H, Step A using the compound (4b) may beomitted. Further, the order of performing Step A using the compound (4b)and Step B using the compound (4c) is not critical.

In addition to N-alkylation using the compound (4b) or (4c) having aleaving group, this production process may also employ N-alkylationusing an epoxy derivative corresponding to the compound (4b) or (4c),and reductive amination using an aldehyde derivative corresponding tothe compound (4b) or (4c).

The N-alkylation using the epoxy derivative corresponding to thecompound (4b) or (4c) can be carried out in the same manner as inProduction Process 1.

The reductive amination using the aldehyde derivative corresponding tothe compound (4b) or (4c) can be carried out using the compound (4a) andthe aldehyde derivative corresponding to the compound (4b) or (4c) inequivalent amounts or one of them in an excess amount, at −45° C. toheating under reflux in the presence of a reducing agent in areaction-inert solvent, for example, at 0° C. to room temperature,usually stirring for 0.1 hour to 5 days. There is no particular limit tothe solvent that can be used herein. Examples of such a solvent includealcohols, ethers, and a mixture thereof. Examples of the reducing agentinclude sodium cyanoborohydride, triacetoxy sodium borohydride, sodiumborohydride, and the like. It may be advantageous in some cases forsmooth progress of the reaction to carry out the reaction in thepresence of a dehydrating agent such as molecular sieves or an acid suchas acetic acid, hydrochloric acid, or titanium (IV) isopropoxidecomplex. Depending on the reaction, there is a case where an iminecompound may be formed by condensation of the compound (4a) with thealdehyde derivative corresponding to the compound (4b) or (4c) and thenmay be isolated as a stable intermediate. Further, the reaction may becarried out in a solvent such as alcohols or ethyl acetate, in thepresence or absence of an acid such as acetic acid or hydrochloric acid,using a reduction catalyst (such as Pd-supported carbon (Pd/C),palladium hydroxide, or Raney nickel), instead of treatment with thereducing agent. In this case, the reaction can be carried out from undercooling to under heating, under a hydrogen atmosphere at normal pressureto 50 atmospheres.

REFERENCE LITERATURE

-   A. R. Katritzky and R. J. K. Taylor, Editors, Comprehensive Organic    Functional Group Transformation II, Vol. 2, Elsevier Pergamon, 2005-   Courses in Experimental Chemistry, 5^(th) edition, edited by The    Chemical Society of Japan, Vol. 14 (2005), Maruzen Co., Ltd.

Further, the starting compound (4a) of this production process can beprepared by deprotection of the amine through the reaction of thecompound (1a) with the protected amine derivative in the same manner asin Production Process 1, or by deprotection of the amino group throughthe reaction of the compound (3a) with the amino-protected amino acidderivative in the same manner as in Production Process 3.

(Starting Material Synthesis)

(1) Production of Compounds (1a) and (2a)

(In the formula, Hal represents halogen, and other symbols are asdefined above. The same shall apply hereinafter).

This production process is a method in which the compound (2a) or (1a)is produced by reacting the tetrahydroisoquinoline derivative (3a) withan acid halide (5a) or (5b).

The reaction can be carried out using the compound (3a) and the compound(5a) or (5b) in equivalent amounts or one of them in an excess amount,from under cooling to under heating, for example, at 0° C. to 80° C.usually stirring for 0.1 hour to 5 days, in a reaction-inert solvent orwithout a solvent. There is no particular limit to the solvent that canbe used herein. Examples of such a solvent include aromatichydrocarbons, ethers, halogenated hydrocarbons, ethyl acetate,acetonitrile, and a mixture thereof. It may be advantageous in somecases for smooth progress of the reaction to carry out the reaction inthe presence of an organic base such as triethylamine,N,N-diisopropylethylamine (DIPEA), pyridine, or N-methylmorpholine, oran inorganic base such as potassium carbonate, sodium carbonate, sodiumhydrogen carbonate, or potassium hydroxide, or an aqueous solutionthereof, or in the presence of 0.01 to 0.2 equivalent amounts,preferably 0.05 to 0.15 equivalent amounts of a catalyst such asN,N-dimethylaminopyridine.

(2) Production of Compound (3a)-1

(In the formula, M is an alkali metal or alkaline earth metal andrepresents an anionic metal salt of R^(1b) showing nucleophilicity inthe form of R^(1b)-M, and other symbols are as defined above. The sameshall apply hereinafter.)

This production process is a method in which the compound (3a) isproduced by subjecting a phenethylamide derivative (6b) obtained byamidation of a phenethylamine derivative (6a) to a ring closure reactionusing a phosphoric acid derivative, or to a condensation reaction usingoxalyl chloride, followed by acid-catalyzed ring cleavage to obtain adihydroisoquinoline derivative (6d), and reduction of the compound (6d)or addition of a nucleophilic reagent to the compound (6d).

The amidation step of the compound (6a) can be carried out in the samemanner as in Production Process 3.

The ring closure step of the compound (6b) can be carried out bystirring the compound (6b) in a reaction-inert solvent or without asolvent, in the presence of a phosphoric acid derivative, usually for 1hour to 5 days. The reaction is typically carried out from under coolingto under heating, for example, from room temperature to heating underreflux. It may be advantageous in some cases to carry out the reactionin the absence of a solvent. The solvent, if used, is not particularlylimited, but examples thereof include high-boiling aromatic hydrocarbonssuch as toluene, and xylene. Examples of the phosphoric acid derivativeinclude diphosphorus pentoxide, a mixture of diphosphorus pentoxide andphosphorus oxychloride, polyphosphoric acid, ethyl polyphosphate, andthe like.

Alternatively, this step can be carried out in such a manner that anoxalyl chloride is reacted with the amide (6b) to construct a2-chlorooxazolone ring, the resulting product is subjected toring-closure condensation in the presence of a Lewis acid catalyst suchas iron chloride to obtain a6,10b-dihydro-5H-[1,3]isoxazolo[2,3-a]isoquinoline-2,3-dione derivative(6c), followed by solvolysis of the derivative (6c) in the presence of astrong acid such as sulfuric acid or using an alkali metal alkoxide suchas sodium methoxide to result in a compound (6d).

When R^(1b) is hydrogen, the compound (3a) wherein R^(1b) is hydrogencan be obtained by reduction of the compound (6d). The reaction iscarried out by treating the compound (6d) with an equivalent or excessamount of a reducing agent, from under cooling to under heating, forexample, at −20° C. to 80° C. usually for 0.1 hour to 3 days, in areaction-inert solvent. There is no particular limit to the solvent thatcan be used herein. Examples of such a solvent include ethers, alcohols,aromatic hydrocarbons, N,N-dimethylformamide (DMF), dimethylsulfoxide(DMSO), ethyl acetate, and a mixture thereof. Examples of the reducingagent include hydride reducing agents such as sodium borohydride,diisobutylaluminum hydride, and lithium aluminum hydride, metal reducingagents such as sodium, zinc, and iron, and other reducing agents asdescribed in the following literature.

REFERENCE LITERATURE

-   M. Hulicky, Reductions in Organic Chemistry, 2^(nd) ed (ACS    Monograph: 188), ACS, 1996-   R. C. Larock, Comprehensive Organic Transformations, 2^(nd) ed, VCH    Publishers, Inc., 1999-   T. J. Donohoe, Oxidation and Reduction in Organic Synthesis (Oxford    Chemistry Primers 6), Oxford Science Publications, 2000-   Courses in Experimental Chemistry, 5^(th) edition, edited by The    Chemical Society of Japan, Vol. 14 (2005), Maruzen Co., Ltd.

When R^(1b) represents a group other than hydrogen, it is possible tomake use of anionic addition by means of a nucleophilic reagent (6e) forthe compound (6d). The reaction can be carried out using the compound(6d) and the compound (6e) in equivalent amounts or one of them in anexcess amount, from under cooling to under heating, for example, at −78°C. to 0° C. usually stirring for 0.1 hour to 5 days, in a reaction-inertsolvent. There is no particular limit to the solvent that can be usedherein. Examples of such a solvent include ethers, aromatichydrocarbons, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), anda mixture thereof. For adjustment of the compound (6e), R^(1b)-magnesiumhalide, R^(1b)-lithium produced by the reaction of the correspondinghalide with magnesium is appropriately used.

In addition, positions of R^(1a) and R^(1b) in the formula may bechanged to each other.

(3) Production of Compound (3a)-2

(the symbols in the formula are as defined above)

This production process is a method in which the compound (3a-2) isproduced by reducing an acetonitrile derivative (7a).

The reaction can be carried out by stirring the compound (7a) in areaction-inert solvent under a hydrogen atmosphere, in the presence of ametal catalyst, usually for 1 hour to 5 days. The reaction is typicallycarried out from under cooling to under heating, for example at roomtemperature. There is no particular limit to the solvent that can beused herein. Examples of such a solvent include alcohols, ethers, water,ethyl acetate, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO) anda mixture thereof. Examples of the metal catalyst that can be preferablyused include palladium catalysts such as Pd-supported carbon (Pd/C),palladium black, and palladium hydroxide, platinum catalysts such asplatinum oxide, rhodium catalysts such as tetrakis triphenylphosphinechloro rhodium, Raney nickel, iron catalysts such as reduced iron, andthe like. Instead of using hydrogen gas, an equivalent or excess amountof formic acid or ammonium formate with regard to the compound (7a) mayalso be used as a hydrogen source.

REFERENCE LITERATURE

-   M. Hudlicky, Reductions in Organic Chemistry, 2nd ed (ACS    Monograph:188), ACS, 1996-   Courses in Experimental Chemistry, 5^(th) edition, edited by The    Chemical Society of Japan, Vol. 19 (2005), Maruzen Co., Ltd.

Further, R^(1a) in the formula may also be R^(1b).

(4) Production of Compound (3a)-3

(the symbols in the formula are as defined above)

This production process is a method in which the compound (3a) isproduced by condensation of the amine derivative (6a) with a ketone(8a).

The reaction can be carried out using the compound (6a) and the compound(8a) in equivalent amounts or one of them in an excess amount, in areaction-inert solvent or without a solvent, in the presence of adehydrating agent or a Lewis acid catalyst, from under cooling to underheating, for example, from room temperature to heating under reflux,usually stirring for 0.1 hour to 5 days. There is no particular limit tothe solvent that can be used herein. Examples of such a solvent includehalogenated hydrocarbons, ethers, and the like. It may be advantageousin some cases for smooth progress of the reaction to carry out thereaction in the presence of a strong acid such as formic acid-aceticanhydride, and trifluoroacetic acid. Examples of the dehydrating agentinclude acid anhydrides such as polyphosphoric acid, acetic anhydride,and trifluoroacetic anhydride. Examples of the Lewis acid catalystinclude titanium tetraisopropoxide and the like.

The compound of the present invention is isolated and purified as itsfree compound, or a pharmaceutically acceptable salt, hydrate, solvateor crystalline polymorph thereof. The pharmaceutically acceptable saltof the compound of the formula (I) can also be prepared in accordancewith a conventional method for a salt formation reaction.

Isolation and purification are carried out by employing common chemicaloperations such as extraction, fractional crystallization, and varioustypes of fraction chromatography.

Various isomers can be prepared by selecting an appropriate startingcompound, or can be separated by making use of the difference in thephysicochemical properties between isomers. For example, the opticalisomer can be derived into an optically pure isomer by means of generaloptical resolution methods (for example, fractional crystallization forinducing diastereomers with optically active bases or acids,chromatography using a chiral column, etc., and the like). In addition,the isomers can also be prepared from an appropriate optically activestarting compound.

The pharmacological activity of the compound of the present inventionwas confirmed by the following tests.

Test Example 1 Test of Compounds on Blockade of N-Type Ca²⁺ Channel

Culture of human fibroblasts (IMR-32 cells), and induction ofdifferentiation were carried out by a modification of the methoddescribed in the literature [Carbone et al., Pflugers Arch. Eur. J.Physiol., 416, 170-179 (1990)]. IMR-32 cells were subcultured in a MEM(Invitrogen Corporation, USA) containing 10% fetal bovine serum (FBS),1% non-essential amino acids, 1% sodium pyruvate, 100 μg/mLstreptomycin, and 100 U/mL penicillin. Upon induction of cellulardifferentiation, 1 mM dibutyryl cyclic adenine monophosphate (dbcAMP)and 2.5 μM 5-bromodeoxyuridine (BrdU) were added to the culture medium,and the cells were cultured for 10 to 11 days to result in expression ofthe human N-type Ca²⁺ channel.

The 10-11 day differentiation-induced IMR-32 cells were seeded at adensity of 6×10⁵ cells/well in a 96-well plate coated withpoly-D-lysine. After the cells were cultured in the culture medium for 3hours or more, Fluo-3 AM was added thereto, followed by incubation at37° C. for 60 minutes. The culture was washed in assay buffer (HBSS, 20mM HEPES, 2.5 mM probenecid, pH 7.4), to which a test compound solutionwas then added in the presence of 1 μM nitrendipine. After 10 minutes,elevation of an intracellular Ca²⁺ concentration induced by high K⁺stimulation with a 50 mM KCl solution was assayed using a FLIPR CalciumAssay Kit (Molecular Devices Corporation, USA). The blocking activity ofa test compound on the N-type Ca²⁺ channel was calculated as a relativevalue, by taking a maximum increase of an intracellular Ca²⁺concentration in the control group as 100%. Next, a concentration of thecompound (IC₅₀ value) which is required for 50% inhibition of anincrease in the intracellular Ca²⁺ concentration was calculated bynonlinear regression analysis.

As a result, the compounds of the present invention exhibited a blockingaction on the N-type Ca²⁺ channel. IC₅₀ values for several compounds ofthe present invention are given in Table 1 below. Abbreviation “Ex” inthe table represents Example No.

TABLE 1 Ex IC₅₀(μM) 1 1.0 2 0.75 117 1.4 121 0.87 134 2.0 157 2.1 1742.1 199 1.1 202 0.78 236 2.0 274 1.5 292 0.89 296 2.4 316 0.89 319 1.3330 1.4 379 1.2 386 1.9 409 1.3 415 2.1 429 1.1 433 2.0 435 1.4 436 1.4449 0.85 461 1.2 473 1.9 474 1.6 476 1.0 478 2.0 480 2.0 490 1.0 5040.62

Test Example 2 Effects of Compounds on Nociceptive Pain Model (FormalinTest)

A mouse formalin test was carried out by a modification of the method asdescribed in the literature [Murakami et al., Eur. J. Pharmacol. 419:175-181 (2001)]. When 20 μL of 2.0% formalin was subcutaneouslyadministered to the paw pads of mice (ddY, male, 5 weeks old), painbehaviors (limb withdrawal and licking behaviors) were induced in thetreated animal limbs. From 15 to 25 minutes after the administration offormalin, the time taken for the onset of pain behaviors was measured tothereby evaluate the inhibitory action of the test compound on painbehaviors of animals. The test compound was orally given 30 minutesprior to the administration of formalin. The evaluation of the testcompound was made from calculation of an inhibition rate (%) in the testcompound-treated group, by taking the time taken for the onset of painbehaviors in the vehicle-treated group as 100%.

Inhibition rate(%)=100−(mean onset time of pain behaviors in testcompound-treated group)/(mean onset time of pain behaviors invehicle-treated group)×100

As a result, the compounds of the present invention exhibited ananalgesic action on formalin-induced pain. Inhibition rates (%) ofseveral compounds of the present invention at a dose of 100 mg/kg aregiven in Table 2 below.

TABLE 2 Inhibition rate Ex (%) 1 52 157 52 415 95 433 60 436 55 575 77

Test Example 3 Effects of Compounds on Neuropathic Pain Model(Antiallodynic Effects in L5/L6 Spinal Nerve-Ligated Rats)

One of the major symptoms in neuropathic pain is a significantly reducedthreshold of response to tactile stimulation (allodynia). Theantiallodynic effects of the compounds of the present invention wereconfirmed by assessing the analgesic action in L5/L6 spinalnerve-ligated rats. The assessment was carried out by the method of Kimand Chung (Pain 50, 355-363, 1992) with some modifications.

Under pentobarbital anesthesia, the left L5 and L6 spinal nerves of maleSD rats (5-6 weeks old) were tightly ligated with silk thread. For theassessment of analgesic action, the von Frey hair test was adopted. Thatis, the animal's hind paw pad was pricked with hair and the loweststrength of hair for limb withdrawal response was designated as aresponse threshold (log gram) to mechanical stimulation. Since it wasconfirmed in preliminary tests that the response threshold of theanimal's hind paw ipsilateral to the side of ligation surgery wassignificantly low during days 7 to 14 after the surgery (in the state ofmechanical allodynia), the antiallodynic effects of the test compoundwere assessed on any day between days 7 and 14 after the surgery. On theday before the assessment of the test compound, the response thresholdbefore administration of the test compound was measured. The animalswere divided into 4 to 5 groups such that mean value differences ofresponse thresholds between groups before administration of the testcompound and within-group variation become small. In the assessment ofthe test compound, the response threshold after administration of thetest compound was measured. The test compound was orally administered 30to 60 minutes before the measurement of the response threshold. Theantiallodynic potency of the test compound was assessed as a recoveryrate (%) in the test compound-treated group, by taking the responsethresholds of ipsilateral and contralateral paws in the vehicle-treatedgroup as 0% and 100%, respectively.

Recovery rate(%)={(mean of response threshold in test compound-treatedgroup)−(mean of response threshold of ipsilateral paw in vehicle-treatedgroup)}/{(mean of response threshold of contralateral paw in thevehicle-treated group)−(mean of response threshold of ipsilateral paw inthe vehicle-treated group)}×100

As a result, the compounds of the present invention exhibited ananalgesic action on mechanical allodynia in the neuropathic pain model.Recovery rates (%) for groups with administration of several compoundsof the present invention are given in Table 3 below.

TABLE 3 Recovery rate (%) Ex (dose) 1 95 (30 mg/kg) 157 97 (30 mg/kg)415 100 (10 mg/kg) 433 80 (10 mg/kg) 436 156 (10 mg/kg) 575 83 (10mg/kg)

Test Example 4 Effects of Compounds on Abdominal Pain Model (Assay ofCRD-Induced Abdominal Pain in Rats)

In response to pressure stimulation caused by colorectal distension(CRD), IBS patients are known to exhibit a reduction of digestiveperception threshold (allodynia) which gives rise to discomfort againstweak stimulus that is not perceived by a normal person and hyperalgesiawhich leads to stronger subjective response to digestive perception thanin a normal person (Gastroenterol. 130: 1377-1390 (2006)), and suchconditions are believed to be responsible for abdominal symptoms.Improving effects of the compounds of the present invention on digestivetract pain were confirmed by assay of CRD-induced abdominal pain inrats. The rat CRD-induced abdominal pain assay was carried out by amodification of the method described in the literature[Neurogastroenterol. Motil. 15: 363-369 (2003)]. When stimulation ofconstant internal pressure is applied to the colorectum of an animal byinflation of a 6-cm long balloon inserted into the anus of the rat(Wistar, male, 250-350 g), abdominal flexion reflex behaviors areinduced due to abdominal pain. A frequency of reflex behaviors occurringduring distension stimulation of 5 minutes was counted to estimate anabdominal pain-inhibitory action of the test compound. The test compoundwas orally administered 30 minutes before the initiation of distensionstimulation. Estimation of the test compound was made by calculating aninhibition rate (%) of abdominal flexion reflex behaviors on thevehicle-treated group.

As a result, the compounds of the present invention exhibited anabdominal pain-inhibitory action. For several compounds of the presentinvention at a dose of 10 mg/kg, inhibition rates (%) of abdominalflexion reflex behaviors upon distension at an internal pressure of 45mmHg are given in Table 4 below.

TABLE 4 Inhibition rate Ex (%) 157 59 415 60 433 43 435 46 436 56 568 61

Test Example 5 Effects of Compounds on Spastic Constipation Model(Loperamide-Induced Colon Bead Transport Delay Test)

Generally, it is known that the onset of constipation in IBS-C is causedby spastic dysmotility of the digestive tract and is similar toopioid-induced constipation in terms of pathophysiology of the disease(Eur. J. Pharmacol. 75: 239-245 (1981), American J. Physiol. 96: 667-676(1931), Nippon Rinsho 64: 1461-1466 (2006)). An improving action of thecompounds of the present invention on spastic constipation was confirmedby a loperamide-induced colorectal bead transit delay test in mice. Themouse loperamide-induced colorectal bead transit delay test was carriedout by a modification of the method described in the literature [J.Smooth Muscle Res. 29:47-53 (1993)]. A 3-mm diameter glass bead isdeeply inserted at a depth of 2 cm into the anus of the mouse (ddY,male, 6 weeks old), and the time taken for excretion of the bead ismeasured. When 0.3 mg/kg of loperamide is subcutaneously administered 30minutes before the insertion of the bead, delay of bead excretion isinduced. With improving effects on the loperamide-induced bead transitdelay, a bowel movement-improving action of the test compound on spasticconstipation was evaluated. The test compound was orally administeredconcurrently with administration of loperamide (30 minutes before theinsertion of the bead). The assessment of the test compound was madefrom calculation of an improvement rate in the bead excretion time ofthe test compound-treated/loperamide-treated group, by taking the beadexcretion time of the non-test compound treated/non-loperamide treated(vehicle-treated/vehicle-treated) group as 100%, and by taking the beadexcretion time of the non-test compound treated/loperamide-treated(vehicle-treated/loperamide-treated) group as 0%.

As a result, the compounds of the present invention exhibited anopioid-induced constipation-improving action. For several compounds ofthe present invention at a dose of 3 mg/kg, improvement rates (%) in thebead excretion time are given in Table 5 below.

TABLE 5 Inhibition rate Ex (%) 157 40 415 88 433 73 435 67 436 59 568 83

Test Example 6 Effects of Compounds in Combined Use with Morphine (1)

Morphine has potent analgesic effects on nociceptive pain through μopioid receptors. For example, morphine exhibits dose-dependentanalgesic effects in a formalin test which is a nociceptive pain model(Pharmacol. Biochem. Behav. 84: 479-486 (2006)). Meanwhile, it is knownthat a selective N-type Ca²⁺ channel-blocking peptide, ω-conotoxin(ω-CTx) also independently exhibits dose-dependent analgesic effects inthe formalin test, and its combined use with morphine enhances analgesiceffects over those obtained by single use of morphine (add-on effects)(Pain 84: 271-281 (2000)). Therefore, it can be confirmed that when thecompounds of the present invention having an N-type Ca²⁺channel-blocking action were used in combination with morphine in theformalin test, a potent antinociceptive pain action comparable to orhigher than single administration of morphine or single administrationof the compound of the present invention is achieved.

Test Example 7 Effects of Compounds in Combined Use with Morphine (2)

It is known that mechanical allodynia observed in L5/L6 spinalnerve-ligated rats exhibits only a partial recovery with treatment ofmorphine. On the other hand, as described hereinbefore, the compounds ofthe present invention exhibit almost 100% recovery effects on mechanicalallodynia in L5/L6 spinal nerve-ligated rats. Therefore, when thecompounds of the present invention were used in combination withmorphine, a potent antineuropathic pain action comparable to or higherthan single administration of morphine or single administration of thecompounds of the present invention can be confirmed by testing theirantiallodynic effects in L5/L6 spinal nerve-ligated rats.

Test Example 8 Effects of Compounds in Combined Use with Morphine (3)

Morphine is a μ opioid receptor agonist having the same action mechanismas loperamide, and has a delay action on colon bead transport in mice,similar to loperamide. Upon administering a dose of morphine whichexhibits an abdominal pain-inhibitory action in the rat CRD-inducedabdominal pain assay and exhibits a transit delay action in the mousecolorectal bead transit test, and a dose of the test compound whichimproves the bead transit delay caused by the above-defined dose ofmorphine, it can be confirmed that such combined use exhibits a potentabdominal pain-inhibitory action comparable to or higher than singleadministration of morphine in the rat CRD-induced abdominal pain assay,and also has an inhibitory action on morphine-induced transit delay inthe bead transit test.

Alternatively, upon administering the test compound with a low dose ofmorphine at which an abdominal pain-inhibitory action is insufficient inthe rat CRD-induced abdominal pain assay, but a delay action is notrecognized in the mouse colon bead transit test, a sufficient abdominalpain-inhibitory action which was not obtained by a low dose of morphinealone can be confirmed.

From the experimental results as described above, it was confirmed thatthe compounds of the present invention have an N-type Ca²⁺channel-blocking action. Therefore, it is clear that the compounds ofthe present invention are useful as an active ingredient of apharmaceutical composition for preventing and/or treating various painssuch as neuropathic pain and nociceptive pain, headaches such asmigraine and cluster headache, central nervous system diseases such asanxiety, depression, epilepsy, cerebral stroke and restless legssyndrome, digestive system diseases such as abdominal pain and irritablebowel syndrome, and urinary system diseases such as overactive bladderand interstitial cystitis.

From the results of the formalin test as described above, it wasconfirmed that the compounds of the present invention have anantinociceptive pain action. In addition, from the test results ofantiallodynic effects in L5/L6 spinal nerve-ligated rats, it wasconfirmed that the compounds of the present invention have anantineuropathic pain action. Upon considering these facts, it is clearthat the compounds of the present invention are useful as an activeingredient of a pharmaceutical composition for preventing and/ortreating various pains including neuropathic pain and nociceptive pain.Further, it is clinically demonstrated that pregabalin, which is a Ca²⁺channel α2δ subunit ligand and is used as an antineuropathic pain agent,exhibits therapeutic effects on fibromyalgia syndrome having a lot incommon with neuropathic pain, in terms of clinical condition. Based onthis point, it can be considered that the compounds of the presentinvention are also useful as an active ingredient of a pharmaceuticalcomposition for preventing and/or treating fibromyalgia syndrome.

From the results of the rat CRD-induced abdominal pain assay asdescribed above, it was demonstrated that the compounds of the presentinvention have an abdominal pain-inhibitory action. Therefore, it isclear that the compounds of the present invention are useful as anactive ingredient of a pharmaceutical composition for preventing and/ortreating abdominal symptoms, particularly abdominal symptoms of IBS.

From the results of the mouse loperamide-induced colorectal bead transitdelay test, it was demonstrated that the compounds of the presentinvention have an opioid-induced constipation-improving action. Based onthis fact, it is clear that the compounds of the present invention areuseful as an active ingredient of a pharmaceutical composition forpreventing and/or treating spastic constipation, particularlyconstipation in OBD. In addition, from the fact that constipation inIBS-C is spastic constipation, similar to constipation caused byopioids, it is clear that the compounds of the present invention arealso useful as an active ingredient of a pharmaceutical composition forpreventing and/or treating constipation in IBS-C.

From the fact demonstrating that the compounds of the present inventionare effective in both of the rat CRD-induced abdominal pain assay andthe mouse loperamide-induced colorectal bead transit delay test, it isclear that the compounds of the present invention are also useful as anactive ingredient of an excellent pharmaceutical composition forpreventing and/or treating IBS-C, having a combination of an abdominalsymptom-improving action and a constipation-improving action.

It is known that use of a selective N-type Ca²⁺ channel-blockingpeptide, ω-conotoxin (ω-CTx) in combination with morphine enhancesanalgesic effects over those obtained by use of morphine alone (add-oneffects) (Pain 84: 271-281 (2000), Life Science 73: 2873-2881 (2003)).Therefore, it can be expected that combined use of the compounds of thepresent invention and opioids results in an excellent pharmaceuticalcomposition for preventing and/or treating pain, which exerts morepotent analgesic effects than single use of opioids.

Opioids are used as a therapeutic agent for severe pain such as cancerpain, but suffer from clinical problems associated with dose-dependentside effects on the digestive system, such as vomiting or constipation(Eur. J. Pharmaceutical Sci. 20: 357-363 (2003)). The compounds of thepresent invention exhibit excellent improving effects on opioid-inducedconstipation (OIC). Based on this fact, it can be expected that thecompounds of the present invention in combined use with opioids wouldresult in a pharmaceutical composition for preventing and/or treatingpain, which inhibits opioid-induced constipation with less side effects.In addition, it can be expected that combined use of the compounds ofthe present invention and a low dose of opioids would result in anexcellent pharmaceutical composition for preventing and/or treatingpain, which is capable of exerting sufficient analgesic effects whilereducing a dose of opioids and which is also capable of decreasing theonset of constipation through a reduction of the opioid dose.

A preparation containing one or two or more kinds of the compound of theformula (I) or a pharmaceutically acceptable salt thereof as an activeingredient can be prepared in accordance with a generally used method,using a pharmaceutically acceptable carrier, excipient, or the like,that is usually used in the art.

The administration can be carried out by oral administration viatablets, pills, capsules, granules, powders, liquid preparations, or thelike, or parenteral administration via injections such as intraarticularinjection, intravenous injection, intramuscular injection, or the like,as well as suppositories, eye drops, eye ointments, percutaneous liquidpreparations, ointments, percutaneous patches, transmucosal liquidpreparations, transmucosal patches, inhalations, and the like.

As solid compositions for oral administration according to the presentinvention, tablets, powders, granules, or the like are used. In such asolid composition, one or two or more kinds of active ingredients aremixed with at least one inert excipient such as lactose, mannitol,glucose, hydroxypropylcellulose, microcrystalline cellulose, starch,polyvinyl pyrrolidone, and/or magnesium aluminometasilicate. Accordingto a conventional method, the composition may contain inert additivessuch as a lubricant such as magnesium stearate, a disintegrator such ascarboxymethyl starch sodium, a stabilizing agent, and a solubilizingaid. As occasion demands, the tablets or the pills may be coated with afilm of a sugar coating, or a gastric or enteric coating agent.

Liquid compositions for oral administration include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, elixirs, or thelike, and contain a generally used inert diluent such as purified wateror ethanol. In addition to the inert diluent, the liquid composition maycontain an adjuvant such as a solubilizing agent, a moistening agent,and a suspending agent, a sweetener, a flavor, an aromatic, and apreservative.

Injections for parenteral administration include sterile aqueous ornon-aqueous solutions, suspensions and emulsions. The aqueous solventincludes, for example, distilled water for injection and physiologicalsaline. Examples of the non-aqueous solvent include propylene glycol,polyethylene glycol, vegetable oils such as olive oil, alcohols such asethanol, Polysorbate 80 (Japanese Pharmacopeia), and the like. Such acomposition may further contain a tonicity agent, a preservative, amoistening agent, an emulsifying agent, a dispersing agent, astabilizing agent, or a solubilizing aid. These are sterilized, forexample, by filtration through a bacteria-retaining filter,incorporation of a sterilizing agent, or irradiation. In addition, thesecan also be used by preparing a sterile solid composition, anddissolving or suspending it in sterile water or a sterile solvent forinjection prior to its use.

External preparations include ointments, plasters, creams, jellies,adhesive skin patches, sprays, lotions, eye drops, eye ointments, andthe like. The external preparation contains generally used ointmentbases, lotion bases, aqueous or non-aqueous liquids, suspensions,emulsions, and the like. Examples of the ointment or lotion basesinclude polyethylene glycol, propylene glycol, white Vaseline, whitebeeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate,stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate,and the like.

Transmucosal preparations such as inhalations and transnasalpreparations are used in a solid, liquid or semi-solid form and may beprepared in accordance with a conventionally known method. For example,a known excipient, and also a pH-adjusting agent, a preservative, asurfactant, a lubricant, a stabilizing agent, a thickening agent, or thelike may be appropriately added thereto. For their administration, anappropriate device for inhalation or blowing may be used. For example, acompound may be administered alone or as a powder of formulated mixture,or as a solution or suspension in combination with a pharmaceuticallyacceptable carrier, using a conventionally known device or sprayer, suchas a measured administration inhalation device. The dry powder inhaleror the like may be for single or multiple administration use, and a drypowder or a powder-containing capsule may be used. Alternatively, it maybe in a form such as a pressurized aerosol spray or the like which usesan appropriate propellant, for example, a suitable gas such aschlorofluoroalkane, hydrofluoroalkane, or carbon dioxide.

In oral administration, the daily dose is generally from about 0.001 to100 mg/kg, preferably from 0.1 to 30 mg/kg, and more preferably 0.1 to10 mg/kg, per body weight, administered in one portion or in 2 to 4divided portions. In the case of intravenous administration, the dailydose is suitably administered from about 0.0001 to 10 mg/kg per bodyweight, once a day or two or more times a day. In addition, atransmucosal agent is administered at a dose from about 0.001 to 100mg/kg per body weight, once a day or two or more times a day. The doseis appropriately decided in response to the individual case by takingthe symptoms, the age, and the gender, and the like into consideration.

The compounds of the present invention can be used in combination withvarious agents for treating or preventing the diseases for which thecompounds of the present invention are considered to be effective.Examples of the drugs that can be used in combination with the compoundsof the present invention include opioids such as morphine,antidepressants such as duloxetine and amitriptylin, antiepileptic drugssuch as pregabalin and mexiletine, non-steroidal anti-inflammatory drugssuch as diclofenac, and the like. For this combined use, the compoundsof the present invention are formulated into appropriate dosage formssuch as liquid preparations, capsules, granules, pills, powders,tablets, external preparations, jellies, sprays, patches, suppositories,and self-contained implantable pumps, and the combined preparation maybe administered simultaneously, or separately and continuously, or at adesired time interval, via an oral, transvenous, percutaneous,transnasal, enteral, spinal epidural, or spinal subarachnoid route. Thepreparations to be co-administered may be a blend, or may be preparedindividually.

Examples

Hereinafter, production processes of the compound of the presentinvention will be described in more detail with reference to Examples.The present invention is not limited to the following Examples. Inaddition, production processes of starting compounds are shown inProduction Examples. The production processes of the compound of thepresent invention are not limited to the production processes of thespecific Examples as described below. The compound of the presentinvention may be produced in accordance with a combination of theseproduction processes or in accordance with a method obvious to a personskilled in the art.

As for Examples, Production Examples and Tables described below, thefollowing abbreviations will be used.

Rex: Production Example number, Ex: Example number, No: compound number,STRUCTURE: structural formula, Data: physicochemical data (FAB:FAB-MS[M+H]⁺, FAN: FAB-MS[M−H]⁻, FA1: FAB-MS[M]⁺, FA2: FAB-MS[M+2H]⁺,ES: ESI-MS[M+H]⁺, ES1: ESI-MS[M]⁺, ES2: ESI-MS[M+2H]⁺, ESNa:ESI-MS[M+Na]⁺, AP: APCI-MS[M+H]⁺, API: APCI-MS[M]⁺, CI: CI[M+H]⁺, CIN:CI[M−H]⁻, CI1: CI[M]⁺, EI: EI[M+H]⁺, EIN: EI[M−H]⁻, EI1: EI[M]⁺, EIBr:EI[M−Br]⁻, NMR: δ (ppm) of peak of ¹H-NMR in DMSO-d₆), N/D: notdetermined, salt: salt (with blank column or no column: it representsthat the compound is a free form), CL: hydrochloride, BR: hydrobromate,OX: oxalate, FM: fumarate, MD: D-mandelate, ML: L-mandelic acid, LL:N-acetyl-L-leucine salt, T1: L-tartrate, T2: D-tartrate, TX:dibenzoyl-D-tartrate, TY: dibenzoyl-L-tartrate, TP:diparatoluoyl-D-tartrate, TQ: diparatoluoyl-L-tartrate, MA: L-malicacid, MB: D-malic acid), Me: methyl, Et: ethyl, nPr: normal propyl, iPr:isopropyl, tBu: tert-butyl, cPr: cyclopropyl, cBu: cyclobutyl, cPen:cyclopentyl, cHex: cyclohexyl, Admt: adamantyl, Ph: phenyl, Bn: benzyl,Thp: tetrahydropyranyl, pipe: piperidinyl, pipa: piperadinyl, CN: cyano,boc: tert-butyloxycarbonyl, Ac: acetyl, MOM: methoxymethyl, TMS:trimethylsilyl, di: di, THF: tetrahydrofuran, DMF:N,N-dimethylformamide, DMSO: dimethyl sulfoxide. The numeral before thesubstituent represents a substitution position, and for example,6-Cl-2-Py represents 6-chloropyridin-2-yl and 3,3-diF-cHex represents3,3-difluorocyclohexyl. Rsyn and Syn: Production method (the numeralsindicate that the compounds were produced using the correspondingstarting materials, with the method similar to the case of compoundsrespectively having the numerals as the production example numbers orExample numbers). In addition, among the compounds of ProductionExamples or Examples in Tables, for the compound in which aconfiguration of a substituent at the 1-position oftetrahydroisoquinoline is not determined but a single configuration isshown in any sides, the configuration in any sides is labeled and thenthe Production Example number or the Example number is given *. On theother hand, for the compound in which a configuration of a substituentat the 1-position of tetrahydroisoquinoline is determined or thecompound in which the configuration is reasonably analogized on thebasis of behavior in chiral column chromatography or activity behaviorin N-type Ca²⁺-blocking test, the configuration is only labeled.

In addition, the compound in which the same number is given subsequentto * represents that the compound is produced using a compound, to whichthe same number is given and in which a configuration of a substituentat the 1-position of tetrahydroisoquinoline is not determined but asingle configuration is labeled in any sides, as a starting material.

Production Example 1

N-(2-cyclohexa-1-en-1-ylethyl)-2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethanamine(431 mg) was dissolved in chloroform (12 mL), and trifluoroaceticanhydride (0.3 mL) was added thereto under ice-cooling, followed bystirring at room temperature for 10 hours and then stirring at 60° C.for 2 hours. The solvent was evaporated, and saturated aqueous sodiumbicarbonate was added to the reaction liquid which was then extractedwith chloroform. The reaction liquid was washed with saturated brine anddried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(chloroform) to obtainN-(2-cyclohexa-1-en-1-ylethyl)-N-[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-2,2,2-trifluoroacetamide(419 mg).

Production Example 2

N-(2-cyclohexa-1-en-1-ylethyl)-N-[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-2,2,2-trifluoroacetamide(408 mg) was dissolved in a 3:1 mixture (8 mL) of acetone-water. To thereaction liquid were added 4-methylmorpholine 4-oxide (200 mg) and asolution of 2.5% osmium tetroxide in tert-butyl alcohol (2.68 mL),followed by stirring at room temperature for 18 hours. Then, thereaction solvent was evaporated under reduced pressure, and water wasadded to the reaction liquid, followed by extraction with chloroform.The extract was washed with saturated brine and dried over magnesiumsulfate. The solvent was evaporated and the resulting residue waspurified by silica gel column chromatography (chloroform-MeOH) to obtainN-[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-N-{2-[cis-1,2-dihydroxycyclohexyl]ethyl}-2,2,2-trifluoroacetamide(276 mg).

Production Example 3

2-(chloroacetyl)-1-cyclohexyl-7-methoxy-1,2,3,4-tetrahydroisoquinoline(700 mg) was dissolved in acetonitrile (15 mL), to which potassiumcarbonate (2.1 g), 2-cyclopenta-1-en-1-lyethanamine hydrochloride (1.6g), and tetra-n-butylammonium iodide (80 mg) were then added, followedby stirring at 70° C. for 5 hours. Thereafter, the solvent wasevaporated, and water was added to the reaction liquid, followed byextraction with EtOAc. The extract was washed with saturated brine anddried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(chloroform-MeOH).

The resulting compound was dissolved in chloroform (10 mL) andtrifluoroacetic anhydride (0.34 mL) was added thereto, followed bystirring at room temperature for 14 hours. Then, the solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtainN-[2-(1-cyclohexyl-7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-N-(2-cyclopenta-1-en-1-ylethyl)-2,2,2-trifluoroacetamide(450 mg).

Production Example 4

(1R)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (L)-tartrate (520 mg)was dissolved in EtOAc (10 mL) and saturated aqueous sodium bicarbonate(10 mL) was added thereto. Under ice-cooling, a solution of chloroacetylchloride (0.14 mL) in EtOAc (5 mL) was added dropwise to the reactionliquid over 5 minutes, followed by stirring at room temperature for 1hour. The reaction liquid was extracted with EtOAc and dried overmagnesium sulfate to obtain(1R)-2-(chloroacetyl)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (415mg).

Production Example 5

7-chloro-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (899mg) was added to saturated aqueous sodium bicarbonate (15 mL), to whichEtOAc (10 mL) was then further added. A solution of chloroacetylchloride (390 mg) in EtOAc (5 mL) was added dropwise to the reactionliquid over 5 minutes. The reaction liquid was stirred for 1 hour,extracted with EtOAc, and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain7-chloro-2-(chloroacetyl)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline(888 mg).

Production Example 6

A mixture of chloroacetyl chloride (1.03 g) and EtOAc (5 mL) was addeddropwise with stirring to a mixture of(1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline (1.58 g), sodium hydrogencarbonate (960 mg), water (25 mL) and EtOAc (25 mL), followed bystirring at room temperature for 2 hours. The reaction liquid wasextracted with EtOAc, and the extract was washed sequentially withsaturated aqueous sodium bicarbonate and saturated brine, dried overmagnesium sulfate, and concentrated under reduced pressure. Theresulting residue was purified by silica gel column (hexane-AcOEt, 4:1)to obtain (1S)-2-(chloroacetyl)-1-phenyl-1,2,3,4-tetrahydroisoquinoline(2.14 g).

Production Example 7

1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (800 mg) wasdissolved in methylene chloride (12 mL), to which triethylamine (1.1 mL)and acryloyl chloride (0.28 mL) were then added under ice-cooling,followed by stirring under ice-cooling for 30 minutes and then stirringat room temperature for 14 hours. Water was added to the reaction liquidwhich was then extracted with chloroform. The extract was washed withsaturated brine and dried over magnesium sulfate. The solvent wasevaporated to obtain2-acryloyl-1-cyclohexyll-1,2,3,4-tetrahydroisoquinoline (856 mg).

Production Example 8

1-benzyl-4-hydroxypiperidine-4-carboxylic acid (951 mg) was dissolved inDMF (25 mL), and N,N′-carbonyldiimidazole (720 mg) was added thereto,followed by stirring at room temperature for 18 hours. Thereafter,N,N-diisopropylethylamine (784 mg) and1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.22 g) wereadded to the reaction liquid, followed by stirring at 60° C. for 18hours. The solvent was evaporated, and water and EtOAc were added to thereaction liquid. The resulting insoluble materials were separatedthrough celite, extracted with EtOAc and dried over magnesium sulfate,and the solvent was evaporated. The resulting residue was purified bysilica gel column chromatography (chloroform-MeOH) and dissolved in1,4-dioxane (12 mL), and di-tert-butyl dicarbonate (1.3 g) was addedthereto, followed by stirring at room temperature for 1 hour. Thesolvent was evaporated and the resulting residue was purified by silicagel column chromatography (hexane-EtOAc and then chloroform-MeOH) toobtain1-benzyl-4-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-4-ol(115 mg).

Production Example 9

1-benzyl-4-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-4-ol(220 mg) was dissolved in MeOH (12 mL), and 20% palladiumhydroxide-supported activated carbon (360 mg) was added thereto,followed by stirring under a hydrogen atmosphere, at room temperatureand normal pressure, for 15 hours. Thereafter, the catalyst wasseparated through celite. The solvent was evaporated to obtain4-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-4-ol(154 mg).

Production Example 10

N-methylmorpholine (0.873 mL) was added to a solution of1-(tert-butoxycarbonyl)-L-proline (1.28 g) in 1,2-dichloroethane (10 mL)under ice-cooling, followed by further addition of pivaloyl chloride(0.734 mL). The reaction liquid was stirred for 1 hour, andN-methylmorpholine (1.09 mL) and1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.00 g) werethen added thereto. The mixture was stirred at room temperature for 15hours. To the reaction solution were added EtOAc and an aqueous 1 M HClsolution. The organic layer was washed with water, a saturated aqueoussodium hydrogen carbonate solution, and saturated brine, dried overmagnesium sulfate, and filtered. The filtrate was concentrated underreduced pressure to obtain tert-butyl(2S)-2-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]pyrrolidine-1-carboxylate(1.79 g).

Production Example 11

1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.00 g) wasdissolved in methylene chloride (20 mL), and pivaloyl chloride (0.98 mL)and 4-methylmorpholine (2.2 mL) were added thereto under ice-cooling.The reaction liquid was stirred at room temperature for 30 minutes andthen ice-cooled, and [(tert-butoxycarbonyl)amino]acetic acid (1.54 g)was added thereto. The reaction liquid was stirred at room temperaturefor 14 hours and then water was added thereto, followed by extractionwith chloroform. The extract was washed with saturated brine, and thendried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(chloroform-MeOH) to obtain tert-butyl[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]carbamate(1.49 g).

Production Example 12

4 M HCl/EtOAc (4 mL) was added to a solution of tert-butyl(2S)-2-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]pyrrolidine-1-carboxylate(1.79 g) in EtOAc (4 mL). The mixture was stirred at room temperaturefor 5 hours. The solvent was evaporated under reduced pressure, andchloroform and a saturated aqueous sodium hydrogen carbonate solutionwere added to the residue. The organic layer was washed with saturatedbrine, dried over magnesium sulfate, filtered, and concentrated toobtain 1-cyclohexyl-2-L-prolyl-1,2,3,4-tetrahydroisoquinoline (1.26 g).

Production Example 13

Tert-butyl[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]carbamate(1.5 g) was dissolved in EtOAc (20 mL), and 4 M HCl/EtOAc (3 mL) wasadded thereto under ice-cooling, followed by stirring at 50° C. for 5hours. Then, the reaction solvent was evaporated. Saturated aqueoussodium bicarbonate was added to the reaction liquid which was thenextracted with chloroform. The extract was washed with saturated brineand dried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(chloroform-MeOH) to obtain2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethanamine (1.09g).

Production Example 14

2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethanamine (695mg) was dissolved in methylene chloride (12 mL), and titaniumtetraisopropoxide (1.1 mL) and 1-cyclohexene-1-carboaldehyde (309 mg)were added thereto, followed by stirring at room temperature for 3hours. Thereafter, the solvent was evaporated, and MeOH (15 mL) and thensodium cyanotrihydroborate (190 mg) were added to the mixture, followedby stirring for 14 hours. The solvent was evaporated, and water andEtOAc were added to the mixture. The mixture was filtered through celiteand extracted with EtOAc. The extract was washed with saturated brineand then dried over magnesium sulfate. The solvent was evaporated andthe resulting residue was purified by silica gel column chromatography(chloroform-MeOH) to obtainN-(cyclohexa-1-en-1-ylmethyl)-2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethanamine(585 mg).

The resulting compound (525 mg) was dissolved in 1,4-dioxane (10 mL),and di-tert-butyl dicarbonate (312 mg) was added thereto, followed bystirring at room temperature for 4 hours. The solvent was evaporated andthe resulting residue was purified by silica gel column chromatography(hexane-EtOAc) to obtain tert-butylN-(cyclohexa-1-en-1-ylmethyl)-N-[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]carbamate(564 mg).

Production Example 15

Chloroacetyl chloride (0.151 mL) was added to a solution of1,1-diphenyl-1,2,3,4-tetrahydroisoquinoline (339 mg) andp-toluenesulfonate monohydrate (11.3 mg) in toluene (5 mL). The mixturewas heated under reflux for 3 hours. The solvent was evaporated underreduced pressure, and EtOAc and an aqueous 1 M HCl solution were addedto the residue. The organic layer was washed with water, a saturatedaqueous sodium hydrogen carbonate solution, and saturated brine, driedover magnesium sulfate, and filtered. The filtrate was concentratedunder reduced pressure to obtain2-(chloroacetyl)-1,1-diphenyl-1,2,3,4-tetrahydroisoquinoline (452 mg).

Production Example 16

10% Pd-supported carbon (900 mg) was added to a solution of2-benzyl-1,1-diphenyl-1,2,3,4-tetrahydroisoquinoline (1.81 g) in a 2:1THF-MeOH mixture (30 mL). The mixture was stirred under a hydrogenatmosphere at room temperature for 16 hours. Further, 10% Pd-supportedcarbon (900 mg) was added to the mixture, followed by stirring for 8hours. The reaction mixture was filtered through celite, and thefiltrate was concentrated under reduced pressure. The residue waspurified by silica gel column chromatography (hexane-EtOAc) to obtain1,1-diphenyl-1,2,3,4-tetrahydroisoquinoline (339 mg).

Production Example 17

In an ice bath under argon flow, a solution of 1.07 M phenylmagnesiumbromide in THF (33.2 mL) was added dropwise to a solution of2-benzyl-1-phenyl-3,4-dihydroisoquinoline hydrobromate (8.95 g) in THF(80 mL) over 1 hour. The mixture was stirred at room temperature for 1hour. A saturated aqueous ammonium chloride solution was added to themixture which was then extracted with EtOAc. The extract was washed withwater and saturated brine, dried over magnesium sulfate, and filtered.The filtrate was concentrated under reduced pressure, and the resultingresidue was purified by silica gel column chromatography (hexane-EtOAc)to obtain 2-benzyl-1,1-diphenyl-1,2,3,4-tetrahydroisoquinoline (1.81 g).

Production Example 18

Sodium borohydride (450 mg) was added with stirring to a solution of6,8-dimethoxy-1-phenyl-3,4-dihydroisoquinoline (1.96 g) in EtOH (50 mL)over 5 minutes. The reaction mixture was stirred at room temperature for2 hours and then further stirred at 60° C. for 1.5 hours. The reactionmixture was cooled to room temperature and concentrated under reducedpressure. An aqueous 3 M HCl solution (60 mL) was added to the resultingresidue, followed by heating under reflux for 3 minutes. After cooling,an aqueous 20% NaOH solution was added to the mixture to have strongalkalinity, followed by extraction with chloroform. The organic layerwas washed with saturated brine, dried over magnesium sulfate, andconcentrated under reduced pressure to obtain6,8-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline (1.88 g).

Production Example 19

1-cyclohexyl-6-methyl-3,4-dihydroisoquinoline (4.84 g) was dissolved inMeOH (100 mL), and then sodium borohydride (966 mg) was added thereto,followed by stirring at room temperature for 3 hours. The solvent wasevaporated under reduced pressure. Water was added to the reactionmixture which was then extracted with chloroform. The extract was driedover magnesium sulfate, and the solvent was evaporated under reducedpressure.

The resulting residue was dissolved in EtOAc (100 mL), and a 4 MHCl/EtOAc solution (8 mL) was added thereto under ice-cooling, followedby stirring at room temperature. The resulting insoluble materials werecollected and washed with EtOAc to obtain1-cyclohexyl-6-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (3.6g).

Production Example 20

Potassium carbonate (92 g) and water (500 mL) were added to1-isopropyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (86g). The reaction mixture was extracted with EtOAc and dried overmagnesium sulfate, and then the solvent was evaporated. To the resultingresidue were added iPrOH (1100 mL) and (+)-mandelic acid (50 g),followed by stirring under heating at 95° C. for dissolution. Themixture was left to cool and stirred at room temperature overnight. Theresulting solid was collected and repeatedly recrystallized three timesusing iPrOH to obtain1-isopropyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline (+)-mandelate (43g) as a single enantiomer.

Production Example 21

1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (31.1 g) was dissolved inEtOH (1.26 L) at 80° C., and (D)-tartaric acid (10.83 g) was then addedthereto. The reaction mixture was left to cool and stirred at roomtemperature overnight. The resulting insoluble materials (16.64 g) werecollected and dried.

The solid was mixed with a solid obtained in the same manner asmentioned above, and the mixture (33.26 g) was dissolved in EtOH (1 L),followed by stirring under heating at reflux for 2 hours and thenstirring at 80° C. for 5 hours. The mixture was stirred at roomtemperature overnight and then the insoluble materials were collected toobtain (1S)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (D)-tartrate(30.8 g).

Production Example 22

Under an argon atmosphere, a 1.0 M borane-THF complex solution (110 mL)was added to a mixture of (1R,2S)-1-amino-2-indanol (8.17 g) and diethylether (200 mL) under stirring at an internal temperature of 5° C. orlower. The mixture was further stirred at room temperature for 1.5hours. The mixture was cooled to an internal temperature of 4° C.1-(2-methoxyphenyl)-3,4-dihydroisoquinoline (10 g) was gradually addedto the mixture at an internal temperature of 5° C. or lower, followed bystirring at the same temperature for 30 minutes. The mixture was stirredat room temperature for 3 days. Trifluoroacetic acid (61 mL) was addedto the reaction mixture to decompose an excess of reagent, furtherfollowed by heating under reflux for 3 hours. After cooling, diethylether was evaporated under reduced pressure and the mixture was heatedunder reflux for 10 minutes. The residue was diluted with chloroform andextracted with concentrated aqueous ammonia to be alkaline. The organiclayer was washed with saturated brine, dried over magnesium sulfate, andconcentrated under reduced pressure. The resulting residue was purifiedby silica gel column chromatography (chloroform-EtOH-aqueous ammonia) toobtain 1-(2-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (8.23 g).

1-(2-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (8.227 g) and(2S,3S)-2,3-bis[(4-methybenzoyl)oxy]succinic acid (13.282 g) weredissolved with stirring in acetonitrile (246 mL) at 70° C. The mixturewas slowly cooled with stirring. The resulting crystal was collected byfiltration, washed with acetonitrile, and dried under reduced pressureto obtain (1S)-1-(2-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline(2S,3S)-2,3-bis[(4-methylbenzoyl)oxy]succinate (16.193 g).

Production Example 23

Under cooling in a dry ice-acetone bath, lithium aluminum hydride (1.03g) was added to THF (30 mL) to make a suspension. A solution of1-[2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinoline (6.22 g) in THF(30 mL) was added dropwise to the suspension under an argon atmosphere.The reaction solution was stirred at room temperature for 15 hours. Thereaction liquid was cooled in ice and then a saturated aqueous Rochellesalt solution (1.5 mL) was added to stop the reaction. The liquid wasstirred at room temperature for 1 hour and magnesium sulfate and celitewere then added thereto. The mixture was filtered through celite, andthe filtrate was concentrated under reduced pressure. The resultingresidue was purified by silica gel column chromatography (hexane-EtOAc)to obtain 1-[2-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisoquinoline(5.42 g).

Production Example 24

N-[2-(4-chlorophenyl)ethyl]cyclohexanecarboxamide (2.03 g) was dissolvedin 1,2-dichloroethane (15 mL), and oxalyl chloride (0.8 mL) was addedthereto under ice-cooling. The reaction mixture was stirred at roomtemperature for 1 hour and then cooled to −20° C. Ferric chloride (1.49g) was added to the mixture, followed by stirring at room temperaturefor 16 hours. An aqueous 1 M HCl solution was added to the mixture whichwas then stirred at room temperature for 30 minutes, followed byextraction with chloroform. The extract was washed with water andsaturated brine, and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was dried to obtain9-chloro-10b-cyclohexyl-6,10b-dihydro-5H-[1,3]oxazolo[2,3-a]isoquinoline-2,3-dione(2.38 g).

Production Example 25

9-chloro-10b-cyclohexyl-6,10b-dihydro-5H-[1,3]oxazolo[2,3-a]isoquinoline-2,3-dione(2.37 g) was dissolved in MeOH (16 mL), and a solution of sulfuric acid(8 mL) in MeOH (24 mL) was added thereto, followed by stirring underheating at reflux for 18 hours. The reaction mixture was left to cooland then the solvent was evaporated. The reaction mixture wasneutralized by an aqueous 1 M sodium hydroxide solution, extracted withchloroform, washed with saturated brine, and then dried over magnesiumsulfate. The solvent was evaporated and then the resulting residue wasdried to obtain 7-chloro-1-cyclohexyl-3,4-dihydroisoquinoline (1.78 g).

Production Example 26

N-[2-(2-chlorophenyl)ethyl]cyclohexanecarboxamide (2.55 g) was dissolvedin 1,2-dichloroethane (25 mL), and oxalyl chloride (1.0 mL) was addedthereto under ice-cooling. The reaction mixture was stirred at roomtemperature for 1 hour and then cooled to −20° C. Iron chloride (1.87 g)was added to the mixture, followed by stirring at room temperature for16 hours. An aqueous 1 M HCl solution was added to the mixture, followedby stirring at room temperature for 30 minutes and extraction withchloroform. The extract was washed with water and saturated brine, anddried over magnesium sulfate. Then, the solvent was evaporated.

The resulting residue (2.55 g) was dissolved in 1,2-dichloroethane (25mL), and oxalyl chloride (1.0 mL) was added thereto under ice-cooling.The reaction mixture was stirred at room temperature for 1 hour and thencooled to −20° C. To the mixture was added iron chloride (1.87 g),followed by stirring at room temperature for 16 hours. An aqueous 1 MHCl solution was added to the mixture which was then stirred at roomtemperature for 30 minutes, followed by extraction with chloroform. Theextract was washed with water and saturated brine, and dried overmagnesium sulfate. The solvent was evaporated and the resulting residuewas dissolved in MeOH (16 mL), and a solution of sulfuric acid (8 mL) inMeOH (24 mL) was added thereto, followed by stirring under heating atreflux for 18 hours. The reaction mixture was left to cool and then thesolvent was evaporated. The reaction mixture was neutralized by anaqueous 1 M sodium hydroxide solution, extracted with chloroform, washedwith saturated brine, and then dried over magnesium sulfate. The solventwas evaporated and the resulting residue was dried to obtain5-chloro-1-cyclohexyl-3,4-dihydroisoquinoline (2.22 g).

Production Example 27

N-[2-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide (5.56 g) wasdissolved in toluene (120 mL), and diphosphorus pentoxide (3.0 g) andphosphorus oxychloride (6.0 mL) were sequentially added thereto,followed by stirring under heating at reflux for 5.5 hours. The reactionmixture was left to cool and then the solvent was evaporated. An aqueous8 M potassium hydroxide solution, water and chloroform were added to theresulting residue to completely dissolve the insoluble materials toachieve a pH of around pH 8, followed by extraction with chloroform. Theextract was washed with saturated brine, and then dried over magnesiumsulfate. The solvent was evaporated and the resulting residue waspurified by silica gel column chromatography (chloroform-MeOH) to obtain1-cyclohexyl-7-methoxy-3,4-dihydroisoquinoline (1.87 g).

Production Example 28

Phosphoric acid (11.9 mL) was added to diphosphorus pentoxide (20.0 g)over 5 minutes. The mixture was stirred at 150° C. for 0.5 hours.3-fluoro-N-(2-phenylethyl)benzamide (5.00 g) was added to the mixture,followed by stirring at 160° C. for 2.5 hours. After cooling, water wasadded to the reaction solution to which 28% aqueous ammonia was thenadded to be alkaline. The reaction solution was extracted with EtOAc,washed with saturated brine, and dried over magnesium sulfate. Afterfiltration, the filtrate was concentrated under reduced pressure toobtain 1-(3-fluorophenyll)-3,4-dihydroisoquinoline (4.87 g).

Production Example 29

Ethyl polyphosphoric acid (50 mL) was added to3,3-difluoro-N-(2-phenylethyl)cyclohexanecarboxamide (6.4 g), followedby stirring under heating at 120° C. for 2 hours. The reaction liquidwas added to ice water (150 mL), extracted with chloroform and driedover magnesium sulfate. The solvent was evaporated to obtain1-(3,3-difluorocyclohexyl)-3,4-dihydroisoquinoline (4.1 g).

Production Example 30

Ethyl polyphosphoric acid (10 mL) was added totrans-4-methyl-N-(2-phenylethyl)cyclohexanecarboxamide (2 g), followedby stirring under heating at 120° C. for 2 hours. Water was added to thereaction liquid which was then extracted with EtOAc. The organic layerwas washed with water and saturated brine, and then dried over magnesiumsulfate. The solvent was evaporated. To the resulting residue were addedEtOH (10 mL) and then sodium borohydride (0.31 g) under ice-cooling,directly followed by stirring for 2 hours. Water was added to thereaction liquid, followed by extraction with EtOAc. The organic layerwas washed with water and saturated brine, and then dried over magnesiumsulfate. The solvent was evaporated to obtain1-(trans-4-methylcyclohexyl)-1,2,3,4-tetrahydroisoquinoline (2 g).

Production Example 31

N-[2-(2-methylphenyl)ethyl]butanamide (4.58 g) was dissolved in xylene(30 mL), and then diphosphorus pentoxide (10 g) was added thereto,followed by stirring at 140° C. for 4 hours. The reaction mixture wasleft to cool and then the solvent was evaporated. An aqueous 8 Mpotassium hydroxide solution, water, and chloroform were used todissolve completely the insoluble materials. The reaction mixture wasadjusted to a pH of around 8, and extracted with chloroform. The extractwas washed with saturated brine, and then dried over magnesium sulfate.The solvent was evaporated under reduced pressure and the resultingresidue was purified by silica gel column chromatography (hexane-EtOAc)to obtain 5-methyl-1-propyl-3,4-dihydroisoquinoline (2.14 g).

Production Example 32

N-[2-(2-bromo-5-methoxyphenyl)ethyl]-2-methoxyacetamide (7.8 g) wasdissolved in xylene (80 mL), and diphosphorus pentoxide (11 g) was addedthereto, followed by stirring at 140° C. for 4 hours. Then, the solventwas evaporated, and an aqueous 6 M sodium hydroxide solution was addedto the reaction mixture to be around a pH of 8. The reaction mixture wasextracted with chloroform, washed with saturated brine, and then driedover magnesium sulfate. The solvent was evaporated, and the resultingresidue was purified by silica gel column chromatography (hexane-EtOAc).

The resulting compound was dissolved in EtOH (30 mL), andN,N-diisopropylethylamine, and 20% palladium hydroxide-supportedactivated carbon (400 mg) was added thereto, followed by stirring undera hydrogen atmosphere, at normal pressure and room temperature, for 3hours. Thereafter, the reaction mixture was filtered through celite toseparate the catalyst, and the solvent was evaporated.

To the resulting residue were added saturated aqueous sodium bicarbonate(30 mL) and then EtOAc (20 mL). A solution of chloroacetyl chloride(1.17 mL) in EtOAc (10 mL) was added dropwise to the reaction liquidover 5 minutes, followed by stirring for 5 hours. Then, the reactionliquid was extracted with EtOAc and dried over magnesium sulfate. Thesolvent was evaporated, and the resulting residue was purified by silicagel column chromatography (hexane-EtOAc) to obtain2-(chloroacetyl)-8-methoxy-1-(methoxymethyl)-1,2,3,4-tetrahydroisoquinoline(367 mg).

Production Example 33

[2-(4-chlorophenyl)ethyl]amine (3.5 g) was dissolved in a 1:2 mixedsolution (45 mL) of EtOAc-saturated aqueous sodium bicarbonate. Asolution of cyclohexanecarbonyl chloride (3.35 mL) in EtOAc (18 mL) wasadded dropwise to the reaction liquid over 5 minutes. After stirring for1.5 hours, the reaction liquid was extracted with EtOAc, washed with anaqueous 1 M sodium hydroxide solution and water, and dried overmagnesium sulfate. The solvent was evaporated and the resulting residuewas dried to obtain N-[2-(4-chlorophenyl)ethyl]cyclohexanecarboxamide(5.69 g).

Production Example 34

4,4-difluorocyclohexanecarboxylic acid (1.48 g) was dissolved inmethylene chloride (20 mL), and1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (1.68 g),1-hydroxybenzotriazole (1.21 g), and (2-phenylethyl)amine (1.2 mL) weresequentially added thereto, followed by stirring at room temperature for18 hours. Then, saturated aqueous sodium bicarbonate was added to thereaction liquid which was then extracted with chloroform. The extractwas washed with water and further saturated brine, and then dried overmagnesium sulfate. The solvent was evaporated and the resulting residuewas purified by silica gel column chromatography (hexane-EtOAc) toobtain 4,4-difluoro-N-(2-phenylethyl)cyclohexanecarboxamide (1.96 g).

Production Example 35

A solution of 1.64 M tert-butyllithium in n-pentane (12 mL) was added toa mixture of 2-(2,2-dimethylpropanoyl)-1,2,3,4-tetrahydroisoquinoline(3.0 g), tetramethylethylenediamine (2.2 ml), and THF (40 mL) at −78° C.The reaction liquid was stirred at −78° C. for 10 minutes. Then, acetone(1.8 mL) was further added to the liquid at −78° C., followed bystirring at −78° C. for 1 hour. Acetic acid (2 mL) was added to thereaction liquid, and the temperature was raised to room temperature. Thereaction liquid was evaporated under reduced pressure. EtOAc and waterwere added thereto, followed by liquid separation. The organic layer waswashed sequentially with an aqueous 5% citric acid solution, a saturatedaqueous sodium hydrogen carbonate solution, and saturated brine, driedover magnesium sulfate and evaporated under reduced pressure. Theresidue was purified by silica gel column chromatography (hexane-EtOAc)to obtain2-[2-(2,2-dimethylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-1-yl]propan-2-ol(2.62 g).

Production Example 36

Trifluoroacetic acid (27 mL) was added to2-[2-(2,2-dimethylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-1-yl]propan-2-ol(2.79 g), followed by stirring at room temperature for 4 hours.Thereafter, the solvent was evaporated and saturated aqueous sodiumbicarbonate was added to the resulting residue, followed by extractionwith EtOAc. The extract was washed with water, and then dried overmagnesium sulfate. The solvent was evaporated to obtain1-methyl-1-(1,2,3,4-tetrahydroisoquinolin-1-yl)ethyl pivalate.

1-methyl-1-(1,2,3,4-tetrahydroisoquinolin-1-yl)ethyl pivalate (2.79 g)was dissolved in a 1:4 mixed solvent (30 mL) of EtOAc-saturated aqueoussodium bicarbonate. A solution of chloroacetyl chloride (0.9 mL) inEtOAc (6 mL) was added dropwise to the reaction liquid underice-cooling, followed by stirring at room temperature for 2 hours andextraction with EtOAc. The extract was washed with saturated brine, andthen dried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(hexane-EtOAc) to obtain1-[2-(chloroacetyl)-1,2,3,4-tetrahydroisoquinolin-1-yl]-1-methylethylpivalate (3.01 g).

Production Example 37

Water (5 mL) and potassium carbonate (1.04 g) were added to a solutionof 6-bromo-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline hydrochloride(1.00 g) in 1,2-dichloroethane (5 mL). To the reaction mixture wereadded di-tert-butyl dicarbonate (726 mg) and furtherdimethylaminopyridine (36.9 mg). The mixture was stirred at roomtemperature for 4 hours and extracted with chloroform. The extract waswashed with a saturated aqueous sodium hydrogen carbonate solution andsaturated brine, dried over magnesium sulfate, filtered, and thenconcentrated under reduced pressure to obtain tert-butyl6-bromo-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.11 g).

Production Example 38

DMF (20 mL) was added to a mixture of tert-butyl6-bromo-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.41 g),zinc cyanide (848 mg), and[1,1′-bis(diphenylphosphino)ferrocene]palladium chloride (535 mg), whichwas then purged with argon gas. Subsequently,tris(dibenzylideneacetone)dipalladium (458 mg) was added to the mixturewhich was then stirred at 120° C. under an argon atmosphere for 10hours. Further, tris(dibenzylideneacetone)dipalladium (200 mg) was addedthereto, followed by stirring for 10 hours. The reaction material wasfiltered through celite, and EtOAc and water were added to the filtrate.The organic layer was collected, washed with water and saturated brine,dried over magnesium sulfate, and filtered. The filtrate wasconcentrated under reduced pressure. The resulting residue was purifiedby silica gel column chromatography (hexane-EtOAc) to obtain tert-butyl6-cyano-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (361 mg).

Production Example 39

4 M HCl/EtOAc (2 mL) was added to a solution of tert-butyl6-cyano-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (361 mg)in EtOAc (1 mL). The mixture was stirred at room temperature for 1 hour.The reaction mixture together with the precipitated crystal was dilutedwith diethyl ether (5 mL). The crystal was collected by filtration,washed with diethyl ether, and dried in air to obtain1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile hydrochloride(259 mg).

Production Example 40

Tert-butyl7-(acetamidemethyl)-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate(861 mg) was dissolved in a 1:1 mixed solution (8 mL) of EtOAc-MeOH, towhich 4 M HCl/EtOAc (2.8 mL) was then added. The reaction mixture wasstirred at 50° C. for 6 hours and then the solvent was evaporated.

To the resulting residue were added saturated aqueous sodium bicarbonate(15 mL) and then EtOAc (10 mL). A solution of chloroacetyl chloride (0.2mL) in EtOAc (5 mL) was added dropwise to the reaction liquid over 5minutes, followed by stirring for 1 hour. The reaction liquid wasextracted with EtOAc and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was dried to obtainN-{[2-(chloroacetyl)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinolin-7-yl]methyl}acetamide(655 mg).

Production Example 41

7-bromo-1-cyclohexyl-3,4-dihydroisoquinoline (9.47 g) was dissolved inN-methyl-2-pyrrolidone (150 mL) to whichtris(dibenzylideneacetone)dipalladium (2.97 g),1,1′-bis(diphenylphosphino)ferrocene (7.19 g), and zinc cyanide (11.5 g)were then added, followed by stirring at 120° C. for 18 hours. Then,water was added to the reaction liquid which was then filtered throughcelite to separate the insoluble materials. The insoluble materials wereextracted with EtOAc, washed with saturated brine, and then dried overmagnesium sulfate. The solvent was evaporated and the resulting residuewas purified by silica gel column chromatography (hexane-EtOAc) toobtain 1-cyclohexyl-3,4-dihydroisoquinoline-7-carbonitrile (7.19 g).

Production Example 42

7-bromo-1-cyclohexyl-3,4-dihydroisoquinoline (4.01 g) was dissolved in1,4-dioxane (100 mL), to which tributyl(1-ethoxyvinyl)tin (7.43 g),potassium fluoride (2.39 g), and tetrakis(triphenylphosphine)palladium(1.58 g) were then added, followed by stirring at 80° C. for 5 hours.Thereafter, to the reaction liquid were further addedtributyl(1-ethoxyvinyl)tin (2.47 g) andtetrakis(triphenylphosphine)palladium (1.58 g), followed by stirring for14 hours. Then, the reaction liquid was filtered through celite and theinsoluble materials were separated. 4 M HCl/dioxane (20 mL) was added tothe insoluble materials, followed by stirring at 60° C. for 30 minutes.The solvent was evaporated and water was added to the mixture which wasthen extracted with EtOAc. The extract was washed with saturated brine,and then dried over magnesium sulfate. The solvent was evaporated andthe resulting residue was purified by silica gel column chromatography(chloroform-MeOH) to obtain1-(1-cyclohexyl-3,4-dihydroisoquinolin-7-yl)ethanone (2.24 g).

Production Example 43

1-(1-cyclohexyl-3,4-dihydroisoquinolin-7-yl)ethanone (600 mg) wasdissolved in THF (6 mL). A solution of 0.5 M Tebbe reagent in toluene(4.7 mL) was added to the reaction liquid under ice-cooling, followed bystirring at room temperature for 45 minutes. Then, diethyl ether and 10drops of an aqueous 1 M NaOH solution were sequentially added to thereaction liquid. The reaction liquid was dried over sodium sulfate andfiltered through celite.

To the resulting solution were added EtOH (8 mL) and 20% palladiumhydroxide-supported activated carbon (900 mg). The solution was stirredunder a hydrogen atmosphere, at room temperature and normal pressure,for 13 hours. Then, the catalyst was separated by filtration throughcelite and then the solvent was evaporated.

To the resulting residue were added saturated aqueous sodium bicarbonate(15 mL) and then EtOAc (10 mL). A solution of chloroacetyl chloride (265mg) in EtOAc (5 mL) was added dropwise to the reaction liquid over 5minutes, followed by stirring for 1 hour. The reaction liquid wasextracted with EtOAc and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain2-(chloroacetyl)-1-cyclohexyl-7-isopropyl-1,2,3,4-tetrahydroisoquinoline(186 mg).

Production Example 44

6-bromo-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.0g) was dissolved in THF (20 mL). A solution of 1.6 M n-butyllithium inn-hexane (6 mL) was added to the reaction liquid at −78° C., followed bystirring at −78° C. for 0.5 hours. Thereafter, acetone (20 mL) was addedto the reaction liquid, followed by further stirring for 2 hours. Thesolvent was evaporated and water was added to the reaction liquid,followed by extraction with chloroform. The extract was washed with asaturated aqueous sodium chloride solution, and then dried overmagnesium sulfate. The solvent was evaporated.

To the resulting residue were added saturated aqueous sodium bicarbonate(15 mL) and then EtOAc (10 mL). A solution of chloroacetyl chloride(0.24 mL) in EtOAc (5 mL) was added dropwise to the reaction liquid over5 minutes, followed by stirring for 18 hours. The reaction liquid wasextracted with EtOAc and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain2-[2-(chloroacetyl)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinolin-6-yl]propan-2-ol(646 mg).

Production Example 45

To 5-bromo-1-isopropyl-8-methoxy-1,2,3,4-tetrahydroisoquinolinehydrochloride (3.0 g) were added EtOH (30 mL), triethylamine (1.3 mL),and 10% palladium-supported carbon (0.30 g), followed by stirring undera hydrogen atmosphere for 2 hours. The reaction liquid was filteredthrough celite and the solvent was evaporated. An aqueous 1 M NaOHsolution was added to the reaction liquid, followed by extraction withEtOAc. The extract was washed with saturated brine, and then dried overmagnesium sulfate. The solvent was evaporated and the resulting residuewas dissolved in EtOAc (30 mL). 4 M HCl/EtOAc (5 mL) was added to themixture, and the precipitated solid was collected to obtain1-isopropyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (2.2g).

Production Example 46

(2-bromo-5-methylphenyl)acetonitrile (8.2 g) was dissolved in THF (60mL) to which a borane-dimethyl sulfide complex (5 mL) was then added,followed by stirring at 80° C. for 4 hours. The reaction liquid wascooled in ice, and MeOH (15 mL) was added thereto, followed by stirringfor a while. Then, the solvent was evaporated. 4 M HCl/dioxane (30 mL)was added to the residue which was then stirred under heating at 50° C.for 1 hour. After being left to cool, toluene (100 mL) was added to themixture and the precipitated solid was collected to obtain2-(2-bromo-5-methylphenyl)ethaneamine hydrochloride (5.5 g).

Production Example 47

Methanesulfonyl chloride (3.9 mL) was added to a mixture of(2-bromo-5-methylphenyl)methanol (9.2 g), dichloromethane (100 mL), andtriethylamine (8 mL) under ice-cooling, followed by stirring at roomtemperature for 5 hours. An aqueous 1 M HCl solution was added to thereaction liquid which was then extracted with chloroform. The organiclayer was dried over magnesium sulfate and filtered. Thereafter, thesolvent was evaporated.

To the resulting residue (11 g) were added EtOH (60 mL), water (40 mL),and sodium cyanide (2.1 g), followed by stirring at 80° C. for 5 hours.Water was added to the reaction liquid, followed by extraction withEtOAc. The organic layer was dried over magnesium sulfate. The solventwas evaporated to obtain (2-bromo-5-methylphenyl)acetonitrile (8.3 g).

Production Example 48

Aluminum chloride (30 g) was added to benzene (60 mL).2,6-dimethylbenzoic acid (10 g) was gradually added to the mixture withstirring under ice-cooling, followed by stirring for 30 minutes. Thetemperature was returned to room temperature, and the mixture wasfurther stirred for 1 hour, followed by stirring under heating at refluxfor 4 hours. The reaction liquid was poured into ice water (300 mL),filtered through celite, and extracted with chloroform. The extract waswashed with an aqueous 1 M NaOH solution, and then dried over magnesiumsulfate. The solvent was evaporated.

The resulting residue (13 g) was dissolved in carbon tetrachloride (150mL). With stirring under heating at reflux, N-bromosuccinimide (10 g)and 2,2′-azobis(isobutylonitrile) (0.20 g) were added thereto, followedby stirring under heating at reflux for 7 hours. The reaction liquid wasleft to cool and filtered. The resulting liquid was washed with asaturated aqueous sodium hydrogen carbonate solution and an aqueoussodium thiosulfate solution, and dried over magnesium sulfate. Thesolvent was evaporated.

To the resulting residue (15 g) were added EtOH (60 mL), water (40 mL),and sodium cyanide (1.5 g), followed by stirring under heating at 80° C.for 5 hours. Water (200 mL) was added to the reaction liquid which wasthen extracted with EtOAc and dried over magnesium sulfate. The solventwas evaporated and the resulting residue was purified by silica gelcolumn chromatography (hexane:chloroform) to obtain(2-benzoyl-3-methylphenyl)acetonitrile (4.7 g).

Production Example 49

To (2-benzoyl-3-methylphenyl)acetonitrile (3.3 g) were added EtOH (40mL), 4 M HCl/EtOAc (5 mL), and platinum oxide (IV) (0.53 g), followed bystirring under a hydrogen atmosphere for 5 hours. The reaction liquidwas filtered through celite and then concentrated. Toluene was added tothe concentrate, followed by extraction with an aqueous 1 M HClsolution. A 28% aqueous ammonia solution was added to the aqueous layer,which was then extracted with toluene and dried over magnesium sulfate.The solvent was evaporated and the residue was dissolved in toluene towhich 4 M HCl/EtOAc (5 mL) was then added, followed by concentration.iPrOH and diisopropyl ether were added to the resulting residue, and theprecipitated solid was collected to obtain8-methyl-1-phenyl-3,4-dihydroisoquinoline hydrochloride (1.5 g).

Production Example 50

To (2-benzoyl-3-methylphenyl)acetonitrile (4.6 g) were added EtOH (70mL), 4 M HCl/EtOAc (15 mL), and platinum oxide (IV) (0.40 g), followedby stirring under a hydrogen atmosphere for 3 days. The reaction liquidwas filtered through celite and then concentrated. Toluene was added tothe concentrate, followed by extraction with an aqueous 1 M HClsolution. A 28% aqueous ammonia solution was added to the aqueous layer,which was then extracted with toluene and dried over magnesium sulfate.The solvent was evaporated and the residue was dissolved in toluene. 4 MHCl/EtOAc (7 mL) was added to the mixture, followed by concentrationunder reduced pressure. iPrOH and diisopropyl ether were added to theresulting residue, and the precipitated solid was collected to obtain1-cyclohexyl-8-methyl-3,4-dihydroisoquinoline hydrochloride (2.2 g).

Production Example 51

A mixture of tetralone (1.50 g), 3-methoxyphenethylamine (1.86 g), andtitanium tetraisopropoxide (4.55 mL) was stirred under an argonatmosphere at 80° C. for 1 hour. The reaction mixture was cooled in anice-MeOH bath. A mixture of formic acid (39 mL) and acetic anhydride (97mL) was added to the reaction mixture under stirring at an internaltemperature of 0° C. or lower. After the addition was complete, thereaction mixture was stirred at 80° C. for 2 hours, and trifluoroaceticacid (158 mL) was added thereto, followed by stirring at an internaltemperature of 70° C. for 3 hours. After the reaction was complete, themixture was cooled to room temperature and concentrated under reducedpressure. The residue was made weak alkaline by using a saturatedaqueous sodium hydrogen carbonate solution and was extracted with EtOAc.The organic layer was washed with saturated brine, dried over magnesiumsulfate, and concentrated under reduced pressure. The residue waspurified by silica gel column chromatography (hexane-EtOAc) to obtain6-methoxy-3,3′,4,4′-tetrahydro-2H,2′H-spiro[isoquinoline-1,1′-naphthalene]-2-carbadehyde(1.86 g).

A mixture of the resulting compound (1.86 g), dioxane (15 mL), andconcentrated hydrochloric acid (3 mL) was refluxed for 2 hours. Afterbeing cooled, the reaction liquid was concentrated under reducedpressure, and the resulting residue was made alkaline by addition ofsaturated aqueous sodium bicarbonate and extracted with chloroform. Theorganic layer was washed with water and saturated brine, dried overmagnesium sulfate, and concentrated under reduced pressure. Theresulting residue was dissolved in EtOAc (40 mL), and saturated aqueoussodium bicarbonate (40 mL) was added thereto. A solution of chloroacetylchloride (700 mg) in EtOAc (10 mL) was added dropwise with stirring tothe mixture, followed by stirring for 1 hour at room temperature. Thereaction mixture was diluted with EtOAc, and the organic layer waswashed with saturated aqueous sodium bicarbonate and saturated brine,dried over magnesium sulfate, and concentrated under reduced pressure.The resulting residue was purified by silica gel column chromatography(hexane-EtOAc) to obtain2-(chloroacetyl)-6-methoxy-3,3′,4,4′-tetrahydro-2H,2′H-spiro[isoquinoline-1,1′-naphthalene](1.28 g).

Production Example 52

To polyphosphoric acid produced from 80% phosphoric acid (25 g) anddiphosphorus pentoxide (25 g) was added a mixture of3-methoxyphenethylamine (5.2 g) and tetrahydro-4H-4-pyrone (4.13 g) atan internal temperature of 90° C. over 5 minutes. Further, the reactionmixture was stirred for 40 minutes, cooled to room temperature, andpoured into ice water (500 mL). Concentrated aqueous ammonia was addedto the reaction mixture to be strongly alkaline, followed by extractionwith EtOAc. The extract was washed with water and saturated brine, driedover magnesium sulfate, and concentrated under reduced pressure. Theresulting residue was purified by silica gel column chromatography(chloroform-EtOH-aqueous ammonia) to obtain6-methoxy-2′,3,3′,4,5′,6′-hexahydro-2H-spiro[isoquinolone-1,4′-pyrane](2.36 g).

Production Example 53

Under cooling in an ice-MeOH bath, THF (80 mL) was added to lithiumaluminum hydride (3.03 g) to make a suspension.Dicyclopropyl[(trimethylsilyl)oxy]acetonitrile (8.36 g) was added to thesuspension. The mixture was stirred at room temperature for 20 hours andcooled in an ice bath. To the mixture were added sodium fluoride (3.35g) and further water (4.23 mL), followed by stirring at room temperaturefor 1 hour. Thereafter, the mixture was filtered through celite. Thefiltrate was concentrated under reduced pressure to obtain an oilymaterial (4.38 g). EtOAc (80 mL) was added to the oily material whichwas then cooled in ice. 4 M HCl/EtOAc (8 mL) was added to the mixture,which was then stirred together with the precipitated solid at roomtemperature for 1 hour. Thereafter, the solid was collected byfiltration, washed with EtAOc, and dried under reduced pressure at 90°C. to obtain 2-amino-1,1-dicyclopropylethanol hydrochloride (3.68 g).

Production Example 54

In an ice bath under an argon atmosphere, zinc iodide (290 mg) was addedto a solution of dicyclopropylmethanone (5.00 g) in 1,2-dichloroethane(50 mL). Subsequently, trimethylsilyl cyanide (6.84 mL) was addeddropwise to the mixture over 10 minutes. The mixture was stirred at roomtemperature for 4 hours and trimethylsilyl cyanide (1.71 mL) was furtheradded thereto, followed by stirring at room temperature for 20 hours.The reaction mixture was poured into a saturated aqueous sodium hydrogencarbonate solution and extracted with EtOAc. The extract was washed witha saturated aqueous sodium hydrogen carbonate solution and saturatedbrine, and dried over magnesium sulfate. Activated carbon was added tothe mixture which was then filtered through celite. The filtrate wasconcentrated under reduced pressure to obtaindicyclopropyl[(trimethylsilyl)oxy]acetonitrile (8.36 g).

Production Example 55

10% palladium-supported carbon (300 mg) was added to a solution of2-benzyl-1-(1-methoxy-1-methylethyl)-1,2,3,4-tetrahydroisoquinoline(1.17 g) in MeOH (12 mL). The reaction material was stirred under ahydrogen atmosphere at room temperature for 8 hours. The reaction liquidwas filtered through celite and the filtrate was concentrated underreduced pressure to obtain1-(1-methoxy-1-methylethyl)-1,2,3,4-tetrahydroisoquinoline (770 mg).

Production Example 56

With cooling in an ice-MeOH bath under an argon atmosphere, a solutionof 2-(2-benzyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propan-2-ol (1.27 g)in THF (7 mL) was added dropwise to a solution of sodium hydride (60%,199 mg) in THF (5 mL), followed by stirring at room temperature for 0.5hours. Then, the reaction liquid was cooled in ice and methyl iodide(0.42 mL) was added thereto. The mixture was stirred at room temperaturefor 8 hours. To the mixture were added sodium hydride (60%, 199 mg) andmethyl iodide (0.42 mL), followed by stirring at room temperature for 12hours. Water was added to the reaction solution, followed by extractionwith EtOAc. The extract was washed with saturated brine, dried overmagnesium sulfate, filtered, and then concentrated under reducedpressure. The resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain2-benzyl-1-(1-methoxy-1-methylethyl)-1,2,3,4-tetrahydroisoquinoline(1.17 g).

Production Example 57

In a dry ice-acetone bath under an argon atmosphere, a solution of 1.0 Mmethyllithium in diethyl ether (16.2 mL) was added dropwise to asolution of ethyl 2-benzyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylate(1.99 g) in THF (20 mL) over 15 minutes. The reaction liquid was stirredin a dry ice-acetone bath for 0.5 hours and then further stirred in anice bath for 1 hour. The reaction liquid was cooled again in the dryice-acetone bath, and a solution of 1.04 M methyllithium in diethylether (3.24 mL) was added thereto. The reaction liquid was stirred inthe dry ice-acetone bath for 0.5 hours and then stirred in the ice bathfor 1 hour. Water was added to the reaction liquid, followed byextraction with EtOAc. The extract was washed with saturated brine,dried over magnesium sulfate, filtered, and concentrated under reducedpressure. The resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain2-(2-benzyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propan-2-ol (1.27 g).

Production Example 58

In an ice bath, sodium triacetoxyborohydride (6.11 g) was added to asolution of ethyl 1,2,3,4-tetrahydroisoquinoline-1-carboxylatehydrochloride (4.98 g) and benzaldehyde (2.72 g) in acetic acid (50 mL).The mixture was stirred at room temperature for 15 hours. A 1 M aqueousNaOH solution was added to the reaction liquid which was then extractedwith chloroform. The extract was washed with water and saturated brine,dried over magnesium sulfate, filtered, and concentrated under reducedpressure. The resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain ethyl2-benzyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylate (1.99 g).

Production Example 59

A solution of 5-bromo-7,8-dimethoxy-1-phenyl-3,4-dihydroisoquinoline(450 mg), EtOH (30 mL), 10% palladium-supported carbon (80 mg) and 28%sodium methoxide in MeOH (0.1 mL) was stirred under a hydrogenatmosphere at room temperature overnight. The insoluble materials weresubjected to filtration and the filtrate was concentrated to obtain7,8-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline (350 mg).

A solution of chloroacetyl chloride (177 mg) in EtOAc (12 mL) was addeddropwise to a mixture of7,8-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline (350 mg), asaturated aqueous sodium hydrogen carbonate solution (50 mL), and EtOAc(50 mL) under stirring. After the dropwise addition was complete, themixture was stirred for 2 hours and extracted with EtOAc. The extractwas washed sequentially with a saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over magnesium sulfate,and concentrated under reduced pressure. The resulting residue waspurified by silica gel column chromatography (chloroform-EtOH) to obtain2-(chloroacetyll)-7,8-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline(349 mg).

Production Example 60

1-cyclohexyl-N-isobutyl-3,4-dihydroisoquinoline-7-carboxamide (689 mg)was dissolved in MeOH (12 mL). Sodium borohydride (100 mg) was added tothe reaction mixture, followed by stirring at room temperature for 5hours. The solvent was evaporated. To the resulting residue were addedwater and chloroform. The residue was extracted with chloroform anddried over magnesium sulfate. Then, the solvent was evaporated underreduced pressure to obtain1-cyclohexyl-N-isobutyl-1,2,3,4-tetrahydroisoquinoline-7-carboxamide.

To the resulting residue were added saturated aqueous sodium bicarbonate(10 mL) and then EtOAc (5 mL). A solution of chloroacetyl chloride (0.19mL) in EtOAc (5 mL) was added dropwise to the reaction liquid over 5minutes, followed by stifling for 1 hour. Then, the reaction liquid wasextracted with EtOAc and dried over magnesium sulfate. The solvent wasevaporated to obtain 2-(chloroacetyll)-1-cyclohexyl-N-isobutyl-1,2,3,4-tetrahydroisoquinoline-7-carboxamide(410 mg).

Production Example 61

5-methoxy-1-(methoxymethyl)-3,4-dihydroisoquinoline (1.7 g) wasdissolved in MeOH (15 mL) to which sodium borohydride (376 mg) was thenadded, followed by stifling at room temperature for 5 hours. The solventwas evaporated under reduced pressure, and water and chloroform wereadded to the mixture. The mixture was extracted with chloroform anddried over magnesium sulfate. The solvent was evaporated.

To the resulting residue were added saturated aqueous sodium bicarbonate(20 mL) and then EtOAc (15 mL). A solution of chloroacetyl chloride(0.66 mL) in EtOAc (5 mL) was added dropwise to the reaction liquid over5 minutes, followed by stirring for 1 hour. The reaction liquid wasextracted with EtOAc and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain2-(chloroacetyl)-5-methoxy-1-(methoxymethyl)-1,2,3,4-tetrahydroisoquinoline(550 mg).

Production Example 62

5-bromo-8-methoxy-1-propyl-1,2,3,4-dihydroisoquinoline (5.5 g) wasdissolved in EtOH (30 mL). To the reaction mixture were added DMF (3.4mL) and 10% palladium-supported carbon (500 mg), followed by stirringunder a hydrogen atmosphere, at normal pressure and room temperature,for 3 hours. Thereafter, the catalyst was separated by filtrationthrough celite and sodium borohydride (740 mg) was added to the reactionmixture, followed by stirring at room temperature for 2 hours. Thesolvent was evaporated under reduced pressure, and water and chloroformwere added to the resulting residue. The mixture was extracted withchloroform and dried over magnesium sulfate. The solvent was evaporatedunder reduced pressure.

The resulting residue was dissolved in EtOAc (10 mL), to which 4 MHCl/EtOAc (15 mL) was then added under ice-cooling, followed by stirringat room temperature. The resulting insoluble materials were collectedand washed with EtOAc to obtain8-methoxy-1-propyl-1,2,3,4-tetrahydroisoquinoline (3.67 g).

Production Example 63

7-bromo-1-cyclohexyl-3,4-dihydroisoquinoline (24.45 g) was dissolved inMeOH (400 mL). The solution was cooled to 0° C. and sodium borohydride(4.8 g) was added thereto, followed by stirring at room temperature for2 hours. Then, the solvent was evaporated under reduced pressure. Waterwas added to the residue, followed by extraction with chloroform. Theorganic layer was dried over magnesium sulfate and then the solvent wasevaporated under reduced pressure. The resulting residue was dissolvedin EtOAc (200 mL), to which 4 M HCl/EtOAc (21 mL) was then added. Theresulting solid was collected.

The resulting residue (1 g) was dissolved in THF (30 mL), followed bycooling at −78° C. To the reaction mixture was added a solution of 2.6 Mn-butyllithium in n-hexane (3.7 mL), followed by stirring for 30minutes. Acetone (30 mL) was added to the mixture at −78° C., and thetemperature was raised to room temperature, followed by stirring for 1hour. Then, the solvent was evaporated under reduced pressure. To theresulting residue was added water, and the mixture was extracted withchloroform. The organic layer was dried over magnesium sulfate and thenthe solvent was evaporated under reduced pressure.

The resulting residue was dissolved in a mixed solution of EtOAc (10 mL)and saturated aqueous sodium bicarbonate (15 mL). A solution ofchloroacetyl chloride (683 mg) in EtOAc (5 mL) was added dropwise to thereaction mixture, followed by stirring at room temperature for two days.Then, water was added to the mixture, followed by extraction with EtOAc.The organic layer was washed with saturated brine and dried overmagnesium sulfate. Thereafter, the solvent was evaporated under reducedpressure. The resulting residue was purified by silica gel columnchromatography (hexane-EtOAc) to obtain2-[2-(chloroacetyl)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinolin-7-yl]propan-2-ol(606 mg).

Production Example 64

1-cyclohexyl-3,4-dihydroisoquinoline-7-carbonitrile (1.01 g) wasdissolved in EtOH (15 mL), to which a 6 M aqueous NaOH solution (7.0 mL)was then added, followed by stirring under heating at reflux for 6hours. Water was added to the mixture which was then washed with EtOAc.A 1 M aqueous HCl solution was added to the mixture to have a pH ofabout 3 and then a saturated aqueous sodium sulfate solution was addedthereto. The mixture was extracted with a 4:1 mixed solution ofchloroform-iPrOH, washed with saturated brine, and then dried overmagnesium sulfate. The solvent was evaporated to obtain1-cyclohexyl-3,4-dihydroisoquinoline-7-carboxylic acid (1.09 g).

Production Example 65

1-cyclohexyl-3,4-dihydroisoquinoline-7-carboxylic acid (1.15 g) wasdissolved in methylene chloride (15 mL).O-(benzotriazol-1-yl)-N,N,N′,N′-tetrahetyluronium hexafluorophosphate(2.03 g), N,N-diisopropylethylamine (1.55 mL), and2-methyl-1-propanamine (0.87 mL) were added thereto, followed bystirring at room temperature for 18 hours. Then, water was added to themixture, followed by extraction with chloroform. The extract was washedwith saturated brine, and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography (chloroform-MeOH) to obtain1-cyclohexyl-N-isobutyl-3,4-dihydroisoquinoline-7-carboxamide (700 mg).

Production Example 66

Sodium methoxide (9.46 g) was added to a suspension of10b-(chloromethyl)-9-ethyl-6,10b-dihydro-5H-[1,3]oxazolo[2,3-a]isoquinoline-2,3-dione(14.0 mL) in MeOH (140 mL) under ice-cooling. The mixture was stirred atroom temperature for 0.5 hours and then heated under reflux for 3 hours.EtOAc and water were added to the mixture, followed by filtration. Theorganic layer of the filtrate was collected, washed with saturatedbrine, and dried over magnesium sulfate. Activated carbon and silica gelwere added thereto, followed by filtration. The filtrate wasconcentrated under reduced pressure to obtain7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinoline (4.75 g).

Production Example 67

Sodium borohydride (900 mg) was added to a mixed solution of a solutionof5,8-dimethoxy-1-phenyl-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline(4.21 g) in THF (30 mL), and EtOH (100 mL) at room temperature understirring. The reaction mixture was stirred at room temperature for 3hours and then stirred at 40° C. for 30 minutes, and concentrated underreduced pressure. To the resulting residue was added a 3 M aqueous HClsolution (30 mL), followed by refluxing for 5 minutes. After cooling,the mixture was made strong alkaline by using a 20% aqueous NaOHsolution and extracted with chloroform. The organic layer was washedwith saturated brine, dried over magnesium sulfate, and concentratedunder reduced pressure to obtain5,8-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline (3.05 g).

Production Example 68

Under an argon atmosphere, a solution of 2,5-dimethoxyphenethylamine(3.175 g) in benzene (4 mL) was added with stirring to a suspension ofbenzaldehyde (1.86 g) and magnesium sulfate (3.89 g) in benzene (10 mL).An exothermic reaction took place, followed by further stirringovernight. After the reaction was complete, the reaction liquid wasfiltered and the filtrate was concentrated under reduced pressure toobtain 2-(2,5-dimethoxyphenyl)-N-[(1E)-phenylmethylene]ethanamine (4.72g).

Production Example 69

2-(2,5-dimethoxyphenyl)-N-[(1E)-phenylmethylene]ethanamine (4.719 g) wasdissolved in trifluoroacetic acid (140 mL), followed by refluxing for 2days. The reaction mixture was cooled to room temperature andtrifluoroacetic anhydride (55 mL) was gradually added thereto. Themixture was refluxed for 3 days, cooled to room temperature, andconcentrated under reduced pressure. The resulting residue was extractedwith a saturated aqueous sodium hydrogen carbonate solution andchloroform. The organic layer was washed with a saturated aqueous sodiumhydrogen carbonate solution and saturated brine, dried over magnesiumsulfate, and concentrated under reduced pressure. The resulting residuewas purified by silica gel column chromatography (hexane-EtOAc) toobtain5,8-dimethoxy-1-phenyll-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline(4.168 g).

Production Example 70

Tert-butyl7-cyano-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.38 g)was dissolved in methylene chloride (40 mL). A solution of 0.99 Misobutylaluminum hydride in n-hexane (7.8 mL) was added thereto,followed by stirring at −78° C. for 4 hours. Then, a solution of 0.99 Misobutylaluminium hydride in n-hexane (28 mL) was further added to thereaction mixture. A saturated aqueous Rochelle salt solution was addedto stop the reaction, followed by stirring overnight. The mixture wasextracted with EtOAc. The extract was washed with saturated brine, andthen dried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(benzene-EtOAc).

The resulting residue was dissolved in an 8:1 mixed solvent (90 mL) ofEtOH-water. Hydroxylamine hydrochloride (812 mg) and sodium acetate (930mg) were added thereto, followed by stirring at room temperature for 28hours. Then, the solvent was evaporated. Water was added to the mixture,which was then extracted with chloroform, washed with saturated brine,and then dried over magnesium sulfate. The solvent was evaporated toobtain tert-butyl1-cyclohexyl-7-[(hydroxyimino)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate(2.03 g).

Production Example 71

Tert-butyl1-cyclohexyl-7-[(hydroxyimino)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate(1.04 g) was dissolved in an 8:1:1 mixed solvent (20 mL) of EtOH-aceticacid-water. 10% palladium-supported activated carbon (500 mg) was addedthereto, followed by stirring under a hydrogen atmosphere, at roomtemperature and normal pressure, for 4 hours. Then, the reaction mixturewas filtered through celite and the solvent was evaporated.

The resulting residue was dissolved in methylene chloride (12 mL), towhich triethylamine (880 mg), acetic anhydride (385 mg), and4-dimethylaminopyridine (70 mg) were then added, followed by stirring atroom temperature for 16 hours. Then, water was added to the mixturewhich was then extracted with chloroform. The extract was washed withsaturated brine, and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography (chloroform) to obtain tert-butyl7-(acetamidemethyl)-1-cyclohexyll-3,4-dihydroisoquinoline-2(1H)-carboxylate(875 mg).

Production Example 72

Tert-butyl1-cyclohexyl-7-[(hydroxyimino)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate(995 mg) was dissolved in EtOH-acetic acid-water (8:1:1, 20 mL). To thereaction mixture was added 10% palladium-supported carbon (480 mg),followed by stirring under a hydrogen atmosphere, at room temperatureand normal pressure, for 4 hours. Then, the reaction mixture wasfiltered through celite and the solvent was evaporated to obtaintert-butyl7-(aminomethyl)-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate(956 mg).

Production Example 73

Tert-butyl7-(aminomethyl)-1-cyclohexyl-3,4-dihydroisoquinoline-2(1H)-carboxylate(999 mg) was dissolved in methylene chloride. Isobutyric acid (0.33 mL),triethylamine (1.2 mL), andO-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(1.32 g) were added thereto, followed by stirring at room temperaturefor 18 hours. Water was added to the mixture which was then extractedwith chloroform. The extract was washed with a 1 M aqueous NaOH solutionand saturated brine, and dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gel columnchromatography to obtaintert-butyl-1-cyclohexyl-7-[(isobutylamino)methyl]-3,4-dihydroisoquinoline-2(1H)-carboxylate(468 mg).

Production Example 74

1-cyclohexyl-3,4-dihydroisoquinolin-7-ol (2 g) was dissolved in MeOH (40mL), to which sodium borohydride (396 mg) was then added, followed bystirring at room temperature for 4 hours. Then, the solvent wasevaporated. Water was added to the mixture which was then extracted withchloroform. The extract was washed with saturated brine, and then driedover magnesium sulfate. The solvent was evaporated.

The resulting residue was dissolved in dioxane (40 mL). Di-tert-butyldicarbonate (2.28 g) was added thereto, followed by stirring at roomtemperature for 2 days. Then, the solvent was evaporated and theresulting residue was purified by silica gel column chromatography(hexane-EtOAc) to obtain tert-butyl1-cyclohexyl-7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.66g).

Production Example 75

Tert-butyl1-cyclohexyl-7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (700mg) was dissolved in acetonitrile (12 mL). 1-chloroacetone (0.2 mL),potassium carbonate (438 mg), and tetra-n-butylammonium iodide (78 mg)were added thereto, followed by stirring at 60° C. for 16 hours. Then,water was added to the mixture which was then extracted with EtOAc. Theextract was washed with saturated brine, and then dried over magnesiumsulfate. The solvent was evaporated and the resulting residue waspurified by silica gel column chromatography (hexane-EtOAc) to obtaintert-butyl1-cyclohexyl-7-(2-oxopropoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate(818 mg).

Production Example 76

Tert-butyl1-cyclohexyl-7-(2-oxopropoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate(808 mg) was dissolved in methylene chloride (15 mL). At −78° C., asolution of bis(2-methoxyethyl)aminosulfur trifluoride (0.65 mL) inmethylene chloride (5 mL) was added dropwise to the reaction mixture,followed by stirring at room temperature for 14 hours. Saturated aqueoussodium bicarbonate was added to the reaction mixture which was thenextracted with chloroform. The extract was washed with saturated brine,and then dried over magnesium sulfate. The solvent was evaporated andthe resulting residue was purified by silica gel column chromatography(hexane-EtOAc) to obtain tert-butyl1-cyclohexyl-7-(2,2-difluoropropoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate(747 mg).

Production Example 77

A 1 M aqueous NaOH solution was added to(1S)-1-isopropyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride(808 mg). The reaction mixture was extracted with chloroform and theorganic layer was dried over magnesium sulfate. The solvent wasevaporated under reduced pressure. A mixed solution of a solution of 1 Mboron tribromide in dichloromethane (13.4 mL), and dichloromethane (10mL) was cooled to −78° C. and a solution of the extraction residue indichloromethane (10 mL) was added dropwise thereto. The temperature wasgradually raised and the reaction mixture was stirred at roomtemperature for 24 hours. Then, saturated aqueous sodium bicarbonate andchloroform were added to the reaction mixture. After liquid separationwas complete, the aqueous layer was used in subsequent reaction.

Di-tert-butyl dicarbonate was added to the resulting aqueous layer,followed by stirring at room temperature for 5 hours. The mixture wasneutralized by a 1 M aqueous HCl solution and extracted with chloroform.The organic layer was washed with water and dried over magnesiumsulfate. Thereafter, the solvent was evaporated under reduced pressureto obtaintert-butyl-(1S)-8-hydroxy-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-carboxylate(973 mg).

Production Example 78

Tert-butyl(1S)-8-hydroxy-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-carboxylate(973 mg) was dissolved in a mixed solution of iPrOH (6 mL) and a 30%aqueous potassium hydroxide solution (3 mL). To the reaction mixture wasadded chlorodifluoromethane by ventilation, followed by stirring at 70°C. for 20 hours. Water was added to the mixture which was then extractedwith chloroform. The organic layer was dried over magnesium sulfate. Thesolvent was evaporated under reduced pressure and then the residue waspurified by silica gel column chromatography (hexane-EtOAc).

The resulting residue (790 mg) was dissolved in EtOAc. 4 M HCl/EtOAc(5.8 mL) was added thereto, followed by stirring at 60° C. for 18 hours.Then, the solvent was evaporated under reduced pressure to obtain(1S)-8-(difluoromethoxy)-1-isopropyl-1,2,3,4-tetrahydroisoquinolinehydrochloride (642 mg).

Production Example 79

A 1 M aqueous NaOH solution was added to(1S)-8-methoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride(1.81 g). The reaction mixture was extracted with chloroform. Theorganic layer was dried over magnesium sulfate and the solvent wasevaporated under reduced pressure. A mixed solution of a solution of 1 Mboron tribromide in dichloromethane (26.3 mL) and dichloromethane (30mL) was cooled to −78° C. and a solution of the extraction residue indichloromethane (10 mL) was added dropwise thereto. The temperature wasgradually raised and the reaction mixture was stirred at roomtemperature for 24 hours. Then, saturated aqueous sodium bicarbonate andchloroform were added to the reaction mixture. After liquid separationwas complete, the organic layer was dried over magnesium sulfate. Thesolvent was evaporated under reduced pressure.

The resulting residue (1.48 g) was dissolved in THF (50 mL). A 1 Maqueous NaOH solution (8 mL) and di-tert-butyl dicarbonate (2.87 g) wereadded thereto, followed by stirring at room temperature for 5 hours.Then, the solvent was evaporated under reduced pressure. To theresulting residue were added water and a 1 M aqueous HCl solution, andthe mixture was extracted with chloroform. The organic layer was washedwith water and dried over magnesium sulfate. Then, the solvent wasevaporated under reduced pressure and the resulting residue was purifiedby silica gel column chromatography (hexane-EtOAc).

The resulting residue (1.24 g) was dissolved in a mixed solution ofiPrOH (20 mL) and a 50% aqueous potassium hydroxide solution (10 mL). Tothe reaction mixture was added chlorodifluoromethane by ventilation,followed by stirring at 70° C. for 14 hours. Water was added to themixture which was then extracted with chloroform. The organic layer wasdried over magnesium sulfate. The solvent was evaporated under reducedpressure and then the resulting residue was purified by silica gelcolumn chromatography (hexane-EtOAc).

The resulting residue (927 mg) was dissolved in EtOAc (25 mL), to which4 M HCl/EtOAc (6.2 mL) was then added, followed by stirring at 60° C.for 18 hours. Then, the solvent was evaporated under reduced pressure toobtain (1S)-8-(difluoromethoxy)-1-phenyl-1,2,3,4-tetrahydroisoquinolinehydrochloride (770 mg).

Production Example 80

28% aqueous ammonia was added to 1-oxiran-2-ylcyclohexanol, followed bystirring for 11 hours. The solvent was evaporated under reduced pressureand then water was removed azeotropically with toluene.

The resulting residue was dissolved in a mixed solution of EtOH-diethylether. Oxalic acid was added thereto, followed by stirring for a while.The resulting insoluble materials were collected to obtain1-(2-amino-1-hydroxyethyl)cyclohexanol oxalate (853 mg).

Production Example 81

(1R,2S)-1-amino-2-indanol (511 mg) was dissolved in toluene (60 mL).Under ice-cooling, a solution of a 1 M borane-THF complex in THF (8.16mL) was added thereto, followed by stirring at room temperature for 1hour. Then, 7-bromo-1-cyclohexyl-3,4-dihydroisoquinoline (1 g) was addedto the mixture, followed by stirring at room temperature for 3 days. Thereaction was stopped by addition of trifluoroacetic acid, followed byfurther stirring at 60° C. for 1 hour. The solvent was evaporated. A 1 Maqueous sodium hydroxide solution was added to the mixture which wasthen extracted with chloroform. The extract was washed with saturatedbrine, and then dried over magnesium sulfate. The solvent was evaporatedand the resulting residue was purified by silica gel columnchromatography (chloroform-MeOH) to obtain crude(1S)-7-bromo-1-cyclohexyl-3,4-tetrahydroisoquinoline (1.06 g). Theresulting crude product (203 mg) was dissolved in EtOH (9 mL). To themixture was added D-(−)-tartaric acid (104 mg) at 80° C. The mixture wasgradually cooled to room temperature, followed by stirring for 12 hours.The resulting insoluble materials were collected to obtain(1S)-7-bromo-1-cyclohexyl-3,4-tetrahydroisoquinoline (72 mg).

Production Example 82

Under an argon atmosphere, a 1.09 M borane-THF solution (18.7 mL) wasadded to a suspension of (1R,2S)-1-aminoindan-2-ol (3.04 g) in toluene(60 mL) under ice-cooling, followed by stirring at room temperature for1 hour. Then, a solution of1-[2[(trifluoromethyl)benzyl]-3,4-dihydroisoquinoline (4.00 g) intoluene (20 mL) was added to the reaction mixture under ice-cooling. Themixture was stirred at 4° C. for 45 hours. Trifluoroacetic acid (20 mL)was added to stop the reaction. The mixture was heated under reflux for1 hour and then cooled. 28% aqueous ammonia (30 mL) was added to themixture to be alkaline. The mixture was extracted with EtOAc. Theextract was washed 3 times and further washed with saturated brine,dried over magnesium sulfate, and then filtered. The filtrate wasconcentrated to obtain a yellow oily material (4.11 g). The oilymaterial was dissolved in acetonitrile (80 mL). To the mixture was addedN-acetyl-L-leucine (2.39 g) at 80° C. The mixture was gradually cooled,followed by stirring at 60° C. for 2 hours and at room temperature for12 hours. When the crystal was precipitated, the crystal was collectedby filtration, cooled in ice, washed with acetonitrile, and dried in airto obtain a crystal (2.48 g). The crystal was recrystallized fromacetonitrile (50 mL) to obtain1-[2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroisoquinolineN-acetyl-L-leucine salt (1.72 g).

Production Example 83

Under an argon atmosphere, a 1.09 M borane-THF solution (48.8 mL) wasadded to a suspension of (1R,2S)-1-aminoindan-2-ol (3.79 g) in toluene(60 mL) under ice-cooling, followed by stirring at room temperature for1 hour. Then, a solution of7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinoline (4.70 g) in THF (40mL) was added to the reaction mixture under ice-cooling. The mixture wasstirred at 4° C. for 8 hours. Trifluoroacetic acid (15 mL) was added tostop the reaction. The mixture was heated under reflux for 1 hour. Tothe mixture were added chloroform and 28% aqueous ammonia. The organiclayer was washed 3 times with water and extracted with a 5% aqueousacetic acid solution. The extract was adjusted to have alkalinity byaddition of 28% aqueous ammonia and extracted with EtOAc. The extractwas washed two times with water and further washed with saturated brine,dried over magnesium sulfate, and then filtered. The filtrate wasconcentrated under reduced pressure to obtain a yellow oily material(3.15 g). The oily material was dissolved in iPrOH (63 mL), to which(2S,3S)-2,3-bis(benzoyloxy)succinic acid (4.14 g) was gradually added at90° C. The mixture was heated under reflux for 1 hour and was graduallycooled to room temperature, followed by stirring at room temperature for3 hours. When the crystal was precipitated, the crystal was collected byfiltration, washed with iPrOH and ether, and dried under reducedpressure to obtain(7-ethyl-1-(methoxymethyl)-1,2,3,4-tetrahydroisoquinoline(2S,3S)-2,3-bis(benzoyloxy)succinate (5.54 g).

Production Example 84

Phosphorus pentoxide (15.85 g) was added to a solution of2-chloro-N-[2-(4-ethylphenyl)ethyl]acetamide (7.87 g) in xylene (140 mL)under stirring at 90° C. over 5 minutes. The reaction mixture was heatedat 120° C. and stirred for 2 hours. The reaction mixture was cooled toroom temperature. The supernatant was removed and the residue was washedsequentially with toluene and ether. Crushed ice (150 g) was added tothe residue, followed by stirring. A 20% aqueous sodium hydroxidesolution was further added to the mixture to be a pH of 10 or higher,and the mixture was extracted with chloroform. The organic layer wascollected, washed with water and saturated brine, and dried overanhydrous magnesium sulfate. To the organic layer was added a 4 MHCl/EtOAc solution (15 mL), and the mixture was concentrated underreduced pressure to obtain1-(chloromethyl)-7-ethyl-3,4-dihydroisoquinoline hydrochloride (8.5 g).

Production Example 85

Tert-butyl(1S)-8-hydroxy-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.53g) was dissolved in dichloromethane (20 mL). 2,6-lutidine (1.1 mL) andtrifluoromethanesulfonic anhydride (0.9 mL) were added thereto at −78°C., followed by stirring at room temperature for 16 hours. Then,saturated aqueous sodium bicarbonate was added to the mixture which wasthen extracted with chloroform. The extract was washed with a saturatedaqueous sodium chloride solution, and then dried over magnesium sulfate.The solvent was evaporated and the resulting residue was purified bysilica gel column chromatography (ethyl acetate:hexane) to obtaintert-butyl(1S)-1-phenyl-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydroisoquinoline-2(1H)-carboxylate(2.08 g).

Production Example 86

To N-[2-(2-bromo-5-methylphenyl)ethyl]-2-methoxyacetamide (3.9 g) wasadded xylene (50 mL), followed by stirring under heating at 60° C.Diphosphorus pentoxide (7.0 g) was added with stirring to the reactionmixture, followed by stirring at 140° C. for 3 hours. After the reactionmixture being left to cool, the supernatant of the reaction mixture wasdiscarded. The mixture was dissolved in water, toluene, and an aqueoussodium hydroxide solution, and extracted with toluene. The extract wasfurther extracted with a 1 M aqueous HCl solution. The recovered aqueouslayer was neutralized, extracted with toluene, and dried over magnesiumsulfate. After filtration was complete, a 4 M HCl/EtOAc solution (5 mL)was added to the layer, and the solvent was evaporated under reducedpressure. To the resulting residue were added EtOH (50 mL), toluene (10mL), and sodium borohydride (1.0 g), followed by stirring for 4 days. Tothe reaction mixture was added a 1 M aqueous HCl solution, followed bystirring for 5 hours. Thereafter, an aqueous sodium hydroxide solutionwas added to the mixture which was then extracted with chloroform. Thesolvent was evaporated. Sodium carbonate (1.0 g), water (30 mL), toluene(30 mL), and chloroacetyl chloride (0.3 mL) were added to the resultingresidue under ice-cooling, followed by stirring at room temperature for17 hours. Water was added to the reaction liquid, which was thenextracted with chloroform. The extract was washed with a 1 M aqueous HClsolution, and then dried over magnesium sulfate. The solvent wasevaporated and the resulting residue was purified by silica gelchromatography to obtain5-bromo-2-(chloroacetyl)-1-(methoxymethyl)-8-methyl-1,2,3,4-tetrahydroisoquinoline(0.323 g).

Production Example 87

8-ethyl-5-methoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride(2.06 g) was dissolved in methylene chloride (40 mL). To the reactionmixture was added a solution of boron tribromide in dichloromethane(13.6 mL) at −78° C., followed by stirring at room temperature for 16hours. Thereafter, a saturated aqueous sodium hydrogen carbonatesolution was added to the reaction mixture to make it alkaline. Then,di-tert-butyl dicarbonate (2.96 g) was added to the reaction solution,followed by stirring at room temperature for 3 hours. The reactionliquid was extracted with chloroform, washed with a saturated aqueoussodium chloride solution, and dried over magnesium sulfate. The solventwas evaporated and the resulting residue was dissolved indichloromethane (20 mL). To the mixture were added 2,6-lutidine (1.8 mL)and trifluoromethanesulfonic anhydride (1.55 mL), followed by stirringat room temperature for 18 hours. Thereafter, water was added to themixture which was then extracted with chloroform. The extract was washedwith a saturated aqueous sodium chloride solution, and then dried overmagnesium sulfate. The solvent was evaporated and the resulting residuewas purified by silica gel column chromatography (EtOAc:hexane). Theresulting residue was dissolved in DMF (30 mL). To the mixture wereadded palladium (II) acetate (305 mg), triethylsilane (5.4 mL), and1,1′-bis(diphenylphosphino)ferrocene (750 mg), followed by stirring at70° C. for 20 hours. Then, water was added to the mixture which was thenfiltered through celite and extracted with diethyl ether. The extractwas washed with a saturated aqueous sodium chloride solution, and driedover magnesium sulfate. The solvent was evaporated and the resultingresidue was purified by silica gel column chromatography (EtOAc:hexane)to obtain tert-butyl8-ethyl-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.29 g).

Production Example 88

Under cooling in an ice bath, a mixture of sodium hydride (suspension of8 g of sodium hydride in mineral oil (60%) washed with hexane) in THF(10 mL) was added to methoxyethanol (100 mL) under stirring over 20minutes to produce sodium 2-methoxyethoxide, followed by furtherstirring for 2 hours. A solution of sodium 2-methoxyethoxide in2-methoxyethanol (55 mL) was added with stirring to a solution of1-(chloromethyl)-7-ethyl-3,4-dihydroisoquinoline hydrochloride (8.5 g)in methoxyethanol (50 mL) under cooling in an ice bath, for 5 minutes.The reaction mixture was heated at 60° C., followed by stirring for 3hours under an argon atmosphere. The reaction mixture was cooled to roomtemperature and diluted with THF (150 mL), followed by filtration. Thefiltrate was concentrated under reduced pressure. To the resultingresidue was added a saturated aqueous ammonium chloride solution and theresidue was extracted with EtOAc. The organic layer was washed withwater and a saturated aqueous sodium chloride solution, dried overmagnesium sulfate, and concentrated under reduced pressure. Theresulting residue was purified by silica gel column chromatography(hexane:EtOAc) to obtain7-ethyl-1-[(2-methoxyethyl)methyl]-3,4-dihydroisoquinoline (2.13 g).

Production Example 89

Tert-butyl(1S)-1-phenyl-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydroisoquinoline-2(1H)-carboxylate(3.75 g) was dissolved in N,N-dimethylacetamide (40 mL). To the reactionmixture were added zinc (537 mg), zinc cyanide (1.15 g), trifluoroaceticpalladium (II) (682 mg), and biphenyl-2-yl(di-tert-butyl)phosphine (1.22g). The temperature was increased from room temperature to 95° C. over45 minutes and then the mixture was stirred at 95° C. for 18 hours.Water was added to the mixture which was then filtered through celite.Thereafter, the mixture was extracted with diethyl ether. The extractwas washed with a saturated aqueous sodium chloride solution, and thendried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(EtOAc:hexane) to obtain tert-butyl(1S)-8-cyano-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (796mg).

Production Example 90

A solution of 1.55 M n-butyllithium in hexane (10.94 mL) was added withstirring to a solution of1-(methoxymethyl)-5-methyl-1,2,3,4-tetrahydroisoquinoline (3.07 g) inTHF (60 mL) under an argon atmosphere, over about 8 minutes, at −70° C.or below, followed by further stirring for 30 minutes. To the reactionmixture was added with stirring a solution of(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 4-methylbenzenesulfinate(3.375 g) in THF (25 ml) over 5 minutes at −70° C. or below, followed byfurther stirring for 1 hour. Thereafter, saturated disodium phosphatewas added to the mixture at the same temperature and the temperature wasincreased to room temperature. The mixture was extracted with ether. Theorganic layer was washed with a saturated aqueous sodium chloridesolution and dried over magnesium sulfate and then the solvent wasevaporated. The resulting residue was purified by silica gel columnchromatography (hexane:EtOAc) to obtain(1R)-1-(methoxymethy)-5-methyl-2-[(R)-(4-methylphenyl)sulfinyl]-1,2,3,4-tetrahydroisoquinoline(2.144 g) (Rf value=0.14).

Production Example 91

To a mixed solution of(1R)-1-(methoxymethyl)-5-methyl-2-[(R)-(4-methylphenyl)sulfinyl]-1,2,3,4-tetrahydroisoquinoline(2.47 g) in EtOH (45 mL) and THF (10 mL) was added concentratedhydrochloric acid (3.1 mL) under stirring at 0° C., followed by furtherstirring for 10 minutes. To the mixture was added saturated sodiumcarbonate water (50 mL), followed by extraction with EtOAc. The organiclayer was washed with a 1 M aqueous sodium hydroxide solution and asaturated aqueous sodium chloride solution, dried over magnesiumsulfate, and then concentrated under reduced pressure. The resultingresidue was purified by silica gel column chromatography(chloroform:EtOH:aqueous ammonia) to obtain(1R)-1-(methoxymethyl)-5-methyl-1,2,3,4-tetrahydroisoquinoline (1.276g).

Chemical structures of the compounds produced by the above-mentionedProduction Examples are shown in Tables 6 to 12. In addition, in thesame manner as in the methods in the above-mentioned ProductionExamples, the compounds of Production Examples shown in Tables 13 to 35are produced using respective corresponding starting materials. The datafrom instrumental analysis of these compounds of Production Examples isshown in Tables 36 to 42.

Example 1

(1S)-2-(chloroacetyl)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (4.496g) was dissolved in acetonitrile (100 mL). To the mixture were addedpotassium carbonate (6.25 g), tetra-n-butylammoniumiodide (679 mg), and1-(aminomethyl)cyclohexanol hydrochloride (4.50 g), followed by stirringat 60° C. for 6 hours. Thereafter, the solvent was evaporated and waterwas added to the reaction mixture, followed by extraction withchloroform. The extract was washed with saturated brine, and then driedover magnesium sulfate. The solvent was evaporated and the resultingresidue was purified by silica gel column chromatography to obtain1-[({2-[(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol(3.02 g).

The resulting compound (3.02 g) was dissolved in EtOH, to which oxalicacid (777 mg) was added. After complete dissolution was achieved, themixture was stirred for a while and the resulting insoluble materialswere collected to obtain1-[({2-(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanoloxalate (2.985 g).

Example 2

2-acryloyl-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (516 mg) wasdissolved in iPrOH (15 mL). To the reaction mixture were added1-(aminomethyl)cyclohexanol hydrochloride (635 mg) and triethylamine(0.59 mL), followed by stirring under heating at reflux for 16 hours.Thereafter, the solvent was evaporated and water was added to themixture, followed by extraction with chloroform. The extract was washedwith saturated brine, and then dried over magnesium sulfate. The solventwas evaporated and the resulting residue was purified by silica gelcolumn chromatography (chloroform-MeOH) and then further purified byalkaline silica gel column chromatography (chloroform) to obtain1-({[3-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl]amino}methyl)cyclohexanol(214 mg).

The resulting compound (214 mg) was dissolved in EtOH (8 mL). Oxalicacid (51 mg) was added to the reaction mixture to obtain1-({[3-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl]amino}methyl)cyclohexanoloxalate (229 mg).

Example 3

1-cyclohexyl-7-isopropoxide-3,4-dihydroisoquinoline (245 mg) wasdissolved in MeOH (6 mL). Thereafter, sodium borohydride (40 mg) wasadded to the reaction liquid, followed by stirring at room temperaturefor 4 hours. The solvent was evaporated under reduced pressure, andwater and chloroform were added to the mixture. The reaction liquid wasextracted with chloroform and dried over magnesium sulfate. Thereafter,the solvent was evaporated under reduced pressure.

Saturated aqueous sodium bicarbonate (6 mL) was added to the resultingresidue, to which EtOAc (3 mL) was added. A solution of chloroacetylchloride (102 mg) in EtOAc (3 mL) was added dropwise to the reactionliquid over 5 minutes, followed by stirring for 1 hour. Thereafter, thereaction liquid was extracted with EtOAc and dried over magnesiumsulfate, and then the solvent was evaporated.

The resulting residue was dissolved in 1,4-dioxane (8 mL).(2R)-1-amino-2-propanol (180 mg) and 1,8-diazabicyclo[5.4.0]undeca-7-en(146 mg) were added thereto, followed by stirring at 50° C. for 3 hours.Thereafter, the solvent was evaporated and water was added to thereaction liquid, followed by extraction with EtOAc. The extract waswashed with saturated brine, and then dried over magnesium sulfate. Thesolvent was evaporated and the resulting residue was purified by silicagel column chromatography (chloroform-MeOH).

The resulting residue (211 mg) was dissolved in a 1:4 mixed solution ofiPrOH-diethyl ether. Oxalic acid (49 mg) was added to the reactionliquid to obtain(2R)-1-{[2-(1-cyclohexyl-7-isopropoxide-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-oloxalate (223 mg).

Example 4

N-(2-cyclohexa-1-en-1-ylethyl)-N-[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-2,2,2-trifluoroacetamide(210 mg) was dissolved in methylene chloride (5 mL). 75%3-chloroperbenzoic acid (152 mg) was added thereto, followed by stirringat room temperature for 18 hours. Thereafter, a saturated aqueous sodiumsulfite solution was added to the reaction liquid, followed by stirringfor a while. The reaction liquid was extracted with chloroform, and theextract was washed with a 1 M aqueous NaOH solution and saturated brine,and then dried over magnesium sulfate.

The solvent was evaporated and the resulting residue was dissolved in a4:1 mixed solvent (7.5 mL) of THF-1.5% sulfuric acid aqueous solution,followed by stirring under heating at reflux for 5 hours. Water wasadded to the reaction liquid which was then extracted with EtOAc. Theextract was washed with saturated brine, and then dried over magnesiumsulfate.

The solvent was evaporated and the resulting residue was dissolved inMeOH (6 mL). To the reaction liquid was added potassium carbonate (304mg), followed by stirring at 60° C. for 5 hours. Thereafter, the solventwas evaporated and water was added to the reaction liquid which was thenextracted with chloroform. The extract was washed with saturated brine,and then dried over magnesium sulfate. The solvent was evaporated andthe resulting residue was purified by silica gel column chromatography(chloroform-MeOH) to obtaintrans-1-(2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethyl)cyclohexane-1,2-diol(93 mg).

The resulting compound (93 mg) was dissolved in a mixed solvent ofchloroform-EtOH. Oxalic acid (22 mg) was added to the reaction liquid toobtaintrans-1-(2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethyl)cyclohexane-1,2-dioloxalate (66 mg).

Example 5

2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-N-(cyclohexylmethyl)-2-oxoethanamine(296 mg) was dissolved in acetonitrile (10 mL). To the reaction liquidwere added 2-bromoethanol (400 mg), potassium carbonate (555 mg), andpotassium iodide (133 mg), followed by stirring under heating at refluxfor 16 hours. Thereafter, the solvent was evaporated and water was addedto the reaction liquid, followed by extraction with chloroform. Theextract was washed with saturated brine, and then dried over magnesiumsulfate. The solvent was evaporated and the resulting residue waspurified by silica gel column chromatography (chloroform-MeOH) to obtain2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl](cyclohexylmethyl)amino}ethanol(155 mg).

The resulting compound (155 mg) was dissolved in EtOH. Oxalic acid (36mg) was added to the reaction liquid to obtain2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl](cyclohexylmethyl)amino}ethanoloxalate (159 mg).

Example 6

A mixture of1-({[2-(5-bromo-1-isopropyl-8-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol(0.14 g), EtOH (10 mL), triethylamine (0.05 mL), and 10%palladium-supported carbon (10 mg) was stirred under a hydrogenatmosphere for 6 hours. The reaction liquid was filtered and the solventwas evaporated. A 1 M NaOH aqueous solution was added to the resultingresidue, followed by extraction with chloroform. The organic layer wasdried over magnesium sulfate and then the solvent was evaporated. Theresulting residue was purified by silica gel column chromatography(chloroform-MeOH). The resulting residue was dissolved in 2-propanol(0.8 mL). To the reaction liquid were added oxalic acid (23 mg) anddiethyl ether (5 mL) and the precipitated solid was collected byfiltration and dried to obtain1-({[2-(1-isopropyl-8-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanoloxalate (0.066 g).

Example 7

2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethanamine (400mg) was dissolved in EtOH (10 mL). To the reaction liquid were added2-methyl-1-oxaspiro[2.5]octane (555 mg) and water (5 mL), followed bystirring under heating at reflux for 2 days. The solvent was evaporatedand water was added to the reaction liquid, followed by extraction withchloroform. The extract was washed with saturated brine, and then driedover magnesium sulfate. The solvent was evaporated and the resultingresidue was purified by silica gel column chromatography(chloroform-MeOH) to obtain1-(1-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethyl)cyclohexanol(585 mg).

The resulting compound (325 mg) was dissolved in a mixed solution ofEtOH-acetonitrile. Oxalic acid (80 mg) was added to the reaction liquidto obtain1-(1-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethyl)cyclohexanoloxalate (292 mg).

Example 8

2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethanol(342 mg) was dissolved in EtOH (5 mL). 1-oxaspiro[2.5]octane (363 mg)and water (5 mL) were added thereto, followed by stirring under heatingat reflux for 2 days. The solvent was evaporated and water was added tothe reaction liquid, followed by extraction with chloroform. The extractwas washed with saturated brine, and then dried over magnesium sulfate.The solvent was evaporated and the resulting residue was purified bysilica gel column chromatography (chloroform-MeOH) to obtain1-({[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl](2-hydroxyethyl)amino}methyl)cyclohexanol(346 mg).

The resulting compound (346 mg) was dissolved in EtOH (10 mL). Oxalicacid (76 mg) was added to the reaction liquid to obtain1-({[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl](2-hydroxyethyl)amino}methyl)cyclohexanoloxalate (210 mg).

Example 9

N-[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-N-{2-[cis-1,2-dihydroxycyclohexyl]ethyl}-2,2,2-trifluoroacetamide(255 mg) was dissolved in MeOH (10 mL). Potassium carbonate (345 mg) wasadded thereto, followed by stirring at 60° C. for 4 hours. The solventwas evaporated and water was added to the reaction liquid, followed byextraction with chloroform. The extract was washed with saturated brine,and then dried over magnesium sulfate. The solvent was evaporated andthe resulting residue was purified by silica gel column chromatography(chloroform-MeOH) to obtaincis-1-(2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethyl)cyclohexane-1,2-diol(212 mg).

The resulting compound (212 mg) was dissolved in EtOH. Oxalic acid (46mg) was added to the reaction liquid to obtaincis-1-(2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethyl)cyclohexane-1,2-dioloxalate (170 mg).

Example 10

Tert-butyl[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyll]{[cis-1,2-dihydroxycyclohexyl]methyl}carbamate(92 mg) was dissolved in EtOAc (4 mL). 4 M HCl/EtOAc (0.45 mL) was addedthereto, followed by stirring at room temperature for 14 hours. Thesolvent was evaporated and a 1 M NaOH aqueous solution was added to theresulting residue, followed by extraction with chloroform. The extractwas washed with saturated brine, and then dried over magnesium sulfate.The solvent was evaporated and the resulting residue was purified bysilica gel column chromatography (chloroform) to obtaincis-1-({[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexane-1,2-diol(174 mg).

The resulting compound (174 mg) was dissolved in iPrOH. Oxalic acid (43mg) was added to the reaction liquid to obtaincis-1-({[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexane-1,2-dioloxalate (88 mg).

Example 11

Tert-butyl[2-(6-carbamoyll-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl][(1-hydroxycyclohexyl)methyl]carbamate(357 mg) was dissolved in EtOAc (8 mL). 4 M HCl/EtOAc (0.85 mL) wasadded to the reaction liquid under ice-cooling, followed by stirring at60° C. for 5 hours. The solvent was evaporated and water was added tothe resulting residue, followed by washing with chloroform. Saturatedaqueous sodium bicarbonate was added to the aqueous layer which was thenadjusted to a pH of around 8, followed by extraction with chloroform.The extract was washed with saturated brine, and then dried overmagnesium sulfate to obtain1-cyclohexyl-2-{N-[(1-hydroxycyclohexyl)methyl]glycyl}-1,2,3,4-tetrahydroisoquinoline-6-carboxamide(116 mg).

The resulting compound (116 mg) was dissolved in a mixed solution ofiPrOH-diethyl ether. Oxalic acid (24 mg) was added to the reactionliquid to obtain1-cyclohexyl-2-{N-[(1-hydroxycyclohexyl)methyl]glycyl}-1,2,3,4-tetrahydroisoquinoline-6-carboxamideoxalate (70 mg).

Example 12

1-[2-(chloroacetyl)-1,2,3,4-tetrahydroisoquinolin-1-yl]-1-methylethylpivalate (1.2 g) was dissolved in acetonitrile (20 mL). Potassiumcarbonate (2.36 g), 1-(aminomethyl)cyclohexanol hydrochloride (2.26 g),and tetra-n-butylammoniumiodide (126 mg) were added thereto, followed bystirring at 60° C. for 5 hours. Water was added to the reaction liquid,followed by extraction with EtOAc. The extract was washed with saturatedbrine, and then dried over magnesium sulfate. The solvent was evaporatedand the resulting residue was purified by silica gel columnchromatography (chloroform-MeOH).

The resulting residue (1.43 g) was dissolved in methylene chloride (20mL). To the reaction liquid was added a solution of 1.01 Mdiisobutylaluminium hydride/n-hexane (9.55 mL) at −78° C., followed bystirring at −78° C. for 5 hours. Thereafter, the temperature wasincreased to 0° C. over 2 hours. To the reaction liquid was added asaturated aqueous Rochelle salt solution, followed by stirring for 20minutes. Then, celite was added to the reaction liquid which was thensubjected to separation by filtration, followed by extraction withchloroform. The extract was washed with saturated brine, and then driedover magnesium sulfate. The solvent was evaporated and the resultingresidue was purified by silica gel column chromatography(chloroform-MeOH) to obtain1-[({2-[1-(1-hydroxy-1-methylethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol(118 mg).

The resulting compound (150 mg) was dissolved in acetonitrile. Oxalicacid (41 mg) was added to the reaction liquid to obtain1-[({2-[1-(1-hydroxy-1-methylethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanoloxalate (151 mg).

Example 13

2-(1-cyclohexyl-7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-(2-{[cis-2-(methoxymethoxy)cyclopentyl]oxy}ethyl)-2-oxoethanamine(500 mg) was dissolved in MeOH (8 mL). To the reaction liquid was added4 M HCl/EtOAc (0.8 mL) under ice-cooling, followed by stirring at 60° C.for 5 hours. The solvent was evaporated and saturated aqueous sodiumbicarbonate was added to the resulting residue, followed by extractionwith chloroform. The extract was washed with saturated brine, and thendried over magnesium sulfate. The solvent was evaporated and theresulting residue was purified by silica gel column chromatography(chloroform-MeOH) to obtaincis-2-(2-{[2-(1-cyclohexyl-7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethoxy)cyclopentanol(380 mg).

The resulting compound (380 mg) was dissolved in iPrOH. Oxalic acid (80mg) was added to the reaction liquid to obtaincis-2-(2-{[2-(1-cyclohexyl-7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}ethoxy)cyclopentanoloxalate (384 mg).

Example 14

1-(4-chloropyridin-2-yl)-1,2,3,4-tetrahydroisoquinoline hydrochloride(200 mg) and potassium carbonate (344 mg) were dissolved in EtOAc-water(1:1, 4 mL) under ice-cooling. Chloroacetyl chloride (0.85 mL) andbenzyltriethylamine hydroboromate (9.2 mg) were added thereto, followedby stirring at room temperature for 1 hour. To the mixture were added2-amino-1,1-dicyclopropylethanol hydrochloride (190 mg) and potassiumcarbonate (246 mg). The mixture was stirred at 50° C. for 8 hours. Theorganic layer was collected, washed with saturate brine, dried overmagnesium sulfate, filtered, and then concentrated under reducedpressure. The resulting residue was purified by silica gel columnchromatography (chloroform-MeOH) to obtain2-({2-[1-(4-chloropyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl-2-oxoethyl]amino}-1,1-dicyclopropylethanol(143 mg) as a yellow oily material. The oily material was dissolved in a3:1 mixed liquid (4 mL) of diethyl ether-iPrOH. Oxalic acid (30.2 mg)was added to the reaction mixture to obtain2-({2-[1-(4-chloropyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl-2-oxoethyl]amino}-1,1-dicyclopropylethanoloxalate (128 mg).

Example 15

To a solution of8-({[2-(1-cyclohexyl-3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]amino}methyl)-1,4-dioxaspiro[4.5]decan-8-ol(324 mg) in THF (2 mL) were added water (1 mL) and concentratedhydrochloric acid (1 mL). The reaction mixture was refluxed for 5 hours.The temperature was cooled to room temperature and sodium hydrogencarbonate was added to the mixture to make it alkaline, followed byextraction with chloroform. The extract was purified by silica gelcolumn chromatography (chloroform-MeOH) to obtain a targeted amine (176mg).

The amine was dissolved in iPrOH (3 mL), to which oxalic acid (41.7 mg)was added, followed by stirring at room temperature for 2 hours. Theresulting crystal was collected by filtration, washed with ether, anddried at 90° C. under reduced pressure to obtain4-({[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)-4-hydroxycyclohexanoneoxalate (139 mg).

Example 16

To a solution of2-(chloroacetyl)-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (12 mg) inacetonitrile (0.5 mL) were added potassium carbonate (3 mg) and(S)-(+)-2-amino-3-cyclohexyl-1-propanol hydrochloride (15 mg), followedby stirring at 80° C. for 4 hours. Thereafter, a saturated aqueousammonium chloride solution was added to the reaction liquid, followed byextraction with chloroform. The solvent was evaporated and the resultingresidue was purified by preparative HPLC to obtain(2S)-3-cyclohexyl-2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-1-ol(4.1 mg).

Example 17

2-(isopentylamino)-ethanol (26 mg) was added to a solution of2-acryloyl-1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (7 mg) in iPrOH(0.1 mL), followed by stirring at 90° C. for 10 hours. Thereafter, thereaction liquid was purified by preparative HPLC to obtain2-[[3-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl](3-methylbutyl)amino]ethanol(3 mg).

Chemical structures of the compounds produced by the above-mentionedExamples are shown in Tables 43 and 44. In addition, in the same manneras in the methods in the above-mentioned Examples, compounds of Examplesshown in Tables 45 to 110 were produced using respective correspondingstarting materials. The data from instrumental analysis of thesecompounds of Examples is shown in Tables 111 to 125.

TABLE 6 Rex/ salt STRUCTURE 1

2

3

 4*

5

6

7

8

9

10 

11 

12 

13 

14 

TABLE 7 Rex/ salt STRUCTURE 15

16

17

18

 19/ CL

 20*/ MD

 21*/ T2

 22/ TP

23

24

25

26

27

28

TABLE 8 Rex/ salt STRUCTURE 29

30

31

32

33

34

35

36

37

38

 39/ CL

40

41

42

TABLE 9 Rex/ salt STRUCTURE 43

44

 45/ CL

 46/ CL

47

48

 49/ CL

 50/ CL

51

52

 53/ CL

54

55

56

TABLE 10 Rex/ salt STRUCTURE 57

58

59

60

61

 62/ CL

63

64

65

66

67

68

69

70

TABLE 11 Rex/ salt STRUCTURE 71

72

73

74

75

76

 77*

 78*/ CL

 79*/ CL

 80/ OX

 81*/ T2

 82*/ LL

 83/ TX

 84/ CL

TABLE 12 Rex/ salt STRUCTURE  85*

86

87

88

 89*

 90*¹

 91*¹

TABLE 13

Rex R^(A) R^(B) 101 —H 2-OMe-Bn 102 —H 4-Thp 103 3-Br cHex 104 2-OMecHex 105 3-Cl cHex 106 3-F cHex 107 —H 2-CF₃-Ph 108 —H 3-F-Ph 109 —H3-CF₃-Ph 110 —H cyclohexen-4-yl 111 —H 2-F-Ph 112 4-OMe cHex 113 2-ClcHex 114 2-Me cHex 115 4-F cHex 116 2-F cHex 117 —H 2-CF₃-5-F-Ph 118 —H2-OCF₃-Ph 119 —H 2-Et-Ph 120 —H 2-Cl-3-Py 121 —H 3-CF₃-Bn 122 4-Me cHex123 4-CF₃ cHex 124 4-F iPr 125 —H —(CH₂)₂—OMe 126 3-F —CH₂—OMe 127 4-F—CH₂—OMe 128 4-Et —CH₂—OMe 129 —H 2-Me-Bn 130 4-Et —CH₂—Cl 131 2-Me nPr132 3-F nPr 133 2-F —CH₂—OMe 134 2-Me —CH₂—OMe 135 4-Me —CH₂—OMe 136 2-FnPr 137 4-Me nPr 138 2-Me iPr 139 2-F Ph 140 4-Me Ph 141 4-Me iPr 1423-Me cHex 143 3-Me iPr 144 3-Me nPr 145 3-Me —CH₂—OMe 146 —H3,3-diF-cHex 147 —H 6-Me-2-Py 148 —H 6-Br-2-Py 149 —H 6-Cl-2-Py 150 —H4-Cl-2-Py 151 —H

152 4-Me —CH₂—OEt 153 4-Me —CH₂—O—(CH₂)₂—OMe  153A 3-F iPr 609 4-Et—CH₂—Cl 624 4-Et nPr 641 4-Et Me 661 —H 2-OMe-5-F-Ph 662 —H 4-CF₃-Bn

TABLE 14

Rex R^(A) R^(B) R^(C) R^(D) 154 iPr —Br —H —OMe 155 cHex —Br —H —OMe 156tBu —Br —H —OMe 157 Ph —Br —H —OMe 158 Ph —H —OMe —OMe 159 cHex —Br —H—F 160 nPr —Br —H —OMe 161 iPr —Br —H Me 162 —CH₂-iPr —Br —H —OMe 610iPr —Br —H —F 615 nPr —Br —H Me 616 nPr —Br —H —F 619 —CH₂—OMe —Br —H Me639 —CH₂Cl —Br —H —F

TABLE 15

Rex R^(A) R^(B) 163 Me —F 164 —F —CH₂—Br 165 —F —CH₂—CN

TABLE 16

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 166 cPen —H —H —H —H 167 cHex —H —Br—H —H 168 cHex —H —H —H —Br 169 cHex —H —H —H —H 170 —CHEt₂ —H —H —H —H171 cHex —H —H —Br —H 172 cHex —H —H CN —H 173 cHex —H —H —H —OMe 174cHex —H —H —F —H 175 cHex —H —H —Cl —H 176 iPr —H —F —H —H 177 4-F-Ph —H—H —H —H 178 4-CN-Ph —H —H —H —H 179 cyclohexen-4-yl —H —H —H —H 1803-CF₃-Ph —H —H —H —H 181 2-CF₃-Ph —H —H —H —H 182 2-F-Ph —H —H —H —H 183cHex —H —H —H —Cl 184 cHex —H —OMe —OMe —H 185 cHex —H —OMe —H —H 186cHex —H —H —OMe —H 187 2-Cl-Ph —H —H —H —H 188 3-F-Ph —H —H —H —H 1893-Cl-Ph —H —H —H —H 190 cHex —H —H —H —F 191 cHex —H —F —H —H 1921-OH-cHex —H —H —H —H 193 2-OMe-Ph —H —H —H —H 194 2-OCF₃-Ph —H —H —H —H195 cHex —H —H —CONH₂ —H 196 2-CF₃-5-F-Ph —H —H —H —H 197 2-OEt-Ph —H —H—H —H 198 tBu —H —H —H —H

TABLE 17

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 199 iPr —H —H —H —H 200 2-Et-Ph —H —H—H —H 201 2-SMe-Ph —H —H —H —H 202 2-OMe-5-F-Ph —H —H —H —H 203 cHex —H—O—CH₂—O— —H 204 4-CF₃-Bn —H —H —H —H 205 2-Cl-Ph —H —Cl —H —H 2062-Cl-Ph —H —F —H —H 207 cHex —H Me —H —H 208 3-CF₃-Bn —H —H —H —H 209cHex —H —CF₃ —H —H 210 4-Me-Ph —H —H —H —H 211 cHex —H Et —H —H 212 cHex—H —CH₂NHCO-iPr —H —H 213 iPr —H —H —OMe —H 214 cBu —H —H —H —H 215—CH₂—OMe —H —H —H —H 216 —CH(Et)Me —H —H —H —H 217 cHex —H —OCH₂CHF₂ —H—H 218 cHex —H —OCH₂CF₂-Me —H —H 219 —(CH₂)₂—OMe —H —H —H —H 220 iPr —H—OMe —OMe —H 221 iPr —H —OMe —H —H 222 tBu —H —OMe —H —H 223 iPr —H —F—H —H 224 —CH₂—OMe —H —F —H —H 225 —CMe₂—OMe —H —H —H —H 226 —CH₂—OMe —HEt —H —H 227 2-F-Bn —H —H —H —H 228 cHex —OMe —H —H —H 229 cHex —OMe —H—H —Br

TABLE 18

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 232 2-OMe-Bn —H —H —H —H 233 2-Me-Bn—H —H —H —H 234 iPr —OMe —H —H —H 235 tBu —OMe —H —H —H 236A 2-CF₃-Bn —H—H —H —H 237 Ph —OMe —H —H —OMe 238 Ph —H —OMe —H —H 241 Ph —H —H Me —H242 iPr —H —H Me —H 243 cHex —H —H Me —H 244 iPr —H Me —H —H 245—CH₂—OMe —H —H —OMe —H 246 Ph —H —H —H Me 247 iPr —H —H —H Me 248 cHex—H —H —H Me 249 nPr —H —H —F —H 250 Ph —H —H —F —H 251 nPr —H —H —H Me252 nPr —H —H —H —OMe 253 nPr —H —F —H —H 254 nPr —H —H —H —F 255—CH₂—OMe —H Me —H —H 256 —CH₂—OMe —H —OMe —H —H 257 nPr —H Me —H —H 258Ph —OMe —H —OMe —H 259 —CH₂—OMe —H —H —H Me 260 —CH₂—OMe —H —H —H —F 261nPr —OMe —H —H —H 262 —CH₂—OMe —H —H Me —H 263 nPr —H —H Me —H 264 cHexMe —H —H —H 265 cHex —F —H —H —H

TABLE 19

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 266 Ph Me —H —H —H 267 Ph —F —H —H —H268 nPr —H —H —OMe —H 269 Ph —H —H —OMe —H 270 4,4-diF-cHex —H —H —H —H271 3,3-diF-cHex —H —H —H —H 272 4-Thp —H —H —H —H 273 2-C1-3-Py —H —H—H —H 274 6-C1-2-Py —H —H —H —H 275 6-Br-2-Py —H —H —H —H 276 6-Me-2-Py—H —H —H —H 277 4-C1-2-Py —H —H —H —H 278 2-Py —H —H —H —H 279 2-Me-Ph—H —H —H —H 280 iPr Me —H —H —Br 281 —CH₂—OEt —H Me —H —H 282 —CH₂-iPr—H —OMe —H —H 283 —CH₂-iPr —OMe —H —H —H 284 —CH₂—O—(CH₂)₂—OMe —H Me —H—H 285

—H —H —H —H 286 1-Admt —H —H —H —H 614 iPr —F —H —H —Br 628 Ph Et —H —H—H 629 Me —H Et —H —H 633 Me —H Me —H —H 635 nPr Me —H —H —Br 638 nPr —F—H —H —Br 655 —CH₂—O—(CH₂)₃—OMe —H Et —H —H 648 —CH₂—O—(CH₂)₂—OMe —H Et—H —H 656 —CH₂—OMe —F —H —H —Br

TABLE 20

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 230* iPr —H —H —OMe —H 240 —CH₂—OMe —HEt —H —H 287 2-OMe-Ph —H —H —H —H 288 Ph —H —H —H —H 289* cHex —H—CMe₂—OH —H —H 290* Ph —OMe —H —H —H 653* Ph —H —H —F —H 660*² —CH₂—OMe—H —H —H Me

TABLE 21

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 231* iPr —H —H —OMe —H 236* 2-CF₃-Bn—H —H —H —H 239 —CH₂—OMe —H Et —H —H 291 2-OMe-Ph —H —H —H —H 292* cHex—H —CMe₂—OH —H —H 293* cHex —H —OMe —H —H 294* Ph —H —OMe —H —H 295* Ph—OMe —H —H —H 296* iPr —O—CHF₂ —H —H —H 297* Ph —O—CHF₂ —H —H —H 644* Ph—CN —H —H —H 651* Ph —H —H —F —H 659*¹ —CH₂—OMe —H —H —H Me

TABLE 22

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 298 cHex —H —H —H Me 299 cHex —H Me Me—H 300 cHex Me —H —H —H 301 —(CH₂)₂—O—(CH₂)₂— —H —H —H 302 Me Me —H —H—H

TABLE 23

Rex salt R^(A) R^(B) R^(C) R^(D) R^(E) 303 Ph —H Me —H —H 304 —CHEt₂ —H—H —H —H 305 cHex —H —H —Br —H 306 iPr —OMe —H —H —Br 307 iPr —H —OMe —H—H 308 cHex —H —OH —H —H 309 cHex —H —H —H —OMe 310 cHex —H —H —F —H 311cHex —H —H —Cl —H 312 2-CF₃-Ph —H —H —H —H 313 cyclohexen-4-yl —H —H —H—H 314 3-CF₃-Ph —H —H —H —H 315 2-F-Ph —H —H —H —H 316 4,4-diF-cHex —H—H —H —H 317 cHex —H —H —H —F 318 cHex —H —F —H —H 319 2-CF₃-5-F-Ph —H—H —H —H 320 2-COCF₃-Ph —H —H —H —H 321 2-OEt-Ph —H —H —H —H 322 2-Et-Ph—H —H —H —H 323 2-SMe-Ph —H —H —H —H 324 2-Cl-Ph —H —Cl —H —H 325 CL2-Cl-Ph —H —F —H —H 326 2-OMe-5-F-Ph —H —H —H —H 327 4-CF₃-Bn —H —H —H—H 328 3-CF₃-Bn —H —H —H —H 329 cHex —H —CF₃ —H —H 330 cHex —H Et —H —H331 —CH(Et)-Me —H —H —H —H 332 cHex —H —OiPr —H —H 333 iPr —H —F —H —H334 —(CH₂)₂—OMe —H —H —H —H 335 —CH₂—OMe —H —F —H —H

TABLE 24

Rex salt R^(A) R^(B) R^(C) R^(D) R^(E) 336 cHex —OMe —H —H —Br 3372-F-Bn —H —H —H —H 338 2-OMe-Bn —H —H —H —H 339 2-Me-Bn —H —H —H —H 340Ph —OMe —H —H Br 341 iPr —H —H —OMe —H 342 —CH₂—OMe —H Me —H —H 343 Ph—OMe —H —OMe —H 344 Ph —H —H —H —F 345 —CH₂—OMe —H —H —OMe —H 346 iPr —H—H —H Me 347 cHex —H —H —H Me 348 iPr —H Me —H —H 349 cHex —H —H Me —H350 iPr —H —H Me —H 351 Ph —H —F —H —H 352 nPr —H —H —H —OMe 353 nPr —HMe —H —H 354 nPr —H —H —H —F 355 nPr —H —OMe —H —H 356 —CH₂—OMe —H —OMe—H —H 357 —CH₂—OMe —H —H —H Me 358 nPr —H —H Me —H 359 nPr —OMe —H —H—Br 360 cHex —F —H —H —Br 361 —CH₂—OMe —H —H —H —OMe 362 CL Ph —F —H —H—H 363 —CH₂—OMe —H —H —H —F 364 4-Thp —H —H —H —H 365 2-Cl-3Py —H —H —H—H 366 6-Me-2-Py —H —H —H —H 367 6-Br-2-Py —H —H —H —H 368 6-Cl-2-P —H—H —H —H 369 4-Cl-2-P —H —H —H —H

TABLE 25

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 370 tBu —OMe —H —H —Br 371 iPr Me —H—H —Br 372 —CH₂—OEt —H Me —H —H 373 —CH₂-iPr —H —OMe —H —H 374 —CH₂-iPr—OMe —H —H —Br 375 —CH₂—O—(CH₂)₂—OMe —H Me —H —H 375A iPr —H —H —F —H612 iPr —F —H —H —Br 620 nPr Me —H —H —Br 621 nPr —F —H —H —Br 625 Ph Et—H —H —OMe 626 nPr —H Et —H —H 637 —CH₂—OMe —F —H —H —Br 643 Me —H Et —H—H

TABLE 26

Rex salt R^(A) R^(B) R^(C) R^(D) R^(E) 376 CL iPr —H —H —OMe —H 377 cHex—H —H —H —H 378 CL cHex —H —H —H —Br 379 —CHEt₂ —H —H —H —H 380 CL cHex—H —H —Br —H 381 CL iPr —OMe —H —H —Br 382 CL cHex —H —H —F —H 383 CLcHex —H —H —Cl —H 384 cyclohexen-4-yl —H —H —H —H 385 3-CF₃-Ph —H —H —H—H 386 2-F-Ph —H —H —H —H 387 CL cHex —H —H —H —OMe 388 CL 4,4-diF-cHex—H —H —H —H 389 CL cHex —H —H —H —Cl 390 CL cHex —H —OMe —H —H 391 CLcHex —H —H —OMe —H 392 3-F-Ph —H —H —H —H 393 CL cHex —H —H —H —F 394 CL2-OCF₃-Ph —H —H —H —H 395 2-CF₃-5-F-Ph —H —H —H —H 396 CL 2-OEt-Ph —H —H—H —H 397 CL 2-Et-Ph —H —H —H —H 398 2-SMe-Ph —H —H —H —H 399 CL2-OMe-5-F-Ph —H —H —H —H 400 4-Thp —H —H —H —H 401 CL 2-Cl-Ph —H —Cl —H—H 402 CL 2-Cl-Ph —H —F —H —H 403 4-CF₃-Bn —H —H —H —H 404 CL cHex —H CN—H —H 405 3-CF₃-Bn —H —H —H —H 406 CL cHex —H —CF₃ —H —H 407 CL cHex —H—CH₂NHCO-iPr —H —H 408 CL —CH(Et)-Me —H —H —H —H

TABLE 27

Rex salt R^(A) R^(B) R^(C) R^(D) R^(E) 409 CL iPr —H —OMe —H —H 500 CLiPr —H —F —H —H 501 —(CH₂)₂—OMe —H —H —H —H 502 —CH₂—OMe —H —F —H —H 503CL cHex —OMe —H —H —Br 504 CL cHex —OMe —H —H —H 505 —CH₂—OMe —H Et —H—H 506 CL 2-F-Bn —H —H —H —H 507 2-OMe-Bn —H —H —H —H 508 2-Me-Bn —H —H—H —H 509 CL tBu —OMe —H —H —Br 510 CL tBu —OMe —H —H —H 514 CL Ph —H —H—H —F 515 CL Ph —H —H —H Me 516 CL iPr —H —H —H Me 517 CL cHex —H —H —HMe 518 —CH₂—OMe —H —H —OMe —H 519 nPr —H —H —F —H 520 CL iPr —H Me —H —H521 CL Ph —H Me —H —H 522 CL iPr —H —H Me —H 523 CL Ph —H —F —H —H 524CL nPr —H —H —H Me 525 CL nPr —H Me —H —H 526 CL nPr —H —H —H —F 527 CLnPr —H —OMe —H —H 528 CL —CH₂—OMe —H Me —H —H 529 nPr —H —H Me —H 530 CLcHex —F —H —H —Br

TABLE 28

Rex salt R^(A) R^(B) R^(C) R^(D) R^(E) 531 BR cHex —F —H —H —H 532 CLcHex Me —H —H —H 533 CL —CH₂—OMe —H —H —H Me 534 CL Ph Me —H —H —H 535CL Ph —F —H —H —H 536 CL 3,3-diF-cHex —H —H —H —H 537 CL 2-Cl-3-Py —H —H—H —H 538 6-Me-2-Py —H —H —H —H 539 6-Br-2-Py —H —H —H —H 540 6-Cl-2-Py—H —H —H —H 541 CL 4-Cl-2-Py —H —H —H —H 542 iPr Me —H —H —Br 543—CH₂—OEt —H Me —H —H 544 —CH₂-iPr —H —OMe —H —H 545 —CH₂-iPr —OMe —H —H—Br 545A OX cPen —H —H —H —H 546 —CH₂-iPr —OMe —H —H —H 546A CL iPr —H—H —F —H 547 —CH₂—O—(CH₂)₂—OMe —H Me —H —H 613 CL iPr —F —H —H —Br 622CL nPr Me —H —H —Br 627 nPr —H Et —H —H 631 CL Me —H Et —H —H 634 Ph Et—H —H —H 640 CL —CH₂—O—(CH₂)₃—OMe —H Et —H —H 647 —CH₂—O—(CH₂)₂—OMe —HEt —H —H 649 CL Ph Et —H —H —OMe 654 —CH₂—OMe —F —H —H —Br

TABLE 29

Rex R^(A) R^(B) R^(C) R^(D) R^(E) 548 cHex —H —H —Br —H 549 cHex —H —H—F —H 550 cHex —H —H —Cl —H 551 cHex —H —H —H —F 552 cHex —H —F —H —H553 cHex —H —CF₃ —H —H 554 cHex —H Et —H —H 555 —(CH₂)₂—OMe —H —H —H —H556 —CH₂—OMe —H —F —H —H 557 2-F-Bn —H —H —H —H 558 2-OMe-Bn —H —H —H —H559 2-Me-Bn —H —H —H —H 560 —CH₂—Cl —H Et —H —H 561 iPr —H —H —H Me 562cHex —H —H —H Me 563 Ph —H —H —H —F 564 cHex —F —H —H —Br 565 —CH₂-iPr—H —OMe —H H 611 iPr —F —H —H —Br 617 nPr Me —H —H —Br 618 nPr —F —H —H—Br 623 Ph Et —H —H —OMe 636 —CH₂—Cl —F —H —H —Br 642 Me —H Et —H —H

TABLE 30

Rex salt R^(A) R^(B) R^(C) R^(D) R^(E) 566 TQ -2-OMe-Ph —H —H —H —H 567*T2 Ph —OMe —H —H —Br 568* CL Ph —OMe —H —H —H 570* T2 iPr —OMe —H —H —Br571* CL iPr —OMe —H —H —H 645* CL Ph —CN —H —H —H 650* T2 Ph —H —H —F —H

TABLE 31

Rex salt R^(A) R^(B) R^(C) R^(D) R^(E) 513 TY —CH₂—OMe —H Et —H —H 547A*ML iPr —H —H —OMe —H 572* T1 cHex —H —H —H —H 575* T1 cHex —H —Br —H —H576* T1 Ph —OMe —H —H —Br 577* CL Ph —OMe —H —H —H 652* T1 Ph —H —H —F—H 658*² —CH₂—OMe —H —H —H Me

TABLE 32

Rex R^(A) R^(B) 578

—H 579

—H 580 1-boc-4-pipe —H 581 —CH₂-(1-boc-4-pipa) —H 582 4-pipe —H 583—CH₂-1-pipa —H 584 boc CN 585 boc —O—CH₂—CHF₂

TABLE 33

Rex R^(A) R^(B) 586

—H 587

—H 588

—H 630 Me Et 632 Me Me 646

Et

TABLE 34

Rex R^(A) R^(b) R^(C) R^(D) 589 —(CH₂)₂—OMe —H —H —H 590

—H —H —H 591 cPr —H —H —H 592 —CH₂-cHex —H —H —H 593 —(CH₂)₂—OH —H —H —H594

—H —H —H 595

boc —H —H 596 —CH₂-(1-OH-cHex) boc —H —CONH₂ 597

—COCF₃ —OMe —H 598

—COCF₃ —OMe —H 599

—H —OMe —H 600

—COCF₃ —OMe —H 601

—H —OMe —H 602 —CH₂-(1-OH-cHex) —H —H —CONH₂

TABLE 35 Rex STRUCTURE 603

604

605

606

607

608

657*²

TABLE 36 Rex Data 1 FAB: 477 2 FAB: 511 3 ES: 493 4 CI: 292 5 FAB: 326 6AP1: 285.87 7 FAB: 270 8 FAB: 433 9 FAB: 343 10 APN: 411 11 FAB: 373 12ES: 313 13 ES: 273 14 FAB: 467 15 ES: 362 16 ES: 286 17 ES: 376 18 AP1:269.96 19 CI: 230 20 FAB: 206 21 ES: 216 22 ES: 240 23 AP: 278 24 FAB:320 25 FAB: 248 26 FAB: 248 27 FAB: 244 28 ES: 226 29 FAB: 250 30 AP:230 31 FAB: 188 32 CI: 284 33 FAB: 266 34 FAB: 268 35 FAB: 276 36 ESNa:374 37 ES: 418 38 ES: 285 39 ES: 241 40 FAB: 363 41 EI: 238 42 FAB: 25643 ES: 334 44 FAB: 350 45 FAB: 206 46 FAB: 214 47 EI1: 209 48 CI: 236 49FAB: 222 50 FAB: 228 51 FA1: 355.98 52 FAB: 234.13 53 ES: 142 54 ES: 18355 ES: 206 56 ES: 297 57 ES: 283 58 NMR (CDCl₃): 1.28 (3 H, t, J = 7Hz), 2.73-2.95 (3H, m), 3.45 (1H, m), 3.80 (1H, d, J = 13.4 Hz), 3.87(1H, d, J = 13.4 Hz), 4.16-4.24 (2H, m), 4.52 (1H, s), 7.11-7.39 (9H,s). 59 ES: 346.05 60 FAB: 391 61 ES: 284 62 CI: 206 63 ESNa: 372 64 ES:258 65 FAB: 313 66 ES: 205 67 FAB: 270.98 68 N/D 69 ES: 366.4 70 FAB:359 71 FAN: 385 72 N/D 73 FAB: 413 74 FA1: 331 75 FAB: 388 76 FAB: 41077 ESNa: 314 78 ES: 242 79 ES2: 277 80 ES: 160 81 ES1: 294 82 ES: 292 83ES: 207 84 N/D 85 FAB: 458 86 CI: 348 87 FAB: 338 88 AP: 248.00 89 ES:357 90 ES: 330.13 91 ES: 192.18

TABLE 37 Rex Rsyn Data 101 34 ES: 270 102 34 AP: 234 103 34 ES: 310, 312104 33 FAB: 262 105 34 ES: 266, 268 106 34 ES: 250 107 33 ES: 294 108 33ES: 244 109 33 ES: 294 110 33 FAB: 230.16 111 33 ES: 244 112 33 FAB: 262113 33 FAB: 266 114 33 FAB: 246 115 33 FAB: 250 116 33 FAB: 250 117 33ES: 312 118 34 ES: 310 119 34 ES: 254 120 34 ES: 261 121 34 ES: 308 12233 FAB: 246 123 33 FAB: 300 124 33 FAB: 210 125 34 ES: 208 126 33 ES:212.0 127 33 ES: 212 128 33 ES: 222.18 129 34 ES: 254 130 33 ES: 226 13133 ES: 206.19 132 33 ES: 210.08 133 33 ES: 212.11 134 33 AP: 208.00 13533 ES: 208.1 136 33 AP: 210.06 137 33 ES: 206.18 138 33 EI1: 204 139 33ES: 244 140 33 FAB: 240 141 33 FAB: 206 142 33 FAB: 246 143 33 FAB: 206144 33 ES: 206.97 145 33 ES: 208.17 146 34 FAB: 268 147 34 ES: 241 14834 ES: 305 149 34 ES: 261 150 34 ES: 261 151 34 AP: 246 152 34 ES: 222153 34 CI: 252 153A 33 FAB: 210 154 33 FAB: 302 155 33 FAB: 340 156 33FAB: 314 157 33 FAB: 334 158 33 ES: 286.79 159 33 FAB: 328 160 33 CI1:300 161 33 CI: 284 162 34 CI1: 314 163 48 EIN: 213 164 48 EIBr: 213 16548 EI1: 239 166 4 FAB: 278 167 4 ES: 372 168 4 ES: 371 169 4 FAB: 292.1170 4 ES: 280 171 4 ES: 370, 372 172 4 ES: 317 173 4 FAB: 322 174 4 ES:310 175 4 AP: 326, 328 176 4 FAB: 270 177 4 ES: 304 178 4 ES: 311 179 4FA2: 291.93 180 4 ES: 354

TABLE 38 Rex Rsyn Data 181 4 ES: 354 182 4 ES: 304 183 4 ES1: 326 184 4FAB: 352.07 185 4 FAB: 322 186 4 FA1: 322 187 4 ES: 322 188 4 ES: 304189 4 ES: 320 190 4 FAB: 310 191 4 ES: 310 192 4 FAB: 308 193 4 ES: 316194 4 ES: 370 195 Syn: 14 N/D 196 4 ES: 372 197 4 ES: 330 198 4 FAB: 266199 4 FAB: 252 200 4 ES: 314 201 4 ES: 332 202 4 ES: 334 203 4 FAB:336.07 204 4 ES: 368 205 4 FAB: 354 206 4 FAB: 338 207 4 FAB: 306 208 4ES: 368 209 4 FAB: 360 210 4 FAB: 300.02 211 60 FAB: 320 212 4 FAB: 391213 4 FAB: 282 214 4 FAB: 264 215 4 ES: 276 216 4 FAB: 266 217 40 FAB:372 218 40 FAB: 386 219 4 ES: 268 220 4 EI1: 311 221 4 CI: 282 222 4FAB: 296 223 4 FAB: 270 224 4 ES: 272 225 4 ES: 282 226 4 ES: 282 227 4ES: 318 228 4 FAB: 322 229 4 FAB: 402 230 4 FAB: 282 231 4 CI: 282 232 4ES: 330 233 4 ES: 314 234 4 FAB: 282 235 4 FAB: 296 236 4 ES: 368 236A 4ES: 368.08 237 4 FAB: 346.11 238 4 FAB: 316.02 239 4 ES: 282 240 4 ES:282 241 4 FAB: 300 242 4 FAB: 266 243 4 ES: 306 244 4 FAB: 266 245 4 ES:284.08 246 4 FAB: 300 247 4 FAB: 266 248 4 FAB: 306 249 4 ES: 270.03 2504 ES: 304 251 4 FAB: 266 252 4 FAB: 282 253 60 ES2: 271.70 254 4 CI: 270255 4 FAB: 268 256 60 FAB: 284 257 4 FAB: 266 258 4 ES2: 347.82 259 4CI: 268

TABLE 39 Rex Rsyn Data 260 60 ESNa: 294 261 4 CI: 282 262 4 ES2: 269.73263 4 ES1: 265.98 264 4 CI: 306 265 4 CI: 310 266 4 CI: 300 267 4 CI:304 268 4 ES: 282.07 269 4 ES: 316 270 4 FAB: 328 271 4 FAB: 328 272 4FAB: 294 273 4 ES: 321 274 4 ES: 321 275 4 ES: 365 276 4 ES: 301 277 4ES: 321 278 4 ES: 287 279 4 FAB: 00 280 4 FAB: 346 281 4 CI: 282 282 4ES: 296 283 4 CI: 296 284 60 CI: 312 285 4 AP: 306 286 4 FAB: 344 287 4ES: 316 288 4 FAB: 286.35 289 44 ESNa: 372 290 4 EI1: 315 291 4 ES: 316292 44 CI: 350 293 4 EI: 321 294 4 FAB: 316 295 4 FAB: 316 296 4 ES: 318297 4 ES: 352 298 4 FAB: 306 299 4 FAB: 320.0 300 4 FAB: 306.06 301 4FAB: 310.12 302 4 FAB: 238 303 27 CI: 222 304 28 ES: 202 305 25 ES: 292,294 306 27 FAB: 282 307 26 EIN: 202 308 26 FAB: 230 309 27 FAB: 244 31025 ES: 232 311 25 ES: 248 312 27 ES: 276 313 27 FA2: 213.28 314 27 ES:276 315 27 ES: 226 316 27 FAB: 250 317 25 ES: 232 318 25 FAB: 232 319 28ES: 294 320 27 ES: 292 321 27 ES: 252 322 27 ES: 236 323 27 ES: 254 32426 FAB: 276 325 26 ES: 260 326 27 ES: 256 327 29 ES: 290 328 29 ES: 291329 25 FAB: 282 330 25 FAB: 242 331 28 EIN: 186 332 27 FAB: 272 333 27FAB: 192 334 25 ES: 190 335 25 ES: 194.22 (M + H) 336 27 FAB: 322 337 25ES: 241 338 25 ES: 252 339 25 ES: 236

TABLE 40 Rex Rsyn Data 340 27 FAB: 318 341 27 EIN: 202 342 31 CI: 190343 31 ES2: 269.20 344 25 ES: 226 345 31 ES: 206.23 346 25 FAB: 188 34725 FAB: 228 348 27 CI: 188 349 26 CI: 228 350 27 CI: 188 351 26 ES: 226352 31 FAB: 204 353 31 FAB: 188 354 31 FAB: 192 355 29 FAB: 204 356 29CI: 206 357 31 CI: 190 358 31 AP: 188.15 359 31 CI1: 282 360 25 EI1: 311361 29 ES: 206 362 49 EIN: 224 363 31 CIN: 192 364 29 AP: 216 365 28 ES:245 366 28 ES: 223 367 28 ES: 287 368 28 ES: 243 369 28 ES: 243 370 27FAB: 296 371 27 EI1: 265 372 31 ES: 204 373 26 ES: 218 374 31 CI1: 296375 31 CI: 234 375A 27 FAB: 192 376 18 FAB: 206 377 18 FA2: 217.3 378 18ES: 294, 296 379 18 ES: 204 380 18 ES: 296 381 18 FAB: 284 382 18 ES:234 383 18 ES: 250 384 18 AP: 214.08 385 18 ES: 278 386 18 ES: 228 38718 FAB: 246 388 18 FAB: 252 389 18 ES: 250 390 18 FAB: 246 391 18 FAB:246 392 18 ES: 228 393 18 FAB: 243 394 18 AP: 294 395 23 ES: 296 396 18ES: 254 397 18 ES: 238 398 18 ES: 256 399 18 ES: 258 400 18 AP: 218 40118 FAB: 278 402 18 FAB: 262 403 18 ES: 292 404 18 FAB: 241 405 18 ES:292 406 18 FAB: 284 407 39 FAB: 315 408 18 ES: 190 409 18 FAB: 206 50018 FAB: 194 501 18 ES: 192 502 18 ES: 197 503 18 FAB: 324 504 45 FAB:246 505 18 ES: 206 506 18 ES: 242 507 18 ES: 254 508 18 ES: 238 509 18FAB: 298

TABLE 41 Rex Rsyn Data 510 45 FAB: 220 513 83 ES: 206 514 18 ES: 228 51518 FAB: 224 516 18 FAB: 190 517 18 FAB: 230 518 18 ES: 208.15 519 18ES2: 195.05 520 18 CI: 190 521 18 CI: 224 522 18 CI: 190 523 18 ES: 228524 18 FAB: 190 525 18 FAB: 190 526 18 FAB: 194 527 18 FAB: 206 528 18CI: 192 529 18 AP: 190.19 530 18 FAB: 312 531 45 FAB: 234 532 18 FAB:230 533 18 ES: 192 534 18 ES: 224 535 18 CI: 228 536 18 FAB: 252 537 18ES: 245 538 18 ES: 225 539 18 ES: 289 540 18 ES: 245 541 18 ES: 245 54218 CI: 268 543 18 ES: 206 544 18 ES: 220 545 18 CI1: 298 546 45 ES: 220547 60 CI: 312 548 24 ES: 364, 366 549 24 ES: 304 550 24 ES: 320 551 24FAB: 304 552 24 FAB: 304 553 24 FAB: 354 554 24 FAB: 314 555 25 ESNa:284 556 24 ES: 266 557 24 ES: 312 558 24 ES: 324 559 24 ES: 308 560 24ES: 280 561 24 FAB: 260 562 24 FAB: 300 563 24 ES: 298 564 24 FAB: 382565 26 N/D 566 22 ES: 240 567 81 EI1: 317 568 45 CI: 240 570 81 ES: 286571 45 ES: 206 572 21 ES: 216 575 81 FAB: 294 576 81 EI1: 317 577 45 CI:240 578 10 ES: 413 579 12 ES: 313 580 10 ES: 427 581 Syn: 1 ES: 442 58212 ES: 327 583  Syn: 10 ES: 342 584 37 FAB: 341 585 75 FAB: 396 586  7FAB: 294.01 587  7 FAB: 264.01 588  7 FAB: 264.03 589 Syn: 1 ES: 331 590Syn: 1 N/D 591 Syn: 1 ES: 313 592 Syn: 1 FAB: 369 593 Syn: 1 FAB: 317594 Syn: 1 ES: 381

TABLE 42 Rex Rsyn Data 595 2 ES: 501 596 14 FAB: 528 597 2 FAN: 541 5981 FAB: 507 599 Syn: 1 FAB: 411 600 2 ES: 526 601 Syn: 1 FAB: 475 602 Syn: 10 N/D 603 Syn: 1 FAB: 360 604 Syn: 1 FAB: 437 605 33 FA2: 261.2606 27 FA2: 243.5 607 18 FA2: 245.4 608 80 AP: 106.0 609 33 ES: 255.99610 33 CI: 288 611 24 CI: 344 612 25 ES: 270 613 18 ES: 272 614 4 CI:350 615 33 CI: 284 616 33 CI: 288 617 24 FAB: 338 618 24 FAB: 342 619 33CI: 286 620 25 EIN: 264 621 25 EIN: 268 622 18 ES: 268 623 24 ES: 338624 33 AP: 220.03 625 25 CI: 266 626 84 AP: 202.06 627 18 AP: 204.00 62840 EI1: 313 629 4 CI: 252 630 7 CI: 230 631 18 ES: 176 632 7 EI1: 215633 4 CI: 238 634 40 EI1: 237 635 4 CI: 344 636 24 FAB: 350 637 66 N/D638 4 CI: 350 639 33 ES: 296 640 88 CI: 264 641 33 EI: 192 642 24 ES:246 643 25 EI1: 173 644 40 FAB: 311 645 40 ES: 235 646 7 CI: 260 647 18ES: 250.25 648 4 ES: 326 649 18 ES: 268 650 21 FAB: 228 651 4 CI: 304652 21 FAB: 228 653 4 FAB: 304 654 18 CI: 274 655 4 CI: 340 656 4 CI:352 657 90 ES: 330.14 658 91 ES: 192.13 659 4 ES: 268.09 660 4 ES:268.09 661 34 ES: 274 662 34 ES: 308

TABLE 43 Ex/ salt STRUCTURE 1/ OX

2/ OX

3/ OX

4/ OX

5/ OX

6/ OX

7/ OX

8/ OX

9/ OX

10/  OX

11/  OX

12/  OX

TABLE 44 Ex/ salt STRUCTURE 13/ OX

14/ OX

15/ OX

16

17

TABLE 45 Ex salt STRUCTURE 101 OX

102 OX

103 OX

104 OX

105 OX

106 OX

107 OX

TABLE 46 Ex salt STRUCTURE 108 OX

109 OX

110 OX

111 OX

112 OX

113 OX

114

TABLE 47 Ex salt STRUCTURE 115

116 OX

117 OX

118 OX

119 OX

120 OX

121 OX

TABLE 48 Ex salt STRUCTURE 122 OX

123 OX

124 OX

125 OX

126 OX

127 OX

128 OX

TABLE 49 Ex salt STRUCTURE 129 OX

130 OX

131 OX

132 OX

133 OX

134 OX

135 OX

TABLE 50 Ex salt STRUCTURE 136 OX

137 OX

138 OX

139 OX

140 OX

141 OX

TABLE 51 Ex salt STRUCTURE 143 FM

144 OX

145 FM

146 OX

147 OX

148 OX

149 OX

TABLE 52 Ex salt STRUCTURE 150 OX

151 OX

152 OX

153 FM

154 OX

155 OX

TABLE 53 Ex salt STRUCTURE 156 OX

157 CL

158 OX

159 OX

160 OX

161 OX

TABLE 54 Ex salt STRUCTURE 162 OX

163 OX

164 OX

165 OX

166 OX

167 OX

TABLE 55 Ex salt STRUCTURE 168 FM

169 FM

170 OX

171 OX

172 OX

173 OX

174 OX

TABLE 56 Ex salt STRUCTURE 175 OX

176 OX

177 OX

178 OX

179 OX

180 OX

181 OX

TABLE 57 Ex salt STRUCTURE 182 OX

183 OX

184 OX

185 OX

186 OX

187 OX

188 OX

TABLE 58 Ex salt STRUCTURE 189 OX

190 OX

191 OX

192 OX

193 OX

194 OX

TABLE 59 Ex salt STRUCTURE 195 OX

196 OX

197 OX

198 OX

199 FM

200 FM

201 FM

TABLE 60 Ex salt STRUCTURE 202 FM

203 OX

204 FM

205 OX

206 OX

207 OX

208 OX

TABLE 61 Ex salt STRUCTURE 209 FM

210 FM

211 OX

212 OX

213 OX

214 OX

215 OX

TABLE 62 Ex salt STRUCTURE 216 OX

217 OX

218 OX

219 OX

220 OX

221 OX

222 OX

TABLE 63 Ex salt STRUCTURE 223 OX

224 OX

225 OX

226 OX

227 OX

228 OX

229 OX

TABLE 64 Ex salt STRUCTURE 230 OX

231 OX

232 OX

233 OX

234 OX

235 OX

236 OX

TABLE 65 Ex salt STRUCTURE 237 OX

238 OX

239 OX

240 OX

241 OX

242 OX

246 OX

TABLE 66 Ex salt STRUCTURE 244 OX

245 OX

246 OX

247 OX

249 OX

250 OX

TABLE 67 Ex salt STRUCTURE 252 OX

253 OX

254 OX

255 OX

256 OX

257 OX

258 OX

259 OX

TABLE 68 Ex salt STRUCTURE 260 OX

261 OX

262 FM

263 FM

264 OX

265 OX

266 OX

TABLE 69 Ex salt STRUCTURE 267 OX

268

269 OX

270 OX

271 OX

272 OX

TABLE 70 Ex salt STRUCTURE 273 OX

274 OX

275 OX

276 OX

277 OX

278 FM

279 OX

TABLE 71 Ex salt STRUCTURE 280 FM

281 OX

282 OX

283 OX

284 OX

285 OX

286 OX

287 OX

TABLE 72 Ex salt STRUCTURE 288 OX

289 OX

290 FM

291 FM

292 OX

293 OX

294 OX

295 OX

TABLE 73 Ex salt STRUCTURE 296 OX

297 OX

298 OX

299 OX

300 OX

301 OX

302 OX

303 OX

TABLE 74 Ex salt STRUCTURE 304 OX

305 OX

306 T2

307 T1

308 OX

309 OX

310 FM

TABLE 75 Ex salt STRUCTURE 311 OX

312 OX

313 OX

314 OX

315 OX

316 OX

317 OX

318 OX

TABLE 76 Ex salt STRUCTURE 319 OX

320 OX

321 OX

322 OX

323 OX

324 OX

325 OX

326 OX

TABLE 77 Ex salt STRUCTURE 327 OX

328 OX

329 OX

330 OX

331 OX

332 BR

333 FM

TABLE 78 Ex salt STRUCTURE 334 OX

335 OX

336 OX

337 OX

338 OX

339 OX

340 OX

341 OX

TABLE 79 Ex salt STRUCTURE 342 OX

343 OX

344 OX

345 OX

346 OX

347 OX

348 OX

349 OX

TABLE 80 Ex salt STRUCTURE 350 OX

351 OX

352 OX

353 OX

354 OX

355 OX

356 OX

TABLE 81 Ex salt STRUCTURE 357 OX

358 OX

359 OX

360 OX

361 OX

362 OX

363 OX

364 OX

TABLE 82 Ex salt STRUCTURE 365 OX

366 OX

367 OX

368 OX

369 OX

370 OX

371 OX

372 OX

TABLE 83 Ex salt STRUCTURE 373 OX

374 OX

375 OX

376 OX

377 OX

378 OX

379 OX

380 OX

TABLE 84 Ex salt STRUCTURE 381 OX

382 OX

383 OX

384 OX

385 OX

386 OX

387 OX

388 OX

TABLE 85 Ex salt STRUCTURE 389 OX

390 OX

391 OX

392 OX

393 OX

394 OX

395 OX

TABLE 86 Ex salt STRUCTURE 396 OX

397 OX

398 OX

399 OX

400 OX

401 OX

402 OX

TABLE 87 Ex salt STRUCTURE 403 OX

404 OX

405 OX

406 OX

407 OX

408 OX

409 OX

TABLE 88 Ex salt STRUCTURE 410 OX

411 OX

412 OX

413 OX

414 OX

415 FM

416 OX

417 OX

TABLE 89 Ex salt STRUCTURE 418 OX

419 OX

420 OX

421 OX

422 OX

423 OX

424 OX

TABLE 90 Ex salt STRUCTURE 425 OX

426 OX

427 OX

428 OX

429 OX

430 OX

431 OX

432 OX

TABLE 91 Ex salt STRUCTURE 433 OX

434 OX

435 FM

436 T2

437 OX

438 OX

439 T1

TABLE 92 Ex salt STRUCTURE 440 OX

441 OX

442 OX

443 OX

444 OX

445 FM

446 FM

447 OX

TABLE 93 Ex salt STRUCTURE 448 FM

449 OX

450 OX

451 OX

452 OX

453 OX

454 OX

455 OX

TABLE 94 Ex salt STRUCTURE 456 OX

457 OX

458

459 OX

460

461 OX

462 OX

463 OX

TABLE 95 Ex salt STRUCTURE 464 OX

465 FM

466 OX

467 OX

468

469 OX

470 OX

471 OX

TABLE 96 Ex salt STRUCTURE 472 OX

473 OX

474 OX

475 OX

476 OX

477 OX

478 OX

479 OX

TABLE 97 Ex salt STRUCTURE 480 OX

481 OX

482 OX

483 OX

484 OX

485 OX

486 OX

487 OX

TABLE 98 Ex salt STRUCTURE 488 OX

489

490 OX

491

492 OX

493 OX

494

495 OX

496 OX

TABLE 99 Ex salt STRUCTURE 497 OX

498 OX

499 OX

500 OX

501 OX

502 OX

503 OX

TABLE 100 Ex salt STRUCTURE 504 OX

505 OX

506 OX

507 OX

508 OX

509 OX

510 OX

TABLE 101 Ex salt STRUCTURE 511

512

513

514

515

516

517

TABLE 102 Ex salt STRUCTURE 518

519

520

521

522

523

524

TABLE 103 Ex salt STRUCTURE 525

526

527

528

529

530

531

TABLE 104 Ex salt STRUCTURE 532

533

534

535

536

TABLE 105 Ex salt STRUCTURE 537 OX

538 OX

539 OX

540 OX

541 OX

542 OX

543 OX

TABLE 106 Ex salt STRUCTURE 544 OX

545 OX

546 OX

547 OX

548 OX

549 OX

550 OX

TABLE 107 Ex salt STRUCTURE 551 OX

552 OX

553 OX

554 OX

555 OX

556 OX

557 OX

TABLE 108 Ex salt STRUCTURE 558 OX

559 OX

560 OX

  561*¹ T1

  562*² T2

563

564

565

TABLE 109 Ex salt STRUCTURE 566

567

568 FM

569 T2

570 T1

571 MB

572 MA

TABLE 110 Ex salt STRUCTURE 573 T1

574 MA

575 OX

576 T2

577 T1

578 MB

579 MA

TABLE 111 Ex Data 1 FAB: 385 2 FAB: 399 3 FAB: 389 4 FAB: 415 5 FAB: 4136 ES: 359 7 FAB: 399 8 FAB: 429 9 FAB: 415 10 FAB: 401 11 FAB: 428 12FAB: 361 13 FAB: 431 14 FAB: 426 15 FAB: 399 16 ES: 413 17 ES: 401

TABLE 112 Ex Syn Data 101 1 FAB: 385 102 1 FAB: 385 103 1 FAB: 385 104 1FAB: 385 105 1 FAB: 423 106 1 FAB: 371 107 1 FAB: 393 108 1 FAB: 393 1091 FAB: 407 110 1 FAB: 407 111 1 FAB: 465 112 1 FAB: 410 113 1 FAB: 403114 1 FAB: 469 115 1 FAB: 469 116 1 FAB: 419 117 1 FAB: 423 118 1 FAB:423 119 1 FAB: 449 120 1 FAB: 371 121 7 FAB: 425 122 1 FAB: 425 123 1FAB: 441 124 1 FAB: 373 125 1 FAB: 373 126 1 FAB: 443 127 1 FAB: 373 1287 FAB: 425 129 5 FAB: 399 130 7 FAB: 399 131 1 FAB: 385 132 1 FAB: 371133 1 FAB: 331 134 1 FAB: 331 135 1 FAB: 334 136 1 FAB: 347 137 1 FAB:343 138 7 FAB: 425 139 7 FAB: 443 140 1 FAB: 387 141 7 FAB: 439 143 1FAB: 317.2 144 1 FAB: 359 145 1 FAB: 345 146 1 FAB: 361 147 1 FAB: 345148 1 FAB: 399 149 2 FAB: 345 150 1 FAB: 415 151 1 FAB: 400.5 152 1 FAB:345 153 1 FAB: 331 154 1 FAB: 413.3 155 1 FAB: 359.3 156 7 FAB: 447 1571 FAB: 361 158 1 FAB: 423 159 1 FAB: 397 160 1 FAB: 343 161 1 FAB: 373162 7 FAB: 455 163 1 FAB: 404 164 1 FAB: 350 165 1 FAB: 447 166 1 FAB:393 167 1 FAB: 447 168 1 FAB: 383.0 169 1 FAB: 329.1 170 7 ES: 401 171 1FAB: 423 172 1 FAB: 343 173 1 FAB: 397 174 1 FAB: 393 175 1 FAB: 373 1761 FAB: 409 177 1 FAB: 439 178 1 FAB: 365 179 1 FAB: 395 180 1 FAB: 439

TABLE 113 Ex Syn Data 181 1 FAB: 409 182 1 FAB: 411 183 1 FAB: 439 184 1FAB: 415 185 1 FAB: 391 186 1 FAB: 419 187 1 FAB: 365 188 1 FAB: 395 1891 FAB: 419 190 1 FAB: 361 191 1 FAB: 391 192 1 FAB: 415 193 1 FAB: 365194 1 FAB: 395 195 1 FAB: 391 196 1 FAB: 421 197 1 FAB: 367 198 1 FAB:397 199 1 FAB: 345.2 200 1 FAB: 445.2 201 1 FAB: 391.2 202 1 FAB: 371.2203 1 FAB: 361 204 1 FAB: 387 205 1 FAB: 413 206 1 FAB: 359 207 1 FAB:389 209 1 FAB: 399.2 210 1 FAB: 317.1 212 1 FAB: 397 213 1 FAB: 361 2141 FAB: 415 215 1 FAB: 349 216 1 FAB: 379 217 1 FAB: 403 218 1 FAB: 349219 1 FA1: 378 220 1 FAB: 413 221 1 FAB: 359 222 1 FAB: 373 223 1 ES:389 224 1 ES: 373 225 1 FAB: 347 226 1 FAB: 319 227 1 ES: 349 228 1 FAB:349 229 1 FAB: 379 230 1 FAB: 403 231 1 FAB: 380 232 1 FAB: 404 233 1FAB: 458 234 1 FAB: 360 235 1 FAB: 414 236 1 FAB: 409 237 1 FAB: 439 2381 FAB: 355 239 1 FAB: 385 240 1 FAB: 411 241 1 FAB: 441 242 1 ES: 369243 1 FAB: 399 244 1 FAB: 414 245 1 FAB: 360 246 1 FAB: 353 247 1 FAB:383 249 1 FAB: 386 250 1 FAB: 356 252 1 FAB: 371 253 1 ES: 401 254 1FAB: 373 255 1 FAB: 403 256 1 FAB: 359 257 1 FAB: 305 258 1 FAB: 335 2591 FAB: 345 260 1 FAB: 291

TABLE 114 Ex Syn Data 261 1 FAB: 321 262 1 FAB: 403.3 263 1 FAB: 375.2264 1 FAB: 387 265 1 FAB: 333 266 1 FAB: 363 267 10 FAB: 374 268 10 N/D269 10 FAB: 404 270 1 FAB: 416 271 1 FAB: 356 272 1 FAB: 386 273 1 FAB:345 274 1 FAB: 375 275 1 FAB: 407 276 1 FAB: 437 277 1 FAB: 414 278 1FAB: 349.14 279 1 FAB: 437 280 1 FAB: 405.2 281 1 FAB: 430 282 1 FAB:399 283 1 FAB: 429 284 1 FAB: 447 285 1 ES: 393 286 1 FAB: 423 287 1FAB: 431 288 1 FAB: 377 289 1 FAB: 407 290 1 FAB: 355.24 291 1 FAB:411.22 292 1 ES: 359 293 1 ES: 389 294 1 FAB: 402 295 1 ES: 379 296 1ES: 325 297 1 ES: 355 298 1 FAB: 371 299 1 FAB: 317 300 1 FAB: 347 301 1FAB: 383 302 1 FAB: 456 303 1 FAB: 430 304 1 FAB: 407 305 1 FAB: 437 3061 FAB: 385 307 1 FAB: 385 308 1 FAB: 389 309 1 FAB: 373 310 1 FAB: 399.2311 1 FAB: 355 312 1 FAB: 417 313 1 FAB: 399 314 1 FAB: 345 315 1 FAB:375 316 1 FAB: 363 317 1 FAB: 309 318 1 FAB: 339 319 1 FAB: 375 320 1FAB: 321 321 1 FAB: 351 322 1 FAB: 357 323 1 FAB: 303 324 1 FAB: 333 3251 FAB: 409 326 1 FAB: 413 327 2 ES: 369 328 1 ES: 417 329 1 FAB: 255 3301 FAB: 381 331 1 FAB: 381 332 2 FAB: 355.1 333 2 FAB: 411.2 334 2 FAB:381.2 335 2 FAB: 381.3 336 2 FAB: 325.2 337 1 FAB: 355 338 1 FAB: 381.31339 9 FAB: 445 340 1 FAB: 373

TABLE 115 Ex Syn Data 341 1 FAB: 359 342 1 FAB: 305 343 1 FAB: 335 344 1FAB: 317 345 1 FAB: 263 346 1 FAB: 347 347 1 FAB: 411 348 1 FAB: 425 3491 FAB: 355 350 2 FAB: 339.1 351 2 FAB: 367.2 352 1 FAB: 415 353 9 FAB:431 354 1 ES: 385 355 1 FAB: 311.2 356 1 FAB: 325.2 357 1 FAB: 367.2 3581 FAB: 399 359 1 FAB: 359 360 1 FAB: 413 361 1 FAB: 373 362 1 FAB: 367363 1 FAB: 405 364 1 FAB: 351 365 1 FAB: 335 366 2 FAB: 325.2 367 1 FAB:363 368 1 FAB: 309 369 1 FAB: 353 370 1 FAB: 421 371 14 FAB: 402 372 1FAB: 349 373 1 FAB: 385 374 2 FAB: 339.4 375 2 FAB: 339.28 376 2 FAB:367.2 377 2 FAB: 381.2 378 2 FAB: 381.3 379 1 FAB: 377 380 1 FAB: 363381 1 FAB: 365 382 1 FAB: 389 383 1 FAB: 417 384 1 FAB: 377 385 1 FAB:381 386 1 FAB: 365 387 1 FAB: 417 388 1 FAB: 349 389 1 FAB: 347 390 1FAB: 375 391 1 FAB: 339.3 392 1 ES: 339.3 393 1 ES: 339.3 394 1 ES:339.3 395 1 FAB: 427 396 1 FAB: 375 397 1 ES: 347 398 1 ES: 355.4 399 1ES: 355.3 400 1 ES: 357 401 1 ES: 383 402 1 FAB: 375 403 1 FAB: 321 4041 FAB: 495 405 1 FAB: 441 406 1 FAB: 415 407 1 FAB: 361 408 1 FAB: 415409 1 FAB: 375 410 1 ES: 395 411 1 FAB: 369 412 1 FAB: 389 413 1 FAB:331 414 1 FAB: 375 415 1 ES: 375 416 1 FAB: 429 417 1 FAB: 401 418 1FAB: 443 419 1 FAB: 415 420 1 FAB: 353

TABLE 116 Ex Syn Data 421 1 FAB: 401 422 1 FAB: 387 423 1 FAB: 401 424 1FAB: 455 425 1 FAB: 407.2 426 1 FAB: 407.2 427 1 FAB: 375 428 1 FAB: 321429 1 FAB: 389 430 1 FAB: 335 431 1 FAB: 429 432 1 FAB: 401 433 1 FAB:407 434 1 FAB: 427 435 1 FAB: 355 436 1 FAB: 375 437 1 FAB: 355 438 1ES: 361 439 1 FAB: 375 440 1 FAB: 385.4 441 1 FAB: 411 442 1 FAB: 357443 1 FAB: 385.3 444 1 FAB: 391 445 1 ES: 355 446 1 ES: 355 447 1 FAB:339 448 1 FAB: 355 449 1 FAB: 359 450 1 ES: 305 451 1 FAB: 345 452 1FAB: 359 453 14 FAB: 339 454 14 FAB: 343 455 14 FAB: 355 456 1 ES: 343457 14 FAB: 343 458 1 ES: 377.86 459 1 FAB: 377.2 460 1 ES: 363.81 461 1FAB: 363.2 462 1 FAB: 345 463 1 FAB: 359 464 1 FAB: 339 465 1 FAB: 409466 1 FAB: 359 467 1 FAB: 375 468 1 ES: 364.31 469 1 FAB: 363.2 470 1FAB: 359 471 1 FAB: 377 472 1 FAB: 375 473 1 FAB: 361 474 1 FAB: 361 4751 ES: 377 476 1 ES: 363 477 1 FAB: 385.4 478 1 ES: 365 479 1 ES: 375 4801 ES: 377 481 1 ES: 403 482 1 ES: 349 483 1 ES: 345 484 1 ES: 397 485 1ES: 343 486 1 ES: 393 487 1 ES: 339 488 1 ES: 399 489 1 ES: 362.13 490 1FAB: 361.3 491 1 ES: 360.29 492 1 FAB: 359.3 493 1 FAB: 355 494 1 AP:375.08 495 1 FAB: 375.2 496 1 ES: 367.3 497 1 FAB: 326 498 1 FAB: 432499 1 ES: 448 500 1 FAB: 393

TABLE 117 Ex Syn Data 501 1 ES: 389 502 14 ES: 409 503 1 ES: 409 504 1ES: 375 505 1 ES: 389 506 1 ES: 321 507 1 ES: 335 508 1 ES: 415 509 1ES: 409 510 1 ES: 405 511 16 ES: 407 512 16 ES: 399 513 16 ES: 413 51416 ES: 423 515 17 ES: 331 516 17 ES: 387 517 17 ES387 518 17 ES: 464 51917 ES: 435 520 17 ES: 435 521 17 ES: 401 522 17 ES: 421 523 17 ES: 481524 17 ES: 387 525 17 ES: 407 526 17 ES: 421 527 16 ES: 419 528 17 ES:371 529 17 ES: 371 530 17 ES: 371 531 17 ES: 385 532 17 ES: 399 533 17ES: 399 534 17 ES: 399 535 17 ES: 371 536 17 ES: 385 537 6 ES: 363 538 6ES: 359 539 6 ES: 363 540 1 FAB: 407 541 1 FAB: 345 542 2 FAB: 359 543 1ES: 353 544 2 FAB: 345 545 1 FAB: 331 546 1 APCI: 319.08 547 1 ES:374.08 548 6 ES: 361 549 1 ES: 357 550 1 ES: 433 551 6 ES: 365 552 1 ES:350 553 1 ES: 404 554 1 ES: 389 555 1 FAB: 419.3 556 1 FAB: 365.2 557 1ES: 343 558 1 ES: 343 559 1 ES: 405 560 1 ES: 357 561 1 ES: 361.3 562 1ES: 361.3 563 1 ES: 437 564 1 ES: 439 565 1 ES: 443 566 1 ES: 441 567 1ES: 441 568 1 ES: 385.3 569 1 ES: 385.2 570 1 ES: 385.3 571 1 ES: 385.3572 1 ES: 385.3 573 1 ES: 375.3 574 1 FAB: 375.2 575 1 FAB: 355 576 1ES: 375.2 577 1 ES: 375.2 578 1 ES: 375.2 579 1 ES: 375.2

TABLE 118 Ex Data 14 NMR: 0.29-0.42(8H, m), 0.85-0.88(2H, m),2.88-4.41(8H, m), 6.24 and 6.49(1H, s), 7.20-7.74(6H, m), 8.43 and8.56(1H, m). 15 NMR: 1.03-2.53(19H, m), 2.93-3.01(4H, m), 3.57-3.72(2H,m), 3.99(1H, d, J = 16.2 Hz), 4.13(1H, d, J = 16.2 Hz), 5.11(1H, d, J =9.6 Hz), 7.16-7.23(4H, m). 101 NMR: 1.01-1.73(11H, m), 2.86(2H, m),3.58(1H, m), 3.67(1H, m), 3.97(1H, m), 4.12(1H, m), 5.11(1H, d, J = 6.9Hz), 7.14-7.22(4H, m). 102 NMR: 1.03-1.72(16H, m), 2.79-3.01(4H, m),3.59(1H, m), 3.68(1H, m), 3.78(1H, m), 4.03(1H, m), 4.16(1H, d, J = 12.0Hz), 5.10(1H, d, J = 6.9 Hz), 7.16-7.22(4H, m). 103 NMR: 1.03-1.83(16H,m), 2.81-3.01(4H, m), 3.24(1H, m), 3.60(1H, m), 3.66(1H, m),3.97-4.19(2H, m), 5.10(1H, d, J = 6.9 Hz), 7.15-7.23(4H, m). 104 NMR:0.88-1.72(19H, m), 2.10(1H, m), 2.51-2.99(4H, m), 3.42(1H, m), 3.58(1H,m), 3.66(1H, m), 3.95(1H, d, J = 11.8 Hz), 4.11(1H, s), 4.28(1H, d, J =11.8 Hz), 5.07(1H, m), 7.15-7.23(4H, m). 105 NMR: 1.00-1.76(25H, m),2.22(1H, s, br), 2.98(2H, m), 3.72(2H, m), 3.94(1H, d, J = 12.0 Hz),4.10(1H, d, J = 12.0 Hz), 5.11(1H, d, J = 6.9 Hz), 7.14-7.23(4H, m). 106NMR: 1.00-2.03(19H, m), 2.87-2.99(4H, m), 3.34(1H, m), 3.66(1H, m),4.04(1H, d, J = 12.1 Hz), 4.19(1H, d, J = 12.1 Hz), 5.10(1H, d, J = 7.5Hz), 7.14-7.23(4H, m). 107 NMR: 0.97-1.66(11H, m), 2.85(2H, m), 3.46(2H,m), 3.67-3.77(3H, m), 4.27(2H, m), 5.10(1H, m), 7.13-7.21(4H, M),7.34-7.43(5H, m). 108 NMR: 0.97-1.66(11H, m), 2.85(2H, m), 3.46(2H, m),3.67-3.77(3H, m), 4.27(2H, m), 5.10(1H, m), 7.13-7.21(4H, M),7.34-7.43(5H, m). 109 NMR: 1.04-1.70(11H, m), 2.77-4.24(7H, m), 5.12(1H,d, J = 6.9 Hz), 7.17-7.34(9H, m). 110 NMR: 1.04-1.70(11H, m),2.77-4.24(7H, m), 5.12(1H, d, J = 6.9 Hz), 7.17-7.34(9H, m). 111 NMR:1.02-1.68(21H, m), 2.82(2H, m), 2.98(2H, m), 3.56-3.67(2H, m), 3.97(1H,d, J = 16.4 Hz), 4.11(1H, d, J = 16.0 Hz), 5.11(1H, d, J = 9.2 Hz),7.13(1H, m), 7.36(1H, m), 7.42(1H, m), 7.47(1H, d, J = 1.6 Hz). 112 NMR:1.00-1.68(21H, m), 2.85(2H, m), 3.03(2H, m), 3.64(2H, m), 3.98(1H, d, J= 16.4 Hz), 4.12(1H, d, J = 16.0 Hz), 5.22(1H, d, J = 9.2 Hz), 7.41(1H,d, J = 8.0 Hz), 7.64(1H, m), 7.69(1H, m), 7.74(1H, s). 113 NMR:1.02-1.67(21H, m), 2.86(2H, m), 2.98(2H, m), 3.56-3.68(2H, m), 3.98(1H,d, J = 16.0 Hz), 4.10(1H, d, J = 16.0 Hz), 5.12(1H, d, J = 9.6 Hz),7.01(1H, m), 7.09(1H, m), 7.21(1H, m). 114 NMR: 1.03-1.64(11H, m),2.77(2H, m), 3.17(2H, m), 3.20-4.11(2H, m), 4.64-4.70(1H, m), 5.05(1H,m), 5.28-5.34(1H, m), 7.07-7.23(14H, m). 115 NMR: 1.03-1.64(11H, m),2.77(2H, m), 3.17(2H, m), 3.20-4.11(2H, m), 4.64-4.70(1H, m), 5.05(1H,m), 5.28-5.34(1H, m), 7.07-7.23(14H, m). 116 NMR: 0.99-1.68(21H, m),2.85(1H, m), 2.98(1H, m), 3.56-3.67(1H, m), 3.98(1H, d, J = 16.2 Hz),4.12(1H, d, J = 16.2 Hz), 5.12(1H, d, J = 9.2 Hz), 7.19-7.33(3H, m). 117NMR: 1.01-1.72(11H, m), 2.95(2H, m), 3.26(2H, m), 3.46-3.67(3H, m),4.03(1H, m), 4.17(1H, m), 4.75(1H, m), 5.12(1H, m), 7.16-7.22(4H, m),7.32-7.38(5H, m).

TABLE 119 Ex Data 118 NMR: 1.01-1.72(11H, m), 2.95(2H, m), 3.26(2H, m),3.46-3.67(3H, m), 4.03(1H, m), 4.17(1H, m), 4.75(1H, m), 5.12(1H, m),7.16-7.22(4H, m), 7.32-7.38(5H, m). 119 NMR: 0.98-1.67(17H, m), 1.88(1H,m), 2.05(1H, m), 2.75(1H, m), 2.97(2H, m), 3.49-4.20(5H, m), 5.11(1H, d,J = 9.2 Hz), 7.12(1H, d, J = 8.4 Hz), 7.36(1H, m), 7.47(1H, s). 120 NMR:1.03-1.68(17H, m), 1.88(1H, m), 2.05(1H, m), 2.77(1H, m), 2.97(2H, m),3.48-4.21(5H, m), 5.11(1H, d, J = 9.2 Hz), 7.16-7.22(4H, m). 121 NMR:1.03-4.77(34H, m), 5.14 and 5.18(1H, d, J = 8.8 Hz), 7.16-7.21(4H, m).122 NMR: 1.03-1.68(11H, m), 2.77-4.25(11H, m), 5.14(1H, d, J = 10.0 Hz),7.01-7.35(8H, m). 123 NMR: 1.03-1.71(11H, m), 2.78-4.25(11H, m),5.14(1H, d, J = 9.2 Hz), 7.20-7.34(8H, m). 124 NMR: 0.97-1.69(20H, m),2.77-4.29(9H, m), 5.12(1H, d, J = 9.2 Hz), 7.16-7.22(4H, m). 125 NMR:0.84-1.70(20H, m), 2.97-4.18(9H, m), 5.12(1H, d, J = 9.2 Hz),7.16-7.23(4H, m). 126 NMR: 1.07-1.81(17H, m), 2.86-2.98(4H, m),3.38-3.70(2H, m), 3.85(4H, s), 4.00(1H, d, J = 16.0 Hz), 4.14(1H, d, J =16.0 Hz), 5.11(1H, d, J = 9.6 Hz), 7.14-7.23(4H, m). 127 NMR:0.85-1.70(20H, m), 2.51-3.04(3H, m), 3.56-4.22(6H, m), 5.12(1H, d, J =9.2 Hz), 7.16-7.22(4H, m). 128 NMR: 1.03-4.77(34H, m), 5.14 and 5.18(1H,d, J = 8.8 Hz), 7.16-7.21(4H, m). 129 NMR: 1.01-1.68(21H, m),2.68-2.99(7H, m), 3.65(2H, m), 4.10(1H, d, J = 16.2 Hz), 4.22(1H, d, J =16.2 Hz), 5.11(1H, dmJ = 9.6 Hz), 7.11-7.22(4H, m). 130 NMR:1.05-1.73(23H, m), 2.86-2.99(4H, m), 3.55-3.67(2H, m), 4.01(1H, d, J =16.4 Hz), 4.14(1H, d, J = 16.4 Hz), 5.11(1H, d, J = 9.2 Hz),7.16-7.23(4H, m). 132 NMR: 1.01-1.71(19H, m), 2.95-3.10(4H, m), 3.54(1H,m), 3.66(1H, m), 4.00(1H, d, J = 16.0 Hz), 4.14(1H, d, J = 16.0 Hz),5.11(1H, d, J = 9.2 Hz), 7.14-7.23(4H, m). 133 NMR: 1.01-1.70(14H, m),2.74-2.97(4H, m), 3.34-4.19(5H, m), 5.10(1H, d, J = 9.6 Hz),7.16-7.22(4H, m). 134 NMR: 1.01-1.70(14H, m), 2.74-2.97(4H, m),3.34-4.19(5H, m), 5.10(1H, d, J = 9.6 Hz), 7.16-7.22(4H, m). 135 NMR:1.01-2.20(15H, m), 2.56-3.81(6H, m), 4.32(1H, d, J = 16.0 Hz), 4.40(1H,m), 4.49(1H, d, J = 16.0 Hz), 5.10(1H, d, J = 9.2 Hz), 7.15-7.23(4H, m).136 NMR: 1.02-1.70(11H, m), 2.95-3.77(9H, m), 4.05(1H, d, J = 16.2 Hz),4.17(1H, d, J = 16.2 Hz), 5.11(1H, d, J = 9.2 Hz), 7.14-7.22(4H, m). 137NMR: 1.03-1.60(11H, m), 1.69(1H, m), 1.85(1H, m), 2.96-4.47(11H, m),5.10(1H, d, J = 9.6 Hz), 7.14-7.22(4H, m). 138 NMR: 0.31(2H, m),0.96-1.70(23H, m), 2.49-4.19(9H, m), 5.11(1H, m), 7.12-7.22(4H, m). 139NMR: 1.06-1.69(21H, m), 2.83-2.96(4H, m), 3.19(3H, s), 3.49-4.20(.12H,m), 5.11(1H, d, J = 9.2 Hz), 7.14-7.21(4H, m). 140 NMR: 1.03-1.70(15H,m), 2.86-2.99(4H, m), 3.34-3.72(6H, m), 3.98(1H, d, J = 16.4 Hz),4.11(1H, d, J = 16.4 Hz), 5.11(1H, d, J = 9.2 Hz)m7.14-7.22(4H, m).

TABLE 120 Ex Data 141 NMR: 0.99-1.97(25H, m), 2.84-3.89(11H, m),5.18(1H, d, J = 9.6 Hz), 7.10-7.18(4H, m). 145 NMR: 1.00-1.67(17H, m),2.84-2.97(4H, m), 3.24-3.67(6H, m), 5.13(1H, d, J = 9.6 Hz),7.11-7.18(4H, m). 146 NMR: 1.03-1.67(11H, m), 2.83-3.97(11H, m),4.02(1H, d, J = 16.2 Hz), 4.14(1H, d, J = 16.2 Hz), 5.11(1H, d, J = 9.6Hz), 7.16-7.22(4H, m). 147 NMR: 0.87(3H, t, J = 7.2 Hz), 1.04-1.70(10H,m), 2.78(1H, m), 2.94-3.00(4H, m), 3.56-4.02(4H, m), 4.04(1H, d, J =16.0 Hz), 4.17(1H, d, J = 16.0 Hz), 5.11(1H, d, J = 9.6 Hz),7.16-7.23(4H, m). 152 NMR: 0.86(3H, t, J = 7.4 Hz), 1.00-1.70(13H, m),2.50(1H, m), 2.92-3.71(6H, m), 4.01(1H, d, J = 16.0 Hz), 4.15(1H, d, J =16.0 Hz), 5.11(1H, d, J = 9.2 Hz), 7.14-7.22(4H, m). 153 NMR:1.00-1.67(14H, m), 2.50-3.75(9H, m), 5.12(1H, d, J = 9.2 Hz), 6.53(2H,s), 7.14-7.19(4H, m). 156 NMR: 1.07-1.96(15H, m), 2.85-5.19(13H, m),7.10-7.47(4H, m). 157 NMR: 1.03-1.71(11H, m), 2.86-3.05(4H, m),3.25-3.37(5H, m), 3.57-3.68(2H, m), 4.01(1H, m), 4.08(1H, d, J = 16.0Hz), 4.19(1H, d, J = 16.0 Hz), 5.10(1H, d, J = 9.2 Hz), 5.58(1H, m),7.16-7.22(4H, m), 8.75(1H, br). 158 NMR: 1.01-1.70(11H, m),2.68-3.00(4H, m), 3.20(1H, m), 3.40(1H, m), 3.54(1H, m), 3.66(1H, m),4.05(1H, d, J = 16.2 Hz), 4.22(1H, d, J = 16.2 Hz), 5.12(1H, d, J = 9.2Hz), 6.69(2H, d, J = 8.0 Hz), 7.03(2H, d, J = 8.4 Hz), 7.16-7.23(4H, m).159 NMR: 1.24-1.56(10H, m), 2.78-3.04(4H, m), 3.55(1H, m), 3.64(1H, m),4.05(1H, d, J = 16.3 Hz), 4.16(1H, d, J = 16.3 Hz), 6.65(1H, s),7.13-7.28(8H, m). 160 NMR: 1.09(3H, m), 2.74-2.82(2H, m), 2.90-3.01(2H,m), 3.52(1H, m), 3.65(1H, m), 3.96(1H, m), 4.09(1H, d, J = 16.0 Hz),4.18(1H, m), 6.65(1H, s), 7.13-7.28(8H, m). 161 NMR: 2.84(1H, m),6.98(1H, m), 3.27-3.37(5H, m), 3.98(1H, m), 4.10(1H, d, J = 16.1 Hz),4.19(1H, m), 6.65(1H, s), 7.13-7.28(4H, m). 163 NMR: 1.15-1.55(10H, m),2.67-3.04(4H, m), 3.63(2H, m), 4.04(1H, d, J = 16 Hz), 4.20(1H, d, J =16 Hz), 6.66(1H, s), 7.26-7.37(4H, m), 7.43(2H, m), 7.80(2H, m). 164NMR: 1.10(6H, d, J = 6 Hz), 2.67-3.03(4H, m), 3.62(2H, m), 3.96(1H, m),4.09(1H, d, J = 16.8 Hz), 4.23(1H, m), 6.66(1H, s), 7.27-7.37(4H, m),7.41(2H, m), 7.80(2H, m). 165 NMR: 1.23-1.57(10H, m), 2.72-3.02(4H, m),3.56(1H, m), 3.69(1H, m), 3.92(1H, d, J = 16.4 Hz), 4.06(1H, d, J = 16.4Hz), 6.73(1H, s), 7.24-7.31(4H, m), 7.47(1H, m), 7.55-7.58(2H, m),7.64(1H, m). 166 NMR: 1.10(6H, m), 2.73-3.03(4H, m), 3.58(1H, m),3.66(1H, m), 3.97(1H, m), 4.11(1H, d, J16.4 Hz), 4.24(1H, m), 6.72(1H,s), 7.25-7.30(4H, m), 7.48(1H, m), 7.55-7.59(2H, m), 7.65(1H, m). 167NMR: 1.22-1.56(10H, m), 2.96-3.12(4H, m), 3.54(1H, m), 3.85(1H, m),4.06(1H, d, J = 16.6 Hz), 4.13(1H, d, J = 16.6 Hz), 6.82(1H, s),7.14-7.31(5H, m), 7.50-7.60(2H, m), 7.80(1H, m).

TABLE 121 Ex Data 171 NMR: 2.80(1H, m), 2.95-2.99(2H, m), 3.07(1H, m),3.23-3.34(5H, m), 3.55(1H, m), 3.85(1H, m), 3.95(1H, m), 4.05-4.19(2H,m), 6.80(2H, m), 7.14-7.31(4H, m), 7.52(1H, m), 7.58(1H, m), 7.79(1H, d,J = 8 Hz). 172 NMR: 1.08(6H, d, J = 6.4 Hz), 2.74-4.21(9H, m), 6.73(1H,s), 7.11-7.34(7H, m). 173 NMR: 1.09-1.57(10H, m), 2.81-3.05(4H, m),3.67-3.72(2H, m), 4.07(1H, d, J = 16.2 Hz), 4.15(1H, d, J = 16.2 Hz),6.73(1H, s), 7.11-7.34(7H, m). 174 NMR: 1.07(6H, d, J = 76.4 Hz),2.72(1H, m), 2.87(1H, m), 2.96-3.12(2H, m), 3.54(1H, m), 3.84-3.94(2H,m), 4.04-4.19(2H, m), 6.80-6.83(2H, m), 7.14-7.31(4H, m), 7.50-7.60(2H,m), 7.80(1H, d, J = 7.6 Hz). 175 NMR: 2.83-3.07(4H, m), 3.24-3.38(5H,m), 3.64-3.72(2H, m), 3.96(1H, m), 4.11-4.21(2H, m), 6.74(1H, s),7.11-7.34(7H, m). 176 NMR: 0.98-1.70(14H, m), 2.72-2.99(4H, m), 3.61(2H,m), 3.96(1H, m), 4.01(1H, d, J = 16 Hz), 4.13(1H, d, J = 16 Hz),5.01(1H, d, J = 9.6 Hz), 7.14(1H, d, J = 8.4 Hz), 7.35-7.47(2H, m). 177NMR: 1.01-1.70(11H, m), 2.82-3.04(4H, m), 3.24-3.36(5H, m), 3.61(2H, m),3.98(1H, m), 4.02(1H, d, J = 16 Hz), 4.14(1H, d, J = 16 Hz), 5.11(1H, d,J = 9.2 Hz), 7.14(1H, d, J = 8.4 Hz), 7.35-7.47(2H, m). 180 NMR:1.97-1.68(11H, m), 2.86(2H, m), 2.99(2H, m), 3.26-3.41(5H, m), 3.62(1H,m), 3.73(1H, m), 3.98(1H, m), 4.09(1H, d, J = 16.2 Hz), 4.18(1H, d, J =16.2 Hz), 5.13(1H, d, J = 9.6 Hz), 7.12-7.23(2H, m), 7.54(1H, d, J = 8Hz). 181 NMR: 0.99-1.68(14H, m), 2.72-3.00(4H, m), 3.62(1H, m), 3.74(1H,m), 3.95(1H, m), 4.08(1H, d, J = 16 Hz), 4.17(1H, d, J = 16 Hz),5.13(1H, d, J = 9.6 Hz), 7.12-7.23(2H, m), 7.54(1H, m). 182 NMR:0.99-1.67(14H, m), 2.72-2.95(4H, m), 3.61(2H, m), 3.95(1H, m), 4.01(1H,d, J = 16 Hz), 4.13(1H, d, J = 16 Hz), 5.14(1H, d, J = 9.6 Hz), 7.19(1H,m), 7.39-7.43(2H, m). 183 NMR: 1.0.95-1.68(11H, m), 2.80-3.04(4H, m),3.24-3.36(5H, m), 3.61(2H, m), 3.98(1H, m), 4.02(1H, d, J = 16 Hz),4.14(1H, d, J = 16 Hz), 5.14(1H, d, J = 9.6 Hz), 7.19(1H, m),7.38-7.42(2H, m). 204 NMR: 1.03-1.66(15H, m), 2.87-2.95(4H, m),3.54-3.80(8H, m), 5.13(1H, d, J = 9.2 Hz), 6.56(2H, s), 7.12-7.19(4H,m). 205 NMR: 1.21-1.54(10H, m), 2.80-3.07(4H, m), 3.59(1H, m), 3.78(1H,m), 4.10(2H, m), 6.76(1H, s), 7.06-7.32(7H, m), 7.49(1H, d, J = 7.2 Hz).206 NMR: 1.08(3H, d, J = 6.4 Hz), 2.70-3.07(4H, m), 3.58(1H, m),3.79(1H, m), 3.94(1H, m), 4.14(2H, m), 6.76(1H, m), 7.04-7.32(7H, m),7.49(1H, d, J = 7.6 Hz). 207 NMR: 2.81-3.04(4H, m), 3.24-3.35(5H, m),3.57(1H, m), 3.78(1H, m), 3.95(1H, m), 4.15(2H, m), 6.76(1H, m),7.05-7.32(7H, m), 7.49(1H, d, J = 8 Hz). 208 NMR: 1.23-1.54(10H, m),2.38 and 2.48(3H, s), 2.81-4.41(8H, m), 6.15 and 6.43(1H, s), 6.83 and7.10(1H, d, J = 7.6 Hz), 7.18-7.32(5H, m), 7.62-7.68(1H, m). 211 NMR:1.10(3H, d, J = 7.2 Hz), 2.74-2.99(4H, m), 3.59-3.64(4H, m), 3.97(1H,m), 4.10(1H, d, J = 16.4 Hz), 4.23(1H, m), 6.63(1H, s), 7.00-7.38(4H,m).

TABLE 122 Ex Data 212 NMR: 1.240-1.58(10H, m), 2.77-3.02(4H, m),3.63(2H, m), 4.06(1H, d, J = 16 Hz), 4.22(1H, d, J = 16 Hz), 6.63(1H,s), 7.01-7.38(8H, m). 220 NMR: 1.24-1.58(10H, m), 2.77-3.05(4H, m),3.57-3.66(2H, m), 4.06(1H, d, J = 16.2 Hz), 4.22(1H, d, J = 16.2 Hz),6.63(1H, s), 7.13-7.41(8H, m). 221 NMR: 1.10(3H, d, J = 6.4 Hz),2.74-3.04(4H, m), 3.56-3.66(2H, m), 3.97(1H, m), 4.10(1H, d, J = 16.4Hz), 4.23(1H, m), 6.63(1H, s), 7.11-7.39(8H, m). 222 NMR: 2.78-3.09(4H,m), 3.27-3.37(7H, m), 3.58-3.63(2H, m), 3.99(1H, m), 4.10(1H, d, J =16.4 Hz), 4.23(1H, m), 6.63(1H, s), 6.99-7.37(8H, m). 223 NMR:2.78-3.09(4H, m), 3.27-3.37(7H, m), 3.56-3.66(2H, m), 3.99(1H, m),4.11(1H, d, J = 16.4 Hz), 4.24(1H, m), 6.64(1H, s), 7.11-7.39(8H, m).224 NMR: 0.79-1.67(21H, m), 2.82-2.99(4H, m), 3.58-3.69(2H, m), 3.99(1H,d, J = 16.4 Hz), 4.12(1H, d, J = 16.4 Hz), 5.32(1H, d, J = 9.6 Hz),7.15-7.23(4H, m). 226 NMR: 0.81-0.89(6H, m), 1.09(3H, m), 1.24-1.41(4H,m), 1.67(1H, m), 2.72-2.99(4H, m), 3.60-3.66(2H, m), 3.95(1H, m),4.02(1H, d, J = 16.2 Hz), 4.14(1H, d, J = 16.2 Hz), 5.32(1H, d, J = 8.8Hz), 7.17-7.23(4H, m). 227 NMR: 0.80-0.88(6H, m), 1.24-1.41(4H, m),1.66(1H, m), 2.79-3.02(4H, m), 3.24-3.35(7H, m), 3.95(1H, m), 3.99(1H,d, J = 16.4 Hz), 4.10(1H, d, J = 16.4 Hz), 5.32(1H, d, J = 8.8 Hz),7.15-7.23(4H, m). 231 NMR: 1.23-1.54(10H, m), 2.81-3.01(4H, m),3.33-4.46(4H, m), 6.22 and 6.50(1H, s), 7.13-8.58(8H, m). 232 NMR:1.07-1.10(3H, m), 2.75-3.02(4H, m), 3.69(1H, m), 3.92-3.98(2H, m),4.12(1H, m), 4.23(1H, m), 6.43(1H, s), 7.20-7.34(4H, m), 7.52(1H, d, J =7.6 Hz), 7.60(1H, m), 7.74(1H, m). 233 NMR: 1.24-1.55(10H, m),2.79-3.01(4H, m), 3.68(1H, m), 3.94(1H, m), 4.06(1H, d, J = 16.2 Hz),4.18(1H, d, J = 16.2 Hz), 6.43(1H, s), 7.20-7.34(4H, m), 7.51(1H, d, J =8 Hz), 7.59(1H, d, J = 7.6 Hz), 7.74(1H, m). 234 NMR: 1.08-1.11(3H, m),2.75-3.02(4H, m), 3.69(1H, m), 3.92-3.98(2H, m), 4.12(1H, d, J = 16 Hz),4.23(1H, m), 6.44(1H, s), 7.20-7.40(4H, m), 7.56(1H, d, J = 7.6 Hz),7.83-7.87(2H, m). 235 NMR: 1.23-1.55(10H, m), 2.82-3.02(4H, m), 3.68(1H,m), 3.95(1H, m), 4.09(1H, d, J = 16.6 Hz), 4.22(1H, d, J = 16.6 Hz),6.45(1H, s), 7.21-7.40(5H, m), 7.57(1H, d, J = 7.2 Hz), 7.85(1H, m). 236NMR: 1.08(3H, d, J = 6.4 Hz), 2.73-3.07(4H, m), 3.58(1H, m), 3.73(1H,m), 3.95(1H, m), 4.13(2H, m), 6.82 and 6.83(1H, s), 7.01-7.46(8H, m).237 NMR: 2.81-3.07(4H, m), 3.23-3.35(5H, m), 3.58(1H, m), 3.72(1H, m),3.97(1H, m), 4.14(2H, m), 6.82 and 6.83(1H, s), 7.00-7.46(8H, m). 238NMR: 1.08-1.11(3H, m), 2.76-3.00(4H, m), 3.68-4.35(8H, m), 6.23-7.33(9H,m). 239 NMR: 2.86-3.10(4H, m), 3.26-3.35(5H, m), 3.35-4.33(8H, m),6.23-7.32(8H, m). 240 NMR: 1.09(3H, d, J = 6.4 Hz), 2.68-3.06(4H, m),3.60(1H, m), 3.87-3.95(2H, m), 4.06-4.21(2H, m), 6.63 and 6.65(1H, s),6.79(1H, m), 7.02(1H, m), 7.18(1H, m), 7.25-7.39(3H, m), 7.89(1H, m).

TABLE 123 Ex Data 241 NMR: 2.76-3.06(4H, m), 3.23-3.34(5H, m), 3.59(1H,m), 3.86-3.95(2H, m), 4.09 and 4.11(1H, d, J = 16.2 Hz), 4.19(1H, d, J =16.8 Hz), 6.63 and 6.66(1H, s), 6.80(1H, m), 7.03(1H, m), 7.18(1H, m),7.25-7.39(3H, m), 7.89(1H, m). 242 NMR: 1.08(3H, d, J = 6.4 Hz),1.29(3H, m), 2.75-4.32(11H, m), 6.70(1H, s), 6.85-7.25(8H, m). 243 NMR:1.29(3H, m), 2.85-4.18(16H, m), 6.71(1H, s), 6.85-7.25(8H, m). 244 NMR:1.26-1.57(10H, m), 2.86-3.01(4 Hm), 3.65(1H, m), 3.99(1H, m), 4.12(1H,d, J = 16.2 Hz), 4.25(1H, d, J = 16.2 Hz), 6.47(1H, s), 7.20-7.43(5H,m), 7.74(1H, m), 8.43(1H, d, J = 5.2 Hz). 245 NMR: 1.09(3H, d, J = 6.4Hz), 2.75-3.00(4H, m), 3.66(1H, m), 3.94-3.98(2H, m), 4.12(1H, d, J =16.2 Hz), 4.22 and 4.24(1H, d, J = 16.2 Hz), 6.47(1H, s), 7.20-7.43(5H,m), 7.72(1H, m), 8.43(1H, d, J = 5.2 Hz). 246 NMR: 1.08(3H, d, J = 5.6Hz), 1.25(3H, t, J = 7.4 Hz), 2.72-3.11(6H, m), 3.38(1H, m), 3.71(1H,m), 3.96(1H, m), 4.12(2H, m), 6.66(1H, d, J = 7.6 Hz), 6.84(1H, s),6.94(1H, d, J = 8 Hz), 7.07(1H, m), 7.16(1H, m), 7.22-7.29(4H, m). 247NMR: 1.25(3H, t, J = 7.6 Hz), 2.72-3.11(7H, m), 3.26(3H, s),3.32-3.37(2H, m), 3.70(1H, m), 3.98(1H, m), 4.13(2H, m), 6.66(1H, d, J =7.6 Hz), 6.85(1H, s), 6.94(1H, d, J = 7.6 Hz), 7.07(1H, m), 7.16(1H, m),7.22-7.29(4H, m). 248 NMR1: 2.93(2H, t, J = 6.8 Hz), 3.72(3H, s),3.77(2H, m), 6.86(1H, m), 7.1(1H, m), 7.23-7.36(5H, m), 7.92(1H, m). 251NMR1: 2.75(2H, t, J = 7 Hz), 3.50(2H, m), 3.56(3H, s), 5.27(1H, br),7.04(2H, m), 7.20-7.31(5H, m), 7.56(2H, m). 252 NMR: 1.08(2H, d, J = 6.4Hz), 5.23(3H, s), 2.62-4.21(9H, m), 6.78(1H, s), 6.91(1H, m), 7.01(1H,m), 7.07(1H, m), 7.14-7.29(4H, m), 7.38(1H, d, J = 8 Hz). 253 NMR:2.53(3H, s), 2.62-4.22(14H, m), 6.77 and .78(1H, s), 6.90(1H, m),7.01(1H, m), 7.07(1H, m), 7.14-7.30(4H, m), 7.38(1H, d, J = 8 Hz). 254NMR: 2.73-4.34(15H, m), 6.63 and 6.64(1H, s), 6.92(1H, m), 7.02-7.07(2H,m), 7.14-7.28(4H, m). 255 NMR: 2.82-4.35(17H, m), 6.63 and 6.4(1H, s),6.91(1H, m), 7.00-7.28(6H, m). 275 NMR: 1.04(3H, d, J = 6.4 Hz),2.49-4.02(11H, m), 5.68(1H, m), 7.18-7.73(8H, m). 276 NMR:2.51-4.05(16H, m), 5.68(1H, m), 7.20-7.71(8H, m). 277 NMR:1.23-1.56(10H, m), 2.79-3.80(6H, m), 4.11(2H, m), 6.67(1H, s), 7.13(1H,d, J = 8 Hz), 7.19-7.38(4H, m), 7.59(1H, m), 8.33(1H, m). 279 NMR:2.57-4.03(16H, m), 5.71(1H, m), 7.04(1H, m), 7.18-7.27(3H, m), 7.34(1H,m), 7.43(1H, m), 7.54(1H, m), 7.68(1H, m). 304 NMR: 0.99-1.05(3H, m),2.17-4.46(11H, m), 5.09 and 5.68(1H, m), 7.19-7.71(8H, m). 305 NMR:2.26-4.90(16H, m), 5.10 and 5.66(1H, m), 5.18-7.70(8H, m). 306 NMR:2.74-4.15(19H, m), 6.26 and 6.75(1H, s), 6.67-7.31(8H, m). 307 NMR:2.74-4.15(19H, m), 6.26 and 6.75(1H, s), 6.67-7.31(8H, m).

TABLE 124 Ex Data 311 NMR: 1.08-1.10(3H, m), 2.73-4.35(12H, m), 6.23 and6.74(1H, s), 6.64-7.33(8H, m). 312 NMR: 2.88-4.35(11H, m), 4.93-4.95(1H,m), 6.22 and 6.75(1H, s), 6.64-7.38(13H, m). 325 NMR: 1.40-1.54(10H, m),2.84-2.99(3H, m), 3.62-3.76(1H, m), 3.80 and 3.93(3H, s), 4.06-4.35(4H,m), 6.23 and 6.73(1H, s), 6.66-7.33(8H, m). 327 NMR: 1.03-1.11(3H, m),2.72-3.21(8H, m), 3.74-4.30(6H, m), 6.33 and 6.76(1H, s), 6.86-7.30(8H,m). 328 NMR: 2.87-4.35(11H, m), 4.93(1H, m), 6.26 and 6.74(1H, s),6.64-7.38(13H, m). 329 NMR: 1.08-1.11(3H, m), 2.74-3.01(4H, m),3.63-4.34(8H, m), 6.25 and 6.73(1H, s), 6.63-7.32(8H, m). 330 NMR:1.47-1.93(6H, m), 2.87-3.79(4H, m), 3.79 and 3.93(3H, s), 4.01-4.36(4H,m), 6.29 and 6.74(1H, s), 6.65-7.33(8H, m). 331 NMR: 1.45-2.00(6H, m),2.88-3.76(4H, m), 3.79 and 3.92(3H, s), 3.96-4.35(4H, m), 6.29 and6.74(1H, s), 6.69-7.32(8H, m). 337 NMR: 2.80-3.21(4H, m), 3.24 and3.31(3H, s), 3.54-5.58(8H, m), 7.19-7.37(9H, m). 346 NMR: 1.23-1.55(10H,m), 2.79-3.22(4H, m), 3.25 and 3.32(3H, s), 3.55-4.52(6H, m), 5.06 and5.58(1H, m), 7.18-7.32(4H, m). 349 NMR: 1.08-1.10(3H, m), 2.72-4.35(12H,m), 6.23 and 6.74(1H, s), 6.64-7.33(8H, m). 354 NMR: 1.35-4.56(24H, m),5.15 and 5.60(1H, m), 7.20-7.33(4H, m). 358 NMR: 1.44-1.47(2H, m),1.64-1.79(10H, m), 2.17-2.20(2H, m), 2.81-4.52(13H, m), 5.06 and5.58(1H, m), 7.18-7.31(4H, m). 359 NMR: 0.30-0.43(8H, m), 0.85-0.88(2H,m), 2.82-4.52(13H, m), 5.08 and 5.59(1H, m), 7.19-7.31(4H, m). 360 NMR:1.44-2.20(14H, m), 2.79-4.43(15H, m), 4.82 and 5.54(1H, m),7.16-7.22(4H, m). 361 NMR: 0.29-0.43(8H, m), 0.85-0.90(2H, m),1.90-4.42(15H, m), 4.83 and 5.53(1H, m), 7.16-7.22(4H, m). 370 NMR:0.28-0.42(8H, m), 0.85-0.88(2H, m), 2.89-3.16(4H, m), 3.63-4.35(7H, m),6.24 and 6.74(1H, s), 6.69-7.33(8H, m). 371 NMR: 0.77-0.82(6H, m),1.41-1.48(4H, m), 2.78-3.01(4H, m), 5.47 and 3.65(1H, m), 3.97-4.39(3H,m), 6.25 and 6.48(1H, s), 7.21-7.73(6H, m), 8.43 and 8.55(1H, m). 372NMR: 0.78-0.83(6H, m), 1.44-1.50(4H, m), 1.89-2.06(2H, m),2.79-4.42(13H, m), 4.83 and 5.53(1H, m), 7.16-7.22(4H, m). 373 NMR:1.45-4.85(25H, m), 5.26 and 5.57(1H, m), 7.21-7.32(4H, m). 379 NMR:0.30-0.43(8H, m), 0.87-0.90(2H, m), 2.77-4.52(13H, m), 5.07 and 5.58(1H,m), 7.04-7.11(2H, m), 7.34-7.40(1H, m). 380 NMR: 0.86-0.94(12H, m),1.84-1.89(2H, m), 2.80-4.52(13H, m), 5.05 and 5.58(1H, m), 7.18-7.32(4H,m). 381 NMR: 1.24-1.55(10H, m), 2.83-4.51(13H, m), 5.07 and 5.57(1H, m),7.05-7.08(2H, m), 7.34-7.39(1H, m). 383 NMR: 1.44-1.77(12H, m),2.17-2.20(2H, m), 2.78-4.52(13H, m), 5.07 and 5.58(1H, m), 7.05-7.09(2H,m), 7.35-7.38(1H, m).

TABLE 125 Ex Data 384 NMR: 0.28-0.44(8H, m), 0.87-0.90(2H, m),2.68-4.53(13H, m), 5.08 and 5.59(1H, m), 7.06-7.25(3H, m). 385 NMR:0.85-0.94(12H, m), 1.84-1.89(2H, m), 2.78-4.51(13H, m), 5.06 and5.58(1H, m), 7.05-7.08(2H, m), 7.35-7.38(1H, m). 386 NMR: 1.27-1.55(10H,m), 2.68-4.48(13H, m), 5.08 and 5.59(1H, m), 7.04-7.12(1H, m),7.19-7.25(2H, m). 387 NMR: 1.44-1.79(12H, m), 2.17-2.20(2H, m),2.69-4.53(13H, m), 5.07 and 5.59(1H, m), 7.06-7.10(1H, m), 7.20-7.26(2H,m). 395 NMR: 1.13-1.78(18H, m), 2.18(2H, m), 2.88-3.16(7H, m), 3.65(1H,m), 3.85(1H, m), 4.04(1H, d, J = 16.6 Hz), 4.15(1H, d, J = 16.6 Hz),5.45(1H, s), 7.14-7.30(4H, m). 396 NMR: 1.12-1.57(16H, m), 2.81-3.07(7H,m), 3.66(1H, m), 3.84(1H, m), 4.04(1H, d, J = 16.2 Hz), 4.15(1H, d, J =16.2 Hz), 5.44(1H, s), 7.14-7.30(4H, m). 397 NMR: 1.13-2.02(12H, m),2.83-3.16(7H, m), 3.69-4.23(4H, m), 5.44(1H, s), 7.14-7.31(4H, m). 400NMR: 1.01-1.07(3H, m), 2.26-4.43(10H, m), 5.00 and 5.69(1H, m),7.05-7.40(8H, m). 401 NMR: 1.25-1.94(6H, m), 2.70-4.46(10H, m), 5.02 and5.67(1H, m), 7.07-7.26(8H, m). 409 NMR: 1.14-1.57(13H, m),2.53-4.50(15H, m), 5.06 and 5.55(1H, m), 7.05-7.12(4H, m). 410 NMR:1.25-1.94(6H, m), 2.38-4.47(13H, m), 4.98 and 5.72(1H, m), 6.79-7.29(8H,m). 411 NMR: 1.02-1.06(3H, m), 2.23-4.38(14H, m), 4.96 and 5.72(1H, m),6.79-7.29(8H, m). 415 NMR: 0.86-0.94(6H, m), 1.15-1.62(10H, m),1.88-2.04(1H, m), 2.60-5.04(12H, m), 6.52(2H, s), 6.72-6.79(2H, m),7.06-7.12(1H, m). 420 NMR: 1.00-1.08(3H, m), 2.10-4.51(14H, m), 4.95 and5.59(1H, m), 6.83-7.28(8H, m). 421 NMR: 1.03(3H, d, J = 7.2 Hz),2.58-2.95(4H, m), 3.76-3.88(2H, m), 4.13(1H, d, J = 16 Hz), 4.18(1H, d,J = 16 Hz), 6.61(1H, d, J = 7.2 Hz), 7.06-7.32(13H, m). 422 NMR:2.67-2.97(4H, m), 3.38(2H, m), 3.80(2H, m), 4.19(2H, s), 6.61(1H, d, J =8 Hz), 7.06-7.32(13H, m). 433 NMR: 0.99-1.11(3H, m), 2.12-4.53(13H, m),4.94 and 5.72(1H, m), 7.03-7.80(8H, m). 434 NMR: 0.99-1.11(3H, m),2.12-4.53(11H, m), 4.94 and 5.71(1H, m), 7.03-7.80(8H, m). 436 NMR:1.14-1.55(13H, m), 2.49-4.50(15H, m), 5.08 and 5.56(1H, m),7.05-7.12(3H, m). 439 NMR: 1.14-1.56(13H, m), 2.49-4.50(15H, m), 5.07and 5.56(1H, m), 7.05-7.12(3H, m). 497 NMR: 1.09-1.10(3H, m),2.75-3.00(4H, m), 3.37-4.48(4H, m), 6.22 and 6.50(1H, s), 7.12-8.58(8H,m).

In addition, structures of other compounds of the present invention areshown in Tables 126 and 127. It is possible to easily produce thesecompounds according to the above-mentioned methods described inproduction processes and Examples, and methods obvious to a personskilled in the art, or modifications thereof.

Further, in the Tables, No represents a number of the compound.

TABLE 126 No Structure 1

2

3

4

5

6

7

8

9

10

11

12

13

14

TABLE 127 No Structure 15

16

17

18

19

20

21

22

23

24

25

The analysis results of several compounds of Production Examples bychiral column chromatography are shown in Tables 128 and 129

In addition, in the Tables, RT represents a retention time (min) and OPrepresents an optical purity (% ee).

TABLE 128 Rex Condition RT OP 20 Column: DAICEL CHIRALPAK AD-RH 4.6 ×150 mm 18.22 >99.5 Detection: UV: 230 nm Flow rate: 0.5 mL/min Eluent:20 mM Phosphate buffer(pH 9)/MeCN = 60/40 Column temperature: 40° C. 21Column: DAICEL CHRALPAK AS-RH 4.6 × 150 mm 24.11 >99.5 Detection: UV210nm Flow rate: 0.8 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN =50/50 Column temperature: 40° C. 22 Column: DAICEL CHRALCEL OJ-RH 4.6 ×150 mm 9.24 99.20 Detection: UV210 nm Flow rate: 0.8 mL/min Eluent: 20mM Phosphate buffer (pH 9)/MeCN = 70/30 Column temperature: 40° C. 81Column: DAICEL CHRALPAK AS-RH 4.6 × 150 mm 15.95 >99 Detection: UV210 nmFlow rate: 0.8 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN = 45/55Column temperature: 40° C. 82 Column: DAICEL CHRALCEL OJ-RH 4.6 × 150 mm43.39 92 Detection: UV210 nm Flow rate: 0.8 mL/min Eluent: 20 mMPhosphate buffer(pH 9)/MeCN = 70/30 Column temperature: 40° C. 83Column: DAICEL CHRALCEL OD-RH 4.6 × 150 mm 52.48 98 Detection: UV210 nmFlow rate: 0.8 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN = 20/80Column temperature: 40° C. 513 Column: DAICEL CHRALCEL OD-RH 4.6 × 150mm 60.99 97.40 Detection: UV210 nm Flow rate: 0.8 mL/min Eluent: 20 mMPhosphate buffer(pH 9)/MeCN = 20/80 Column temperature: 40° C. 547AColumn: DAICEL CHIRALPAK AD-RH 4.6 × 150 mm 15 95 Detection: UV: 230 nmFlow rate: 0.5 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN = 60/40Column temperature: 40° C.

TABLE 129 Rex Condition RT OP 566 Column: DAICEL CHRALCEL OJ-RH 4.6 ×150 mm 11.28 98.30 Detection: UV210 nm Flow rate: 0.8 mL/min Eluent: 20mM Phosphate buffer(pH 9)/MeCN = 70/30 Column temperature: 40° C. 567Column: DAICEL CHRALCEL OD-RH 4.6 × 150 mm 28.60 >99 Detection: UV230 nmFlow rate: 0.8 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN = 45/55Column temperature: 40° C. 570 Column: DAICEL CHRALCEL OD-RH 4.6 × 150mm 36.76 >99 Detection: UV210 nm Flow rate: 0.8 mL/min Eluent: 20 mMPhosphate buffer(pH 9)/MeCN = 60/40 Column temperature: 40° C. 572Column: DAICEL CHRALPAK AS-RH 4.6 × 150 mm 20.86 >99.5 Detection: UV210nm Flow rate: 0.8 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN =50/50 Column temperature: 40° C. 575 Column: DAICEL CHRALPAK AS-RH 4.6 ×150 mm 17.02 >99 Detection: UV210 nm Flow rate: 0.8 mL/min Eluent: 20 mMPhosphate buffer(pH 9)/MeCN = 45/55 Column temperature: 40° C. 576Column: DAICEL CHRALCEL OD-RH 4.6 × 150 mm 22.72 >99 Detection: UV230 nmFlow rate: 0.8 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN = 45/55Column temperature: 40° C. 650 Column: DAICEL CHRALCEL OD-RH 4.6 × 150mm 25.06 >99 Detection: UV210 nm Flow rate: 0.8 mL/min Eluent: 20 mMPhosphate buffer(pH 9)/MeCN = 65/35 Column temperature: 40° C. 652Column: DAICEL CHRALCEL OD-RH 4.6 × 150 mm 26.7 >99 Detection: UV210 nmFlow rate: 0.8 mL/min Eluent: 20 mM Phosphate buffer(pH 9)/MeCN = 65/35Column temperature: 40° C.

INDUSTRIAL APPLICABILITY

The compound of the present invention can be used as a pharmaceuticalcomposition for preventing and/or treating various pains includingneuropathic pain and nociceptive pain, headaches such as migraine andcluster headache, central nervous system diseases such as anxiety,depression, epilepsy, cerebral stroke and restless legs syndrome,abdominal symptoms such as abdominal pain and abdominal distension,stool abnormalities such as diarrhea and constipation, digestive systemdiseases such as irritable bowel syndrome, urinary system diseases suchas overactive bladder and interstitial cystitis, etc.

1. A compound of the formula (I):

wherein the symbols in the formula have the following meanings: R^(1a)and R^(1b): are the same or different and may be —H, C₁₋₆ alkyl whichmay be substituted, cycloalkyl which may be substituted, aryl which maybe substituted, or an aromatic hetero ring which may be substituted,provided that both of R^(1a) and R^(1b) cannot be —H, and R^(1a) andR^(1b), when taken together with the carbon atom to which they areattached, may represent cycloalkyl which may be substituted, R^(3a),R^(3b), R^(4a) and R^(ab): are the same or different and may be —H, orC₁₋₆ alkyl, R⁵, R⁶, R⁷ and R⁸: are the same or different and may be —H,C₁₋₆ alkyl which may be substituted, —O—(C₁₋₆alkyl) which may besubstituted, cyano, carbamoyl which may be substituted with one or twoC₁₋₆alkyl, or halogen, and any two adjacent groups of R⁵, R⁶, R⁷ and R⁸when taken together may form —O—CH₂—O— or —O—(CH₂)₂—O—, R¹¹, R¹², R¹³,R¹⁵ and R¹⁶: are the same or different and may be —H or C₁₋₆alkyl, R²¹:is —H, C₁₋₆ alkyl which may be substituted, or cycloalkyl which may besubstituted, R²²: is (1) cycloalkyl which is substituted with one ormore groups selected from the group consisting of —OH and —CH₂OH andwhich may be further substituted; (2) C₁₋₈ alkyl substituted with one ortwo —OH, wherein the C₁₋₈ alkyl may further have a substituent, and oneor two methylene groups (—CH₂—) contained in this alkyl chain may bereplaced with —O—; or (3) C₁₋₆ alkyl substituted with cycloalkyl whichis substituted with one or more groups selected from the groupconsisting of —OH and —CH₂OH and which may be further substituted,wherein the C₁₋₆ alkyl may be substituted with —OH, and one or twomethylene groups (—CH₂—) contained in this alkyl chain may be replacedwith —O—; and n and m: are the same or different and are 0 or 1, whereinR¹² and R²¹ when taken together may form methylene, ethylene, ortrimethylene, and in this case, R¹¹ may represent —OH, or R²¹ and R²²,when taken together with the nitrogen atom to which they are attached,may form azetidine, pyrrolidine, piperidine, azepane, azocane,morpholine, tetrahydroisoquinoline or thiomorpholine which aresubstituted with —OH or C₁₋₆ alkyl substituted with —OH; or apharmaceutically acceptable salt thereof.
 2. The compound according toclaim 1, wherein m is 0, n is 0, and R^(1a), R^(3a), R^(3b), R^(4a),R^(4b), R¹¹, R¹² and R²¹ are each —H; or a pharmaceutically acceptablesalt thereof.
 3. The compound according to claim 2, wherein R^(1b) isisopropyl, methoxymethyl, phenyl, 2-(trifluoromethyl)benzyl, orcyclohexyl; or a pharmaceutically acceptable salt thereof.
 4. Thecompound according to claim 2, wherein R⁵, R⁶, R⁷ and R⁸ are the same ordifferent and are independently selected from the group consisting of—H, methyl, ethyl, methoxy, and fluoro; or a pharmaceutically acceptablesalt thereof.
 5. The compound according to claim 2, wherein R²² is2-hydroxypropan-1-yl, 2-hydroxy-3-methoxypropan-1-yl, or(1-hydroxycyclohexyl)methyl; or a pharmaceutically acceptable saltthereof.
 6. The compound according to claim 1, which is1-[({2-[(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,(2S)-1-({2-[(1S)-1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)-3-methoxypropan-2-ol,1-({[2-(1(1S)-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,(2R)-1-({2-[(1S)-8-methoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)propan-2-ol,1-[({2-[(1R)-7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,(2S)-1-methoxy-3-[(2-oxo-2-{1(1S)-[2-(trifluoromethyl)benzyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,1-({[3-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-3-oxopropyl]amino}methyl)cyclohexanol,(2R)-1-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,(2R)-1-[(2-oxo-2-{1-[2-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,(2S)-1-{[2-(1-cyclohexyl-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}-3-methoxypropan-2-ol,(2R)-1-({2-oxo-2-[(1S)-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}amino)propan-2-ol,1-[({2-[7-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,1-[({2-[7-ethyl-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,1-({[2-(1-isopropyl-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,1-[({2-[5-methoxy-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,1-[({2-[1-(methoxymethyl)-6-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,(1S,2S)-2-{[2-(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}-1-phenylpropane-1,3-diol,1-({(2R)-2-[(1-cyclohexyl-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]pyrrolidin-1-yl}methyl)cyclohexanol,(2R)-1-{[2-(1-cyclohexyl-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,1-({[2-(3′,4′-dihydro-2′H-spiro[cyclohexane-1,1′-isoquinolin]-2′-yl)-2-oxoethyl]amino}methyl)cyclohexanol,(2R)-1-[(2-oxo-2-{1-[2-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinolin-2(1H)-yl}ethyl)amino]propan-2-ol,(2R)-1-{[2-(1-cyclohexyl-7-ethyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}propan-2-ol,1-({[2-(6-fluoro-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,1,1-dicyclopropyl-2-({2-[6-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)ethanol,1-({[2-(1-tert-butyl-8-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,1-({[2-(1-isopropyl-6-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,1-({[2-(6-fluoro-1-propyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,1-[({2-[1-(methoxymethyl)-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,1-({[2-(5-fluoro-1-propyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]amino}methyl)cyclohexanol,1-[({2-[5-fluoro-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,1-[({2-[8-methoxy-1-(methoxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,1-[({2-[1-(ethoxymethyl)-7-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)methyl]cyclohexanol,or(1R,2S)-2-({2-[(1R)-1-(2-methoxyphenyl)-3,4-dihydroisoquinolin-2(1H)-yl]-2-oxoethyl}amino)cyclopentanol;or a pharmaceutically acceptable salt thereof.
 7. A pharmaceuticalcomposition comprising a compound of claim 1 or a pharmaceuticallyacceptable salt thereof and a pharmaceutically acceptable excipient. 8.An N-type Ca²⁺ channel blocker comprising a compound of claim 1 or apharmaceutically acceptable salt thereof.
 9. A pharmaceuticalcomposition for preventing or treating pain, neuropathic pain, abdominalsymptom, spastic constipation, opioid-induced constipation, irritablebowel syndrome, or constipation-type irritable bowel syndrome,comprising a compound of claim 1 or a pharmaceutically acceptable saltthereof.
 10. The pharmaceutical composition according to claim 9, whichis a pharmaceutical composition for preventing or treating pain.
 11. Thepharmaceutical composition according to claim 10, which is apharmaceutical composition for preventing or treating neuropathic pain.12. The pharmaceutical composition according to claim 9, which is apharmaceutical composition for preventing or treating abdominal symptom.13. The pharmaceutical composition according to claim 9, which is apharmaceutical composition for preventing or treating spasticconstipation.
 14. The pharmaceutical composition according to claim 13,which is a pharmaceutical composition for preventing or treatingopioid-induced constipation.
 15. The pharmaceutical compositionaccording to claim 9, which is a pharmaceutical composition forpreventing or treating irritable bowel syndrome.
 16. The pharmaceuticalcomposition according to claim 15, which is a pharmaceutical compositionfor preventing or treating constipation-type irritable bowel syndrome.17. A pharmaceutical composition comprising a compound of claim 1 or apharmaceutically acceptable salt thereof and an opioid as activeingredients.
 18. A pharmaceutical composition comprising a compound ofclaim 1 or a pharmaceutically acceptable salt thereof as an activeingredient, wherein the composition is used in combination with anopioid.
 19. A method for the manufacture of a pharmaceutical compositionfor preventing or treating pain, neuropathic pain, abdominal symptom,spastic constipation, opioid-induced constipation, irritable bowelsyndrome, or constipation-type irritable bowel syndrome comprisingincorporating into said composition a compound of claim 1 or apharmaceutically acceptable salt thereof.
 20. An active ingredient of apharmaceutical composition for preventing or treating pain, neuropathicpain, abdominal symptom, spastic constipation, opioid-inducedconstipation, irritable bowel syndrome, or constipation-type irritablebowel syndrome comprising the compound of claim
 1. 21. A method forpreventing or treating pain, neuropathic pain, abdominal symptom,spastic constipation, opioid-induced constipation, irritable bowelsyndrome, or constipation-type irritable bowel syndrome, comprisingadministering to a patient in need thereof an effective amount of acompound of claim 1 or a pharmaceutically acceptable salt thereof.